
<html lang="en"     class="pb-page"  data-request-id="e14fcaf6-f8d1-4a7f-b03e-d178d9ef554c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-20;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00991;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4" /></meta><meta name="dc.Creator" content="Delphine  Charvin" /></meta><meta name="dc.Creator" content="Vincent  Pomel" /></meta><meta name="dc.Creator" content="Millan  Ortiz" /></meta><meta name="dc.Creator" content="Mélanie  Frauli" /></meta><meta name="dc.Creator" content="Sophie  Scheffler" /></meta><meta name="dc.Creator" content="Edith  Steinberg" /></meta><meta name="dc.Creator" content="Luc  Baron" /></meta><meta name="dc.Creator" content="Laurène  Deshons" /></meta><meta name="dc.Creator" content="Rachel  Rudigier" /></meta><meta name="dc.Creator" content="Delphine  Thiarc" /></meta><meta name="dc.Creator" content="Christophe  Morice" /></meta><meta name="dc.Creator" content="Baptiste  Manteau" /></meta><meta name="dc.Creator" content="Stanislas  Mayer" /></meta><meta name="dc.Creator" content="Danielle  Graham" /></meta><meta name="dc.Creator" content="Bruno  Giethlen" /></meta><meta name="dc.Creator" content="Nadia  Brugger" /></meta><meta name="dc.Creator" content="Gaël  Hédou" /></meta><meta name="dc.Creator" content="François  Conquet" /></meta><meta name="dc.Creator" content="Stephan  Schann" /></meta><meta name="dc.Description" content="The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been suc..." /></meta><meta name="Description" content="The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been suc..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 12, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00991" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00991" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00991" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00991" /></link>
        
    
    

<title>Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00991" /></meta><meta property="og:title" content="Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0015.jpeg" /></meta><meta property="og:description" content="The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been successfully developed enough to be tested in the clinic. In the present paper, we report for the first time the medicinal chemistry efforts conducted around the pharmacological tool (−)-PHCCC. This work led to the identification of compound 40, a potent and selective mGluR4 positive allosteric modulator (PAM) with good water solubility and demonstrating consistent activity across validated preclinical rodent models of PD motor symptoms after intraperitoneal administration: haloperidol-induced catalepsy in mouse and the rat 6-hydroxydopamine (6-OHDA) lesion model. Moreover, we also describe the identification of compound 60 a close analogue of compound 40 with improved pharmacokinetic profile after oral administration. On the basis of its favorable and unique preclinical profile, compound 60 (PXT002331, now foliglurax) was nominated as a candidate for clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00991"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00991">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00991&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00991&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00991&amp;href=/doi/10.1021/acs.jmedchem.7b00991" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8515-8537</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00922" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01050" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Delphine++Charvin">Delphine Charvin</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4801-7800" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vincent++Pomel">Vincent Pomel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Millan++Ortiz">Millan Ortiz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%A9lanie++Frauli">Mélanie Frauli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sophie++Scheffler">Sophie Scheffler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edith++Steinberg">Edith Steinberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luc++Baron">Luc Baron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laur%C3%A8ne++Deshons">Laurène Deshons</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Rudigier">Rachel Rudigier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Delphine++Thiarc">Delphine Thiarc</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christophe++Morice">Christophe Morice</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Baptiste++Manteau">Baptiste Manteau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stanislas++Mayer">Stanislas Mayer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danielle++Graham">Danielle Graham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruno++Giethlen">Bruno Giethlen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nadia++Brugger">Nadia Brugger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ga%C3%ABl++H%C3%A9dou">Gaël Hédou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fran%C3%A7ois++Conquet">François Conquet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephan++Schann">Stephan Schann</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Prexton Therapeutics, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Domain Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Prestwick Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">EMD Serono, 45A Middlesex Turnpike, Billerica, Massachusetts 0182, United States</span></div><div class="corresp-info"><strong>*</strong>For D.C.: phone, +41 79 833 11 32; e-mail, <a href="/cdn-cgi/l/email-protection#4d0928213d25242328630e252c3f3b24230d3d3f28353922233925283f2c3d283839242e3e632e2220"><span class="__cf_email__" data-cfemail="e0a4858c9088898e85cea388819296898ea090928598948f8e948885928190859594898393ce838f8d">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.S.: phone, +33 390 40 61 50; e-mail, <a href="/cdn-cgi/l/email-protection#5e2d2d3d363f30301e3a31333f37302a363b2c3f2e3b2b2a373d2d703d3133"><span class="__cf_email__" data-cfemail="651616060d040b0b25010a08040c0b110d001704150010110c06164b060a08">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00991&amp;href=/doi/10.1021%2Facs.jmedchem.7b00991" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8515–8537</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 13, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 July 2017</li><li><span class="item_label"><b>Published</b> online</span>12 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 October 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00991" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00991</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00991"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4111</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00991" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Delphine&quot;,&quot;last_name&quot;:&quot;Charvin&quot;},{&quot;first_name&quot;:&quot;Vincent&quot;,&quot;last_name&quot;:&quot;Pomel&quot;},{&quot;first_name&quot;:&quot;Millan&quot;,&quot;last_name&quot;:&quot;Ortiz&quot;},{&quot;first_name&quot;:&quot;Mélanie&quot;,&quot;last_name&quot;:&quot;Frauli&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;Scheffler&quot;},{&quot;first_name&quot;:&quot;Edith&quot;,&quot;last_name&quot;:&quot;Steinberg&quot;},{&quot;first_name&quot;:&quot;Luc&quot;,&quot;last_name&quot;:&quot;Baron&quot;},{&quot;first_name&quot;:&quot;Laurène&quot;,&quot;last_name&quot;:&quot;Deshons&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Rudigier&quot;},{&quot;first_name&quot;:&quot;Delphine&quot;,&quot;last_name&quot;:&quot;Thiarc&quot;},{&quot;first_name&quot;:&quot;Christophe&quot;,&quot;last_name&quot;:&quot;Morice&quot;},{&quot;first_name&quot;:&quot;Baptiste&quot;,&quot;last_name&quot;:&quot;Manteau&quot;},{&quot;first_name&quot;:&quot;Stanislas&quot;,&quot;last_name&quot;:&quot;Mayer&quot;},{&quot;first_name&quot;:&quot;Danielle&quot;,&quot;last_name&quot;:&quot;Graham&quot;},{&quot;first_name&quot;:&quot;Bruno&quot;,&quot;last_name&quot;:&quot;Giethlen&quot;},{&quot;first_name&quot;:&quot;Nadia&quot;,&quot;last_name&quot;:&quot;Brugger&quot;},{&quot;first_name&quot;:&quot;Gaël&quot;,&quot;last_name&quot;:&quot;Hédou&quot;},{&quot;first_name&quot;:&quot;François&quot;,&quot;last_name&quot;:&quot;Conquet&quot;},{&quot;first_name&quot;:&quot;Stephan&quot;,&quot;last_name&quot;:&quot;Schann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8515-8537&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00991&quot;},&quot;abstract&quot;:&quot;The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been successfully developed enough to be tested in the clinic. In the present paper, we report for the first time the medicinal chemistry efforts conducted around the pharmacological tool (−)-PHCCC. This work led to the identification of compound 40, a potent and selective mGluR4 positive allosteric modulator (PAM) with good water solubility and demonstrating consistent activity across validated preclinical rodent models of PD motor symptoms after intraperitoneal administration: haloperidol-induced catalepsy in mouse and the rat 6-hydroxydopamine (6-OHDA) lesion model. Moreover, we also describe the identification of compound 60 a close analogue of compound 40 with improved pharmacokinetic profile after oral administration. On the basis of its favorable and unique preclinical profile, compound 60 (PXT002331, now foliglurax)&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00991&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00991" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00991&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00991" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00991&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00991" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00991&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00991&amp;href=/doi/10.1021/acs.jmedchem.7b00991" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00991" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00991" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00991%26sid%3Dliteratum%253Aachs%26pmid%3D28902994%26genre%3Darticle%26aulast%3DCharvin%26date%3D2017%26atitle%3DDiscovery%252C%2BStructure%25E2%2580%2593Activity%2BRelationship%252C%2Band%2BAntiparkinsonian%2BEffect%2Bof%2Ba%2BPotent%2Band%2BBrain-Penetrant%2BChemical%2BSeries%2Bof%2BPositive%2BAllosteric%2BModulators%2Bof%2BMetabotropic%2BGlutamate%2BReceptor%2B4%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D20%26spage%3D8515%26epage%3D8537%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/jmcmar.2017.60.issue-20/20171026/jmcmar.2017.60.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been successfully developed enough to be tested in the clinic. In the present paper, we report for the first time the medicinal chemistry efforts conducted around the pharmacological tool (−)-PHCCC. This work led to the identification of compound <b>40</b>, a potent and selective mGluR4 positive allosteric modulator (PAM) with good water solubility and demonstrating consistent activity across validated preclinical rodent models of PD motor symptoms after intraperitoneal administration: haloperidol-induced catalepsy in mouse and the rat 6-hydroxydopamine (6-OHDA) lesion model. Moreover, we also describe the identification of compound <b>60</b> a close analogue of compound <b>40</b> with improved pharmacokinetic profile after oral administration. On the basis of its favorable and unique preclinical profile, compound <b>60</b> (PXT002331, now foliglurax) was nominated as a candidate for clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is a chronic neurodegenerative disorder affecting more than six million people worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It results from the loss of dopamine neurons in the basal ganglia (BG), a brain region responsible for the control of motor functions. Available treatments, mainly based on dopamine replenishment, are only effective at managing early PD symptoms.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As the disease progresses, these treatments become less effective and produce debilitating side effects.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Among them, dyskinesia (or L-dopa-induced dyskinesia, LID), characterized by involuntary movements appearing after several years of L-dopa therapy, represents a serious challenge for late-stage PD treatment.</div><div class="NLM_p">Over the past decade, novel therapeutic strategies targeting nondopaminergic transmissions have emerged.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Among them, modulation of presynaptic glutamate receptors such as metabotropic glutamate receptor 4 (mGluR4) has proven to be a promising approach to normalize the BG circuitry.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> To date, eight mGluRs have been cloned and classified in three groups according to their sequence homologies, pharmacological properties, and signal transduction mechanisms: group I includes mGluR1 and mGluR5, group II mGluR2 and mGluR3, and group III mGluR4, mGluR6, mGluR7, and mGluR8.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Given its expression in desired regions of the BG motor circuit, its presynaptic localization, and its physiological function to decrease neurotransmitter release, the mGluR4 receptor has received much interest as a therapeutic target for a L-dopa-sparing strategy in PD. Indeed, mGluR4 localizes presynaptically at striatopallidal fibers where its activation circumvents dopamine action via the indirect pathway.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Initial modulation of mGluR4 was made with nonselective group III mGluR agonists (activating mGluR4, mGluR6, mGluR7, and mGluR8) such as L-AP4 or ACPT-I (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). These highly polar pharmacological tools were used to demonstrate the potential of group III activation in several in vitro and in vivo paradigms of PD.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> More selective tools came later with positive allosteric modulators (PAMs) such as (−)-PHCCC,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> ADX88178,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Lu AF21934,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or VU0418506<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Allosteric modulation offers several advantages over orthosteric approaches such as the possibility to obtain subtype selectivity and the access to druggable compounds more amenable to medicinal chemistry strategies. However, despite more than a decade of chemical optimization, none of these mGluR4 PAMs has progressed in the clinic.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of reference mGluR4 ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper, we report for the first time the medicinal chemistry work based on (−)-PHCCC, which led to a novel chromenone-oxime series with improved properties. We demonstrate that this effort led to the identification of compounds with an improved profile, up to the discovery of compound <b>60</b> (PXT002331),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> which is currently in clinical development. We also describe more in depth compound <b>40</b> (6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one oxime, PXT001687)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> as a representative candidate of the series with significant antiparkinsonian activity in preclinical rodent models of Parkinson’s disease.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">SAR from (−)-PHCCC to Compound <b>40</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">(−)-<i>N</i>-Phenyl-7-(hydroxyimino)cyclopropa[<i>b</i>]chromen-1a-carboxamide ((−)-PHCCC, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) is the first partially selective mGluR4 PAM described in the literature.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> It constitutes an unprecedented pharmacological tool that, in its racemic form, was used by multiple teams to demonstrate the therapeutic potential of mGluR4 potentiation in several disease paradigms including Parkinson’s disease,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> anxiety,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> medulloblastoma,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> pain,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> and multiple sclerosis.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, (−)-PHCCC does not constitute a good drug candidate as it suffers from weak micromolar potency (EC<sub>50</sub> = 2.25 μM on mGluR4 with the racemic form), residual mGluR1 NAM activity, and poor brain penetration, forcing pharmacologists to use central administration or toxic DMSO vehicles. Several medicinal chemistry explorations were conducted around (−)-PHCCC in order to improve its properties, but limited successes were reported and this scaffold was long considered as “flat” with any chemical modifications resulting in a loss of mGluR4 PAM activity.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27-29)</a> The only optimized derivative found was VU0359516<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), a 2-pyridyl amide analogue described with a 10-fold improvement in potency and no longer side activity on mGluR1.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">Despite these disappointing reports, we decided to re-examine the potential of (−)-PHCCC scaffold by checking importance of the cyclopropane and amide moieties. Indeed, we considered that removal of the chiral centers of (−)-PHCCC and replacement of the amide right-hand side were key in order to simplify the scaffold for an optimization effort and to increase chances of brain penetration. Analogue <b>1</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) was synthesized and was found to retain some level of PAM activity on mGluR4 (EC<sub>50</sub> = 14.2 μM). Interestingly, this molecule <b>1</b> was previously reported by a team from Vanderbilt University as being inactive at 30 μM in a Gqi5 functional test (compound <b>1i</b> in Supporting Information of ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>), whereas it behaves as a full PAM in our chimeric Gi/Gq (GqTOP) assay. This illustrates the differences that can be measured depending on the in vitro model systems used<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and underlines the importance of validating the compounds activity in animal models in the early steps of an optimization program.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Exploration of the Aromatic Substituents of Chromenone Oxime Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are the mean (±SD) of a minimum of three independent experiments. NA: not active.</p></div></div><div></div></div><div class="NLM_p">Synthetic routes of the different compounds described in this article are detailed in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Supporting Information</a> (SI).</div><div class="NLM_p">Encouraged by the result obtained with <b>1</b>, we decided to further explore the styryl moiety and prepared a library of rigidified analogues (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). First, rigidification with a naphthyl or several 5–6 and 6–6 bicyclic heterocyclic groups led to very weak or inactive analogues <b>2</b>–<b>8</b>. However, quinolinyl <b>9</b>–<b>10</b> and isoquinolinyl <b>11</b> were active, and position of the nitrogen α to the link with the chromenone oxime central core seems to be important to reach submicromolar potency, compound <b>11</b> showing a 7-fold improved potency compared with PHCCC. This was further confirmed with good levels of potency obtained with other 6–6 and 6–5 bicyclic heterocycles, <b>12</b>–<b>19</b> all having a nitrogen atom positioned similarly as in isoquinolinyl <b>11</b>, and with the absence of activity of compound <b>20</b>, isomer of the active compounds <b>14</b> or <b>17</b>. Interestingly, although a bicyclic heterocyle with a “rightly” positioned nitrogen is crucial for activity, it seems to be sensitive to decoration as the methyl substitution of <b>21</b> prevents mGluR4 PAM activity.</div><div class="NLM_p">In parallel to the study of aromatic substituents of the chromenone oxime described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, we decided to expand the exploration of the core scaffold with analogues of the representative compound <b>11</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). First, we observed that modifications of the oxime function, changed for a keto function in <b>22</b> or substituted by a methyl group in <b>23</b>, resulted in inactive molecules. As a matter of fact, this observation correlates with the results obtained by Williams et al., showing that modifications of the oxime moiety of VU0359516 always result in loss of activity.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Second, we explored the influence of small substituents on the core group. We observed that substitution of position 3, close to the oxime moiety, with a methyl group (compound <b>24</b>) was not tolerated. This was not the case for position 6 (compounds <b>25</b>–<b>29</b>) and position 7 (compounds <b>30</b> and <b>31</b>) that do tolerate small substituents ranging from methyl to bromine atom. However, position 8 appeared to be more sensitive as the chloro substituted <b>32</b> was inactive on mGluR4. We then explored the possibility to add larger groups at positions 6 and 7 that are chemically more accessible. All the tested bulkier groups resulted in compounds still potent on mGluR4 with EC<sub>50</sub> ranging between 0.75 to 9.8 μM (compounds <b>33</b>–<b>38</b>). Both polar and nonpolar groups were introduced, illustrating the fact that positions 6 and 7 can constitute a handle to improve different properties of the molecules.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of the Core Chomenone Oxime of Compound <b>11</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0009.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">substituents</th><th class="colsep0 rowsep0" align="center">mGluR4 PAM EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">substituents</th><th class="colsep0 rowsep0" align="center">mGluR4 PAM EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">0.31 ± 0.18</td><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">7-Br</td><td class="colsep0 rowsep0" align="center">1.72 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">7-OMe</td><td class="colsep0 rowsep0" align="center">1.16 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">8-Cl</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">6-cyclopropyl</td><td class="colsep0 rowsep0" align="center">1.01 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">6-Me</td><td class="colsep0 rowsep0" align="center">0.98 ± 1.08</td><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">6-O-(CH<sub>2</sub>)<sub>2</sub>-OMe</td><td class="colsep0 rowsep0" align="center">0.75 ± 0.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">6-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="center">2.47 ± 1.72</td><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">6- O-(CH<sub>2</sub>)<sub>2</sub>-methylpiperazine</td><td class="colsep0 rowsep0" align="center">9.84 ± 4.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">6-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="center">1.63 ± 1.59</td><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">6- NH-(CH<sub>2</sub>)<sub>3</sub>-methylpiperazine</td><td class="colsep0 rowsep0" align="center">5.26 ± 2.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">6-Br</td><td class="colsep0 rowsep0" align="center">0.69 ± 0.04</td><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">7-<i>O</i>-(CH<sub>2</sub>)<sub>2</sub>-OMe</td><td class="colsep0 rowsep0" align="center">3.01 ± 2.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">6-OMe</td><td class="colsep0 rowsep0" align="center">1.39 ± 0.56</td><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">7-(CH<sub>2</sub>)<sub>2</sub>-phenyl</td><td class="colsep0 rowsep0" align="center">1.74 ± 0.76</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Values are the mean (±SD) of a minimum of three independent experiments. NA: non active.</p></div></div></div><div class="NLM_p">On the basis of the observations made with compound <b>11</b> analogues, we next investigated the effects of introductions of polar groups on position 6 of compound <b>14</b> that showed mGluR4 PAM activity with a potency of 110 nM. The objective of this investigation was to increase the solubility of <b>14</b> that was rather poor (0.2 μM in Milli-Q water), making the in vivo characterization of this molecule challenging. It was found that, to a greater extent than with compound <b>11</b>, introduction of polar groups was well tolerated and even slightly improved the mGluR4 PAM activity with compound <b>40</b> that seemed to bear an ideal substituent in terms of polarity and/or basicity (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Water solubility was also clearly improved, with a 53000-fold increase for the HCl salt of compound <b>40</b> compared with <b>14</b>. However, all polar groups were not similarly tolerated, as illustrated with compounds <b>42</b> and <b>43</b> that exert more than 10-fold decrease of activity compared with compound <b>14</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Introduction of Polar Groups on Molecule <b>14</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0010.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values are the mean (±SD) of a minimum of three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Thermodynamic solubility measured in milli-Q water. ND: not determined.</p></div></div><div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">In Vitro Properties of Compound <b>40</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Having identified compound <b>40</b>, a potent mGluR4 PAM with clearly improved water solubility, we further extended its characterization in vitro. Its mode of action on mGluR4 was studied using the human recombinant receptor expressed in a transfected human cell line (HEK 293 cells). These cells were also transfected with a plasmid encoding a chimeric G protein that allowed redirection of the activation signal to intracellular calcium pathway. Receptor activity was then detected by changes in intracellular calcium, measured using a fluorescent calcium-sensitive dye (Fluo4AM, Molecular Probes). Agonist and PAM activities of compound <b>40</b> were consecutively evaluated on the same cell plate. Agonist activity was first tested for 10 min with the addition of the compound alone in the cell media. Cells were then stimulated by addition of glutamate at a concentration that resulted in 20% of the maximal effect (EC<sub>20</sub>), and fluorescence was recorded for an additional 3 min. Agonist or PAM activities were evaluated in comparison to, respectively, basal signals evoked either by the buffer or an EC<sub>20</sub> glutamate concentration. For potency and efficacy determination, a concentration–response test of compound <b>40</b> was performed. In addition, the mode of action of compound <b>40</b> was further characterized in experiments assessing the shift of glutamate concentration–response curves. In this alternative setting, 10 concentrations of glutamate (ranging over 4.5 logs) were tested alone or in the presence of 4 concentrations of compound <b>40</b> (ranging from 0.1 to 3 μM). Potency of glutamate, alone or in the presence of compound <b>40</b>, was determined and used to calculate the fold-increase in the apparent affinity of glutamate. Results showed that in these cell lines, compound <b>40</b> had a low agonist activity, with an average stimulation of the receptor of 19 ± 12% at 3 μM. However, as a PAM, compound <b>40</b> potentiated the response of human mGluR4 to glutamate with a potency of 46 ± 18 nM and amplified the effects of the EC<sub>20</sub> glutamate concentration to 77 ± 2% of the maximal response to glutamate (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). For comparison, in the same cellular assay, PHCCC exerts mGluR4 PAM effects with a potency of 2.25 ± 1.07 μM, which represents an approximately 50-fold improvement in potency for compound <b>40</b>. It should be noted here that no clear structure–activity relationship was observed with regard to efficacy modulation as most of the active PAMs described in this study resulted in an efficacy between 75% and 100% of the maximal response to glutamate. Moreover, increasing concentrations of compound <b>40</b> progressively produced a leftward shift in the glutamate concentration–response relationship and increased the potency of glutamate for mGluR4 by approximately 10-fold at 3 μM (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). Compound <b>40</b> had a similar profile in a distinct cell assay that measured the cAMP response following mGluR4 stimulation. Indeed, in this second cellular assay, compound <b>40</b> potentiated the response of human mGluR4 to a glutamate EC<sub>20</sub> with a potency of 70 nM (compared to PHCCC, which had a potency of 2.5 μM; data not shown) and induced a leftward shift of the glutamate concentration–response curve. In cell lines expressing the rat mGluR4, compound <b>40</b> was slightly more potent with an EC<sub>50</sub> of 27 ± 2 nM, and the responses were enhanced to 75 ± 2% of the maximal response to glutamate (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S1</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro properties of compound <b>40</b>. (A) Agonist and PAM activities of compound <b>40</b> were consecutively evaluated in HEK293 cells expressing human mGluR4. In these cell lines, compound <b>40</b> potentiated the increases in intracellular calcium concentrations induced by an EC<sub>20</sub> glutamate (PAM effect) but had a minor agonist activity in absence of glutamate. (B) Increasing concentrations of compound <b>40</b> induced a 10-fold leftward shift of the glutamate concentration–response curves in these cell lines. (A,B) Each point represents the mean (±SD) of duplicate determination from a representative experiment. (C) Selectivity profile of compound <b>40</b> among mGluRs. Compound <b>40</b> was tested at 1 μM on HEK293 cells expressing each of the human mGluR, alone or in the presence of either an EC<sub>20</sub> or an EC<sub>80</sub> glutamate. The corresponding glutamate concentrations were determined for each receptor subtype. L-AP4 has been used instead of glutamate on hmGluR7. Each bar represents the mean (+SEM) of activities measured in at least two (when not active) or three experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Then the selectivity of compound <b>40</b> for mGluR4 was investigated using human cell lines (HEK 293) expressing each of the other human mGluRs as well as by measuring inhibition of orthosteric ligand binding on the other glutamate receptors, namely NMDA, AMPA, and kainate, on membranes from rat cerebral cortex. Compound <b>40</b> had no effect on iGluRs, neither on group I (mGluR1 and 5) nor on group II (mGluR2 and 3) mGluRs up to 10 μM, the highest concentration tested. Among group III mGluRs, compound <b>40</b> showed 13-times higher selectivity for mGluR4 than for mGluR6, was not active on mGluR7 and had a very partial agonist activity on mGluR8 with an average stimulation of the receptor of 23 ± 7% at 10 μM (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). It has to be noted that expression of mGluR6 is strictly restricted to the retina.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Thus, it is not expected that an activity of compound <b>40</b> on mGluR6 may be confounding with a potential antiparkinsonian effect in animal models. Finally, not only the potency but also the selectivity for mGluR4 has been improved compared with (−)-PHCCC because compound <b>40</b> has no longer any activity on mGluR1.</div><div class="NLM_p last">Additionally, compound <b>40</b> was also evaluated on other targets of importance for Parkinson’s disease. Compound <b>40</b> at 10 μM showed no functional activity (neither agonist nor PAM nor antagonist activity) on D1, D2<sub>L</sub>, and A<sub>2A</sub> receptors. No effect was observed up to 10 μM on COMT, MAO-A, and MAO-B, reducing the risk for interaction with L-dopa metabolism in animal models and in Parkinson’s disease patients. Finally, activity of compound <b>40</b> was also assessed on a panel of diverse kinases (e.g., Flt3, GSK3β, IRAK4, JAK3, TAK1). Except for a 64% inhibition of Flt3, no kinase inhibition was detected at 10 μM. Altogether, these results demonstrate that compound <b>40</b> is both potent and selective for mGluR4.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Pharmacokinetic Properties of Compound <b>40</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We next evaluated the pharmacokinetic properties of compound <b>40</b> in rat and mouse. Following intravenous administration, compound <b>40</b> had a very similar pharmacokinetic profile in both species, with a high clearance (113 and 117 mL/min/kg in rat and in mouse, respectively), a high volume of distribution (6.5 and 6 L/kg in rat and mouse, respectively), and a short half-life (44 and 12 min in rat and mouse, respectively) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In both mouse and rat, compound concentrations were 3-fold higher in the brain than in plasma, indicating that the compound is CNS penetrant and has a preferential exposure in brain (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mean PK Parameters of Compound <b>40</b> Following Intravenous Administration at 1 mg/kg in Rat, and at 2 mg/kg in Mouse</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>40</b></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–∞</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">CL<sub>p</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±">brain/plasma</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 mg/kg iv (rat)</td><td class="colsep0 rowsep0" align="char" char="±">444 ± 93<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">44 ± 9<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">166 ± 36<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">113 ± 29<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 0.75<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.04<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a>,<a class="ref internalNav" href="#t4fn4" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 mg/kg iv (mouse)</td><td class="colsep0 rowsep0" align="char" char="±">753 ± 80<a class="ref internalNav" href="#t4fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1.8<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">269 ± 39.8<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">123 ± 18.2<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.8<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.3<a class="ref internalNav" href="#t4fn3" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn5" aria-label="d">d</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup>a</sup><p class="last">Values are the mean (±SEM) of 3 animals</p></div><div class="footnote" id="t4fn3"><sup>b</sup><p class="last">Values are the mean (±SEM) of 2 animals.</p></div><div class="footnote" id="t4fn4"><sup>c</sup><p class="last">Ratio calculated at 1 h postdose.</p></div><div class="footnote" id="t4fn5"><sup>d</sup><p class="last">Ratio calculated at 30 min postdose.</p></div></div></div><div class="NLM_p">Compound <b>40</b> was administered intraperitoneally at 10 and 30 mg/kg or orally at 10 mg/kg in rats (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Higher than dose-proportional increases were observed in plasma <i>C</i><sub>max</sub> and AUC<sub>0–∞</sub> following intraperitoneal administration from 10 to 30 mg/kg, and plasma concentrations were at maximum 15 min after administration. Measurements made after oral administration of 10 mg/kg revealed that the compound has a medium oral bioavailability in rats (<i>F</i> = 54%). All animals were exposed to compound <b>40</b> at the first sampling time, 15 min postoral dose, confirming drug absorption, with <i>C</i><sub>max</sub> reached 20 min after administration (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Following a single dose of compound <b>40</b>, complete elimination was observed, with concentrations between 2% and 10% of the maximum concentrations observed at 24 h postdose. The mean half-life was 7.3 h with an oral dose of 10 mg/kg. The pharmacokinetics of compound <b>40</b> in mouse is qualitatively similar to those in rat.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mean PK Parameters of Compound <b>40</b> in Rat Following Intraperitoneal or Oral Administration and in Mouse Following Oral Administration<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>40</b></th><th class="colsep0 rowsep0" align="center" char="±">plasma <i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">plasma <i>T</i><sub>max</sub> (min)</th><th class="colsep0 rowsep0" align="center">plasma <i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">plasma AUC<sub>0–inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">[brain]<sub>30 min</sub> (ng/g)</th><th class="colsep0 rowsep0" align="center" char="±">brain/plasma<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">brain/rEC<sub>50</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg ip (rat)</td><td class="colsep0 rowsep0" align="char" char="±">1498 ± 62</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0</td><td class="colsep0 rowsep0" align="center">4.0 ± 0.16</td><td class="colsep0 rowsep0" align="center">2245 ± 269</td><td class="colsep0 rowsep0" align="char" char="±">5647 ± 765</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30 mg/kg ip (rat)</td><td class="colsep0 rowsep0" align="char" char="±">9324 ± 745</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0</td><td class="colsep0 rowsep0" align="center">4.5 ± 0.7</td><td class="colsep0 rowsep0" align="center">11349 ± 1 433</td><td class="colsep0 rowsep0" align="char" char="±">22792 ± 1 111</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.05</td><td class="colsep0 rowsep0" align="char" char=".">14.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg po (rat)</td><td class="colsep0 rowsep0" align="char" char="±">135 ± 39</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 5</td><td class="colsep0 rowsep0" align="center">7.3 ± 1.7</td><td class="colsep0 rowsep0" align="center">903 ± 223</td><td class="colsep0 rowsep0" align="char" char="±">454 ± 28</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg po (mouse)</td><td class="colsep0 rowsep0" align="char" char="±">229 ± 50</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 0</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char="±">390 ± 78</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.34</td><td class="colsep0 rowsep0" align="char" char=".">0.2<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">ND: not determined. rEC<sub>50</sub>: EC<sub>50</sub> measured in cell lines overexpressing the rat mGluR4 receptor. Values are the mean (±SEM) of 3 rats or 2 mice.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Ratio calculated at 30 min postdose.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">The mouse EC<sub>50</sub> was assumed to be the same as the rEC<sub>50</sub>.</p></div></div></div><div class="NLM_p">This PK profile, together with the high brain protein binding measured in rat brain homogenate (99.24%), revealed that brain exposures are greater than the in vitro EC<sub>50</sub> values after intraperitoneal administration of 10 and 30 mg/kg but not after oral administration of 10 mg/kg in rat (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Assuming a linear PK profile after oral administration, a dose of 100 mg/kg would have to be administered in rats in order to reach brain exposures greater than EC<sub>50</sub> and expect to see a pharmacodynamic effect in vivo.</div><div class="NLM_p last">On the basis of these in vitro and in vivo parameters, compound <b>40</b> was chosen for further characterization in rodent models of Parkinson’s disease, and SAR efforts were pursued in order to improve the oral PK profile of the series.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Parkinson’s Disease Models</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As a preliminary model of Parkinson’s disease motor symptoms, the ability of compound <b>40</b> to reverse haloperidol-induced catalepsy was assessed in mouse. Mice received an injection of haloperidol (0.5 mg/kg, ip) to induce catalepsy, and 1 h later, while catalepsy was present, animals were administered an ip dose of compound <b>40</b>. Catalepsy was then assessed 40 min after compound <b>40</b> dosing. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A, compound <b>40</b> produced a dose-dependent reversal of catalepsy, with significant effects obtained between 3 and 30 mg/kg ip, which is in accordance with the prediction based on the PK profile of compound <b>40</b>. In this study, we measured the compound exposure in mouse brain at the end of the experiment to determine the in vivo EC<sub>50</sub>. Using the free fraction previously determined in rat brain (0.76%), we extrapolated the concentrations of free compound <b>40</b> in brain from the measured total brain concentrations (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Table S1</a>). The corresponding PK/PD relationship is shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B and indicates that the in vivo EC<sub>50</sub> in brain is around 5 nM, which corresponds well with the in vitro EC<sub>50</sub> on rat mGluR4 (27 nM), inferring that the effect seen in this model is mGluR4-related.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reversal of haloperidol-induced catalepsy in mice by compound <b>40</b>. Mice were administered haloperidol (0.5 mg/kg, ip), and 1 h later, when catalepsy was present, they received an ip dose of compound <b>40</b> or vehicle. Catalepsy was assessed 40 min after compound <b>40</b> dosing. (A) Each bar represents the mean (+SD) latency to move on a vertical grid (immobility time). *<i>p</i> < 0.05 when compared to Vehicle (one-way ANOVA followed by Dunn’s multiple comparison) (<i>n</i> = 8/group). (B) Relationship between efficacy in reversal of haloperidol-induced catalepsy and compound <b>40</b> unbound fraction exposed in the brain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next evaluated the effects of compound <b>40</b> in a more elaborated rodent model of Parkinson’s disease motor symptoms. Compound <b>40</b> was administered to rats that had previously undergone a bilateral lesion of the striatum induced by 6-hydroxydopamine (6-OHDA). In most models utilizing the neurotoxin 6-OHDA, animals are dopamine depleted only unilaterally.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> While dopamine loss in human PD can be asymmetrical at the earliest stages of the disease, it ultimately results in dopamine loss in both hemispheres.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> To select a context that is closer to the human condition, we chose a model where dopamine is being depleted bilaterally. Male Sprague–Dawley rats received bilateral injections of 6-OHDA into the striatum, which induced parkinsonian motor deficits indicated by reduced spontaneous activity and rearing in the open field arena (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A, SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S2a</a>). Thus, active time, slow activity (i.e., nonstereotyped activity), and rearing time were significantly reduced to 64%, 66%, and 68% respectively, by the 6-OHDA-induced bilateral lesion compared with presurgery (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S2a</a>, “Post” versus “Pre”). When administered alone, compound <b>40</b> (30 mg/kg, ip) induced an increase in active time, slow activity, and rearing time compared with vehicle administration (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figures S2a and 4a</a>). The time course analysis reveals that effects of compound <b>40</b> on slow activity were observable during the 30–120 min postadministration period (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Comparison of pharmacokinetics and pharmacodynamic effects demonstrates an excellent correlation between the increase of compound <b>40</b> exposure in brain (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B) and the efficacy in improving the slow activity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Indeed, compound <b>40</b> effects become observable from 30 min postadministration, and at 30 and 60 min after ip dosing at 30 mg/kg, brain exposures were respectively 14.5- and 7.6-fold greater than the in vitro EC<sub>50</sub> at rat mGluR4 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B), supporting that the effect seen in this model is mGluR4-related. Assuming a linear brain/plasma ratio over time, brain exposure would barely reach the mGluR4 EC<sub>50</sub> at 120 min after administration, which is in accordance with the loss of effect of compound <b>40</b> at that time point in this rat model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A,B).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiparkinsonian effect of stand-alone compound <b>40</b> treatment on locomotor activity of 6-OHDA-lesioned rats. (A) Time-course of spontaneous locomotor activity in adult male Sprague–Dawley rats before (“Presurgery, vehicle”, dotted line) or after 6-OHDA-induced striatal lesions. Lesioned rats were treated either with vehicle (“Postsurgery, vehicle”, gray curve) or with compound <b>40</b> at 30 mg/kg ip (“Postsurgery, <b>40</b>”, black curve). Each time-point represents the mean counts (±SEM) for every 5 min. Compound <b>40</b> was administered ip at T0. (<i>n</i> = 10). (B) Compound <b>40</b> plasma and brain exposures in rats dosed with 30 mg/kg ip. Brain exposure was measured 30 and 60 min after administration. Brain levels at 120 and 240 min (c) were extrapolated from measured plasma exposure by using an average brain/plasma ratio of 3.25 as determined at 30 and 60 min. Unbound fraction of compound <b>40</b> in brain (a) was calculated by using the brain protein binding previously measured (99.24%, i.e. 0.76% unbound fraction). Brain unbound over rEC<sub>50</sub> ratio (b) was then calculated by using the in vitro rat mGluR4 EC<sub>50</sub> obtained in HEK293 cells (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a recent study, Jenkins et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> have shown that treatment of rodents with 6-OHDA may slightly decrease the expression of mGluR4 in brain. Although we have used a different model, where 6-OHDA induced a milder bilateral lesion, it was important to do this PK/PD correlation in order to support target engagement in the antiparkinsonian effects of compound <b>40</b>.</div><div class="NLM_p">Then, parkinsonian rats received L-dopa either alone or in combination with compound <b>40</b>. As expected, L-dopa was effective in improving motor performance, inducing a dose-dependent increase in locomotor activity compared with vehicle administration (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Dose–response curves performed with L-dopa (3, 6, and 20 mg/kg) showed that 20 mg/kg L-dopa represented an optimal antiparkinsonian dose, restoring the motor activity of the rats to normal levels (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A), while the dose of 6 mg/kg L-dopa was selected as an ineffective subthreshold dose for use in subsequent experiments. When compound <b>40</b> was coadministered with the subthreshold low dose of L-dopa, we observed a significant improvement in motor performance that showed dose dependence for compound <b>40</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Thus, the combination of 6 mg/kg L-Dopa and 10 mg/kg compound <b>40</b> was able to fully reverse the motor deficit of parkinsonian rats and reached the same level of efficacy as the high dose of 20 mg/kg L-dopa (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Consequently, in this rat model of Parkinson’s disease, administration of compound <b>40</b> (10 mg/kg, ip) allowed a decrease by 70% of the dose of L-dopa while maintaining the same antiparkinsonian efficacy. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B, compound <b>40</b> induced a dose- and time-dependent antiparkinsonian effect, with the highest improvement obtained at the dose of 10 mg/kg (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A), from 30 to 120 min postadministration of compound <b>40</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). At the highest dose of 30 mg/kg, the antiparkinsonian effect of compound <b>40</b> in combination with 6 mg/kg of L-dopa has reached a plateau with a maximal efficacy equivalent to the normal activity of prelesion rats (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antiparkinsonian effect of the combined treatment with compound <b>40</b> and a low suboptimal dose of L-dopa on locomotor activity of 6-OHDA-lesioned rats. (A) Total spontaneous locomotor activity values are presented. Data are expressed as mean of group (+SEM) and analyzed using one-way analysis of variance (ANOVA) repeated measures followed by Dunnett’s multiple comparisons. ***<i>p</i> < 0.001, **<i>p</i> < 0.01, * <i>p</i> < 0.05 vs Post Veh. The dotted horizontal lines represent the mean locomotor activity of the control conditions in 6-OHDA-lesioned rats: optimal L-dopa (upper line) and vehicle (lower line). Pre Veh: rats activity before the surgery, after vehicle ip administration. Post Veh: activity of the same animals after the surgery and stabilization of the 6-OHDA-induced striatal lesion, after vehicle ip administration; compound <b>40</b> ip administration. (<i>n</i> = 10). (B) Time-course of spontaneous locomotor activity of 6-OHDA-lesioned rats treated either with a low suboptimal dose of L-dopa alone (“6 mg/kg L-dopa”, gray curve) or with addition of compound <b>40</b> at 10 mg/kg ip (“6 mg/kg L-dopa + 10 mg/kg compound <b>40</b>”, black curve). Each time-point represents the mean counts (±SEM) for every 5 min (<i>n</i> = 10).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this model consisting of a partial bilateral lesion of the striatum induced by 6-OHDA, the dose of 20 mg/kg L-dopa did not induce dyskinesia. However, this dose produced an increase of rearing activity that is above normal activity measured before the lesion (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S3a</a>). This abnormally high rearing activity is considered as an early sign of potential dyskinesia development in this model. Thus, it is noteworthy that none of the conditions tested with compound <b>40</b> induced an overactive rearing behavior, neither the high dose of compound <b>40</b> alone nor any dose of compound <b>40</b> in combination with L-dopa (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S3b</a>). Consequently, in this model of Parkinson’s disease, compound <b>40</b> completely reversed the motor deficits without increasing the risk of developing dyskinesia.</div><div class="NLM_p last">As a first conclusion, in the 6-OHDA rat model of Parkinson’s disease motor symptoms, administration of compound <b>40</b> allowed a decrease by 70% of the dose of L-dopa while maintaining the same antiparkinsonian efficacy without inducing any adverse event such as overactive rearing, stereotyped behavior or dyskinesia. These results show supportive evidence that compound <b>40</b> could be developed as a potential L-dopa-sparing treatment in PD, preserving maximal antiparkinsonian benefits without the need to use high L-dopa dosage. Importantly, compound <b>40</b> demonstrated consistent antiparkinsonian activities in two rodent models and exhibited robust PK/PD relationship.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Further Improvements of PK Properties, Identification of Candidate <b>60</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Encouraged by the promising results in PD models obtained with ip administration of compound <b>40</b>, we next decided to pursue the optimization of the PK profile with the objective of obtaining an optimized compound with increased brain exposure over time and thus improved potential target engagement after oral administration. <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> and SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S4</a> show the brain exposures of diverse molecules with good mGluR4 PAM activities (EC<sub>50</sub> between 4 and 165 nM). As a comparator, concentrations of 454 and 262 ng/g of compound <b>40</b> were measured in rat brains 30 and 60 min postadministration of an oral dose of 10 mg/kg (<a class="ref internalNav" href="#tbl5" aria-label="Tables 5">Tables 5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Within the same pyrrolopyrimidine series (HET = A in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>), we did not identify substituent that give rise to a better brain exposure. Indeed, replacements of the morpholine moiety of compound <b>40</b> by a 4-(dimethylamino)-piperidine (compound <b>44</b>), a close amide (compound <b>45</b>) or urea (compound <b>46</b>), or pyridine moieties (compounds <b>47</b> and <b>48</b>) were detrimental to brain exposures (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). As a consequence, none of these first analogues of compound <b>40</b> had brain exposure at concentrations higher than 100 ng/g at 30 or 60 min when given orally at 10 mg/kg. By contrast, changing the right-hand side heterocycle moiety for a thienopyridine (HET = B in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) seemed rather beneficial for brain exposure. Indeed, compound <b>49</b> showed much higher brain concentrations 60 min postdosing compared with the close compound <b>40</b> and was even detected with concentrations above 200 ng/g 90 min after oral administration (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). This encouraged us to explore further thienopyridine with similar basic left-hand side chains (compounds <b>50</b>–<b>52</b>), but these three compounds did not show improvement compared with <b>49</b> despite a similar or more potent activity. Similarly to what was observed in pyrrolopyrimidine series, introduction of an aromatic group (compounds <b>53</b>–<b>56</b>) or modifications of the morpholine moiety for close piperidine or azetidine analogues (compounds <b>56</b>–<b>59</b>) also resulted in very low brain exposures (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Interestingly, however, some of these compounds showed a clear increase in their mGluR4 PAM potency as illustrated with molecules <b>55</b>–<b>57</b>. Finally, the only chemical change in <b>49</b> resulting in an increased brain exposure was the replacement of the oxygen atom linking the chromenone oxime scaffold with the left-hand side chain by a −CH<sub>2</sub>– group. Indeed, compound <b>60</b> was found at concentrations well-above 400 ng/g (∼1 μM) up to 90 min after dosing (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). This isosteric modification did not alter the mGluR4 PAM activity because compound <b>60</b> exerts a PAM activity on mGluR4 with an EC<sub>50</sub> that is similar to the ones of close analogues <b>49</b> or <b>40</b> (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Further Optimization of Brain Penetration</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0012.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0013.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Values are the mean (±SD) of a minimum of three independent experiments.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Values of brain concentrations are mean of three rats following oral administration at 10 mg/kg. BLQ: concentration below lower limit of quantification (1 ng/mL). ND: not determined.</p></div></div><div></div></div><div class="NLM_p">Having identified compound <b>60</b> as a potent mGluR4 PAM with clearly improved brain exposure following oral administration, we further extended its characterization. Key characteristics of compound <b>60</b> are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. The in vitro properties of compound <b>60</b> are very close to those of compound <b>40</b>. Indeed, compound <b>60</b> had minor agonist activity, with an average stimulation of the receptor of 32 ± 8% at 15 μM, and acted as a PAM on mGluR4, with a potency of 79 ± 19 nM, amplifying the effects of the EC<sub>20</sub> glutamate concentration to 70 ± 5% of the maximal response to glutamate (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S5</a>). Compound <b>60</b> increased the apparent affinity of glutamate for mGluR4 by 10-fold (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S5</a>) and had no effect on NMDA, AMPA, kainate, group I (mGluR1 and 5), or group II (mGluR2 and 3) mGluRs up to 10 μM, the highest concentration tested. Among group III mGluRs, compound <b>60</b> showed more than 15-, 110- and 50-times higher selectivity for mGluR4 than for mGluR6, -7, and -8, respectively (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, SI, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Figure S5</a>). Compound <b>60</b> had no effect on COMT, MAO-A, or MAO-B at 10 μM in enzymatic assays (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), reducing the risk for interaction with L-dopa metabolism.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Summary of Key Parameters for Compound <b>60</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0014.gif" alt="" id="fx8" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">in vitro pharmacology<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">hum ago EC<sub>50</sub></th><th class="rowsep1 colsep0" align="center">hum PAM EC<sub>50</sub></th><th class="rowsep1 colsep0" colspan="3" align="center">(hum fold shift)</th><th class="rowsep1 colsep0" align="center">rat PAM EC<sub>50</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">mGluR4</th><th class="colsep0 rowsep0" align="center">>15 μM</th><th class="colsep0 rowsep0" align="center">79 nM</th><th class="colsep0 rowsep0" align="center">10 (at 3 μM)</th><th class="colsep0 rowsep0" align="center">10 (at 3 μM)</th><th class="colsep0 rowsep0" align="center">10 (at 3 μM)</th><th class="colsep0 rowsep0" align="center">47 nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity</td><td class="colsep0 rowsep0" align="center">group I</td><td class="colsep0 rowsep0" align="center">group II</td><td class="colsep0 rowsep0" align="center">mGlu6</td><td class="colsep0 rowsep0" align="center">mGlu7</td><td class="colsep0 rowsep0" align="center">mGlu8</td><td class="colsep0 rowsep0" align="center">NMDA, AMPA, kainate</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">15×</td><td class="colsep0 rowsep0" align="center">110×</td><td class="colsep0 rowsep0" align="center">50×</td><td class="colsep0 rowsep0" align="center">not active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">specificity</td><td class="colsep0 rowsep0" align="center">COMT</td><td class="colsep0 rowsep0" align="center">MAO-A</td><td class="colsep0 rowsep0" align="center">MAO-B</td><td class="colsep0 rowsep0" align="center">MAO-B</td><td class="colsep0 rowsep0" align="center">MAO-B</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center">not active</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="+">in vivo pharmacokinetics (rat)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">1 mg/kg (iv)</th><th class="colsep0 rowsep0" align="center" char="+">plasma <i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="+"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="+">plasma AUC<sub>0–inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="+">CL<sub>p</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="+"><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="+">brain/plasma<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="+">325 + 30</td><td class="colsep0 rowsep0" align="char" char="+">0.90 + 0.15</td><td class="colsep0 rowsep0" align="char" char="+">163 + 15</td><td class="colsep0 rowsep0" align="char" char="+">104 + 10</td><td class="colsep0 rowsep0" align="char" char="+">8.02 + 1.28</td><td class="colsep0 rowsep0" align="char" char="+">8.4 + 0.7</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col><col align="char" char="+" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">10 mg/kg po</th><th class="colsep0 rowsep0" align="center" char=".">plasma <i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">plasma <i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">plasma AUC<sub>0–inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">brain AUC<sub>0–inf</sub> (h·ng/g)</th><th class="colsep0 rowsep0" align="center" char=".">brain/plasma<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="+">94 + 21</td><td class="colsep0 rowsep0" align="char" char="+">1.17 + 0.44</td><td class="colsep0 rowsep0" align="char" char="+">432 + 126</td><td class="colsep0 rowsep0" align="char" char="+">2713 + 544</td><td class="colsep0 rowsep0" align="char" char="+">6.6 + 0.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Activities were measured at least in duplicates. Values are the mean of at least three experiments.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Values are the mean (±SEM) of three rats.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Ratio calculated at 1 h postdose.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Ratio of AUC<sub>0–inf</sub>.</p></div></div></div><div class="NLM_p">PK characteristics of compound <b>60</b> in rats are given in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> and <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Compound <b>60</b> displayed excellent CNS penetration after oral dosing, with more than 6-fold (and up to 13.5-fold depending on the dose) higher exposure in brain than in plasma (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Moreover, the close correlation between plasma and brain concentration curves over time indicates that plasma concentrations are good predictors of compound <b>60</b> concentration levels and kinetics in the brain (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK profile of compound <b>60</b> in plasma and brain following oral administration at 25 mg/kg (in water) to Sprague–Dawley rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Altogether, these characteristics demonstrate that compound <b>60</b> is a potent and selective mGluR4 PAM, with high brain exposure measured after oral administration. The compound <b>60</b> will be extensively characterized in another article, to be published in due course.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">After a thorough development from (−)-PHCCC and extensive knowledge gained on the medicinal chemistry and pharmacology of mGluR4 PAMs, it has been possible to generate a novel series of compounds with an improved profile and with significant antiparkinsonian activity demonstrated in validated rodent models of PD motor symptoms. On the basis of its complete preclinical profile, compound <b>60</b> has been identified as the most promising candidate, which could be further evaluated in the clinic.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">All reagents were commercial grade and used without further purification. Commercially available anhydrous solvents were used for reactions conducted under inert atmosphere. Silica gel generally used for column chromatography was SDS silica gel (60AAC 40–63 μM). Thin layer chromatography was carried out using precoated silica gel F-254 plate. <sup>1</sup>H NMR spectra were recorded on a Bruker AMX-400 operating at 400.33 MHz. <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE I 400 Fourier transform spectrometer, operating at 100.67 MHz, using a 5 mm QNP probe operating at 300 K. Proton chemical shifts are listed relative to residual CDCl<sub>3</sub> (7.27 ppm), DMSO-<i>d</i><sub>6</sub> (2.51 ppm) or D<sub>2</sub>O (4.60 ppm). Splitting patterns are designated as s (singlet), d (doublet), dd (double–doublet), t (triplet), tt (triplet–triplet), td (triplet-doublet), q (quartet), quint (quintuplet), sex (sextuplet), sept (septuplet), m (multiplet), b (broad). For <sup>13</sup>C NMR spectrum: The chemical shifts (δ) were measured in ppm and referenced from the central peak of DMSO-<i>d</i><sub>6</sub> (39.5 ppm). Electrospray MS spectra were obtained on a Waters micromass platform LCMS spectrometer. All mass spectra were full-scan experiments (mass range 100–800 amu). Mass spectra were obtained using electrospray ionization. The HPLC system was a Waters platform with a 2767 sample manager, a 2525 pump, and a photodiode array detector (190–400 nM). The column used was an XBridge C18 3.5 μM (4.6 mm × 50 mm) in analytical mode and an XBridge C18 OBD 5 μM (30 mm × 100 mm) in preparative mode. The mobile phase in both cases consisted in an appropriate gradient of A and B. A was water with 0.05% of TFA and B was MeOH with 0.05% of TFA. Flow rate was 1 mL per min in analytical mode and 25 mL min in preparative mode. All LCMS were performed at room temperature. At the end of each preparative HPLC, the tubes were collected and TFA was neutralized with potassium carbonate before extraction or filtration of the product. Microwave experiments were performed on a Biotage Initiator. The microwave modulates the power in order to reach the selected temperature as fast as possible. The time of each experiment is the time at the selected temperature. High resolution mass spectroscopy was measured for compounds <b>40</b> and <b>60</b> using a LC-UV-MS/MS Agilent 1200 with a QToF 6520 detector in + ESI. Melting points are measure on a Barnstead Electrothermal 9100 and are not corrected. Oxime final compounds were isolated as >95% of isomer <i>E</i> according to NMR analysis. The purity of final compounds was measured by HPLC and was found to be above 95%.</div><div class="NLM_p">General synthetic routes of all compounds described in this article are detailed in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">Supporting Information</a>. A few key intermediates were prepared for all these syntheses, they were numbered with three-digit numbers, and their preparations are described after the description of compound <b>1</b>–<b>60</b> syntheses.</div><div id="sec8_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2-Styryl-chromen-4-one Oxime (<b>1</b>)</h4><div class="NLM_p last">2-Styryl-chromen-4-one was prepared in a manner analogous to <b>2</b> (73%), starting from cinnamoyl chloride. LCMS, <i>m</i>/<i>z</i> = 249.0 [M + H]<sup>+</sup>. Then, oxime formation was obtained as follows: a mixture of 2-styryl-chromen-4-one (150 mg, 0.60 mmol) and hydroxylamine hydrochloride (84 mg, 1.2 mmol) in anhydrous methanol (12 mL) was subjected to microwave irradiation at 130 °C for 20 min. Methanol was removed under vacuum, and the crude solid was purified by column chromatography on silica gel (using 0–30% ethyl acetate in cyclohexane as eluent) to give 2-styryl-chromen-4-one oxime (<b>1</b>, 65 mg, 41%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.98 (s, 1H), 7.86 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.68–7.65 (m, 2H), 7.52–7.46 (m, 1H), 7.45–7.33 (m, 5H), 7.27–7.22 (m, 1H), 7.11 (d, <i>J</i> = 16.1 Hz, 1H), 6.70 (s, 1H). MS (ESI+): 264.1 [C<sub>17</sub>H<sub>13</sub>NO<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 196–199 °C.</div></div><div id="sec8_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-Naphthalen-2-yl-chromen-4-one oxime (<b>2</b>)</h4><div class="NLM_p">To a cold suspension of 2-naphthoic acid (2.0 g, 11.6 mmol) in dichloromethane (60 mL) were added oxalyl chloride (1.1 mL, 12.6 mmol) and dimethylformamide (50 μL). The reaction mixture was stirred at room temperature for 2 h and concentrated to dryness to give crude 2-naphthoic acid chloride (2.5 g). The crude acid chloride was dissolved in dry pyridine (50 mL), cooled to 0 °C, and 2-hydroxy-acetophenone (1.43 g, 10.5 mmol) added. The reaction mixture was heated at 60 °C for 2 h before being poured onto ice-cold water (150 mL). The solution was acidified to pH 1 with concentrated hydrochloric acid, and the precipitate was collected by filtration, washed with water, and dried under vacuum to give naphthalene-2-carboxylic acid 2′-acetyl-phenyl ester (2.7 g, 80%). The crude ester was dissolved in DMSO (30 mL), and crushed potassium hydroxide (1.4 g, 25.8 mmol) was added. The reaction mixture was stirred at room temperature for 14 h before being poured onto ice-cold water and acidified to pH 3–4 with a 6N aqueous hydrochloric acid solution. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum to give 1-(2-hydroxy-phenyl)-3-naphthalen-2-yl-propane-1,3-dione (1.44 g, 86%). The crude diketone was dissolved in DMSO (25 mL), and <i>para</i>-toluenesulfonic acid monohydrate (660 mg, 3.47 mmol) was added. The reaction mixture was heated at 90 °C for 4 h before being poured onto ice-cold water. The resulting precipitate was collected by filtration, then dissolved in dichloromethane, dried over sodium sulfate, and concentrated under vacuum. Purification by column chromatography on silica gel (using cyclohexane/ethyl acetate: 80/20 as eluent) gave 2-naphthalen-2-yl-chromen-4-one (956 mg, 70%) as a brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (s, 1H), 8.26 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 8.02–7.87 (m, 4H), 7.74 (td, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.65 (dd, <i>J</i> = 8.2, 1.0 Hz, 1H), 7.62–7.55 (m, 2H), 7.45 (td, <i>J</i> = 8.1, 1.1 Hz, 1H), 6.99 (s, 1H).</div><div class="NLM_p last"><b>2</b> was prepared in a manner analogous to <b>11</b> (69%, 2 steps), starting from 2-naphthalen-2-yl-chromen-4-one. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.06 (s, 1H), 8.56 (s, 1H), 8.14–8.06 (m, 1H), 8.04–7.95 (m, 3H), 7.92 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.64–7.56 (m, 2H), 7.55–7.47 (m, 2H), 7.34–7.26 (m, 1H), 7.28 (s, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.3, 151.1, 142.0, 134.3, 133.6, 132.6, 130.5, 129.4, 128.7, 127.6, 127.1, 126.9, 125.2, 122.7, 122.3, 118.6, 117.7, 107.3, 93.9 ppm. MS (ESI+): 288.0 [C<sub>19</sub>H<sub>13</sub>NO<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 224–226 °C.</div></div><div id="sec8_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2-Benzofuran-2-yl-chromen-4-one Oxime (<b>3</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (13%), starting from 2-benzofuran-2-yl-chromen-4-one. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.23 (s, 1H), 7.90 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.77 (d, <i>J</i> = 7.5 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.57 (s, 1H), 7.54–7.28 (m, 5H), 7.14 (s, 1H). MS (ESI+): 277.98 [C<sub>17</sub>H<sub>11</sub>NO<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-Benzo[<i>b</i>]thiophen-2-yl-chromen-4-one Oxime (<b>4</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (26%, overall yield), starting from benzo[b]thiophene-2-carbonyl chloride. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.19 (s, 1H), 8.14 (s, 1H), 8.07–8.04 (m, 1H), 7.97–7.94 (m, 1H), 7.90 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.56–7.26 (m, 5H), 7.04 (s, 1H). MS (ESI+): 294.02 [C<sub>17</sub>H<sub>11</sub>NO<sub>2</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-(1<i>H</i>-Indol-2-yl)-chromen-4-one Oxime (<b>5</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (1%, overall yield), starting from 1<i>H</i>-indole-2-carboxylic acid. It was purified by preparative HPLC. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 11.00 (s, 1H), 7.90 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 7.9 Hz, 1H), 7.55–7.50 (m, 1H), 7.44 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.40 (dd, <i>J</i> = 8.1, 0.8 Hz, 1H), 7.30–7.26 (m, 1H), 7.23–7.19 (m, 2H), 7.11 (d, <i>J</i> = 1.6 Hz, 1H), 7.10–7.04 (m, 1H). MS (ESI+): 277.0 [C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-(1-Methyl-1<i>H</i>-indol-2-yl)-chromen-4-one Oxime (<b>6</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (1%, overall yield), starting from 1-methyl-1<i>H</i>-indole-2-carboxylic acid. It was purified by preparative HPLC. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.02 (s, 1H), 7.91 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 7.9 Hz, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.55–7.49 (m, 1H), 7.42 (dd, <i>J</i> = 8.4, 1.2 Hz, 1H), 7.33–7.26 (m, 2H), 7.12–7.07 (m, 1H), 7.06 (s, 1H), 6.93 (s, 1H), 3.93 (s, 3H). MS (ESI+): 291.06 [C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 194–196 °C.</div></div><div id="sec8_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-Quinolin-2-yl-chromen-4-one Oxime (<b>7</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (24%, overall yield), starting from quinaldoyl chloride. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.20 (s, 1H), 8.59 (d, <i>J</i> = 8.5 Hz, 1H), 8.19 (d, <i>J</i> = 8.5 Hz, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.93 (d, <i>J</i> = 8.5 Hz, 1H), 7.85 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.80 (s, 1H), 7.68 (td, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.60–7.49 (m, 2H), 7.31 (td, <i>J</i> = 7.5, 1.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.3, 151.0, 149.8, 147.2, 142.0, 137.7, 130.7, 130.5, 129.2, 128.0, 127.9, 127.5, 125.2, 122.3, 118.9, 117.9, 117.6, 95.6 ppm. MS (ESI+): 289.0 [C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 232–235 °C.</div></div><div id="sec8_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Quinoxalin-2-yl-chromen-4-one Oxime (<b>8</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (7%, overall yield), starting from 2-quinoxaloyl chloride. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.29 (s, 1H), 9.57 (s, 1H), 8.22–8.15 (m, 2H), 7.95–7.90 (m, 3H), 7.76 (s, 1H), 7.56–7.54 (m, 2H), 7.34–7.28 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.0, 150.9, 144.9, 142.3, 142.1, 141.7, 141.0, 131.3, 131.2, 130.8, 129.4, 129.0, 125.4, 122.2, 118.7, 118.0, 96.9 ppm. MS (ESI+): 290.09 [C<sub>17</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 263–265 °C.</div></div><div id="sec8_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Quinolin-3-yl-chromen-4-one Oxime (<b>9</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (10%, overall yield), starting from quinoline-3-carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.18 (s, 1H), 9.43 (d, <i>J</i> = 2.4 Hz, 1H), 9.97 (d, <i>J</i> = 2.4 Hz, 1H), 8.16 (dd, <i>J</i> = 8.3, 1.2 Hz, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 1H), 7.92 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.86 (ddd, <i>J</i> = 8.4, 6.9, 1.4 Hz, 1H), 7.71 (ddd, <i>J</i> = 8.0, 6.9, 1.1 Hz, 1H), 7.58–7.50 (m, 2H), 7.40 (s, 1H), 7.31 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.4, 151.0, 147.8, 147.1, 141.8, 132.9, 130.8, 130.6, 128.9, 128.7, 127.5, 126.9, 125.3, 125.1, 122.2, 118.6, 117.7, 94.8 ppm. MS (ESI+): 289.06 [C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 225–228 °C.</div></div><div id="sec8_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Quinolin-6-yl-chromen-4-one Oxime (<b>10</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>2</b> (4%, overall yield), starting from quinoline-6-carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.13 (s, 1H), 8.97 (dd, <i>J</i> = 4.3, 1.7 Hz, 1H), 8.65 (d, <i>J</i> = 1.9 Hz, 1H), 8.54 (dd, <i>J</i> = 8.3, 1.0 Hz, 1H), 8.28 (dd, <i>J</i> = 8.9, 1.9 Hz, 1H), 8.12 (d, <i>J</i> = 8.9 Hz, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.63 (dd, <i>J</i> = 8.3, 4.3 Hz, 1H), 7.55–7.48 (m, 2H), 7.34–7.28 (m, 2H). MS (ESI+): 289.02 [C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 222–224 °C.</div></div><div id="sec8_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Isoquinolin-3-yl-chromen-4-one Oxime (<b>11</b>)</h4><div class="NLM_p">To a suspension of 2-isoquinolin-3-yl-chromen-4-one (<b>22</b>, 459 mg, 1.67 mmol) in methanol (11 mL) was added <i>O</i>-<i>tert</i>-butyl hydroxylamine hydrochloride (421 mg, 3.35 mmol). The mixture was subjected to microwave irradiation at 130 °C for 30 min. Methanol was removed under vacuum, and the residue was purified by column chromatography on silica gel (using a gradient of 0–5% ethyl acetate in cyclohexane as eluent) to give 2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (387 mg, 67%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.29 (s, 1H), 8.30 (s, 1H), 8.10 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 8.01 (d, <i>J</i> = 7.7 Hz, 1H), 7.95 (d, <i>J</i> = 7.9 Hz, 1H), 7.80 (s, 1H), 7.75 (td, <i>J</i> = 7.0, 1.1 Hz, 1H), 7.65 (td, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.42 (td, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.34 (dd, <i>J</i> = 8.3, 1.3 Hz, 1H), 7.21 (td, <i>J</i> = 7.4, 1.3 Hz, 1H), 1.43 (s, 9H).</div><div class="NLM_p last">To an ice-cooled solution of 2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (136 mg, 0.39 mmol) in dichloromethane (10 mL) was cautiously added a 1 M solution of titanium tetrachloride in dichloromethane (1.2 mL, 1.2 mmol). The reaction mixture was stirred at 0 °C for 2 h then at room temperature for 3 h. The reaction mixture was poured onto ice-cold water (100 mL), basified using a 6N aqueous solution of sodium hydroxide until pH 10, and the resulting yellow precipitate collected by filtration. The solid was washed with water, dried under vacuum, and purified by column chromatography on silica gel (using a gradient of cychlohexane/ethyl acetate/dichloromethane: 80/10/10 to 0/50/50 as eluent) to give 2-isoquinolin-3-yl-chromen-4-one oxime (<b>11</b>, 71 mg, 62%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11,08 (s, 1H), 9.42 (s, 1H), 8.50 (s, 1H), 8.22 (d, <i>J</i> = 7.9 Hz, 1H), 8.15 (d, <i>J</i> = 7.9 Hz, 1H), 7.93 (dd, <i>J</i> = 8.1, 1.2 Hz, 1H), 7.88 (td, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.78 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 7.77 (s, 1H), 7.60–7.48 (m, 2H), 7.31 (td, <i>J</i> = 7.4, 1.3 Hz, 1H). MS (ESI+): 289.3 [C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 247–249 °C.</div></div><div id="sec8_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-[2,6]Naphthyridin-3-yl-chromen-4-one Oxime (<b>12</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>11</b>, starting from [2,6]naphthyridine-3-carboxylic acid methyl ester. It was purified by preparative HPLC. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.17 (s, 1H), 9.61 (s, 1H), 9.57 (s, 1H), 8.81 (d, <i>J</i> = 5.6 Hz, 1H), 8.67 (s, 1H), 8.13 (d, <i>J</i> = 5.6 Hz, 1H), 7.93 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 7.79 (s, 1H), 7.57 (td, <i>J</i> = 8.4, 1.2 Hz, 1H), 7.52 (d, <i>J</i> = 7.6 Hz, 1H), 7.32 (td, <i>J</i> = 8.0, 1.2 Hz, 1H). MS (ESI+): 290.1 [C<sub>17</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div><div id="sec8_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> [2,6]Naphthyridine-3-carboxylic Acid Methyl Ester</h5><div class="NLM_p last">Compound was prepared as follows: To a cold solution of 4-dimethoxymethyl-pyridine-3-carbaldehyde<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (400 mg, 1.91 mmol) in dichloromethane (10 mL) was slowly added a solution of acetylamino-(dimethoxy-phosphoryl)-acetic acid methyl ester<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (503 mg, 2.1 mmol) and 1.8-diazabicyclo[5.4.0]undec-7-ene (0.31 mL, 2.10 mmol). The reaction mixture was stirred at 0 °C for 1 h, then at room temperature for 18 h, before being poured onto a cold saturated solution of sodium bicarbonate and extracted twice with dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated to dryness. The residue was dissolved in toluene (49 mL), and <i>para</i>-toluenesulfonic acid (315 mg, 1.66 mmol) was added. The reaction mixture was refluxed for 18 h before being concentrated under vacuum. The brown residue was dissolved in ethyl acetate, washed with a saturated solution of sodium bicarbonate and brine, dried over sodium sulfate, and concentrated under vacuum to give [2,6]naphthyridine-3-carboxylic acid methyl ester (241 mg, 62%) as a brown solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.49 (s, 1H), 9.43 (s, 1H), 8.87 (d, <i>J</i> = 5.6 Hz, 1H), 8.72 (s, 1H), 7.88 (d, J = 5.6 Hz, 1H), 4.09 (s, 3H).</div></div></div><div id="sec8_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-[1,6]Naphthyridin-3-yl-chromen-4-one Oxime (<b>13</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>11</b>, starting from [1,6]naphthyridine-3-carboxylic acid methyl ester. It was purified by preparative HPLC. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.16 (s, 1H), 9.52 (s, 1H), 9.25–9.15 (m, 1H), 8.70–8.60 (m, 1H), 8.50 (s, 1H), 7.93 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.83 (s, 1H), 7.82–7.72 (m, 1H), 7.65–7.50 (m, 2H), 7.35–7.25 (m, 1H). MS (ESI+): 290.1 [C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div><div id="sec8_1_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> [1,6]Naphthyridine-3-carboxylic Acid Methyl Ester</h5><div class="NLM_p last">Compound was prepared in a manner analogous to [2,6]naphthyridine-3-carboxylic acid methyl ester (43%), starting from 3-diethoxymethyl-pyridine-2-carbaldehyde<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> instead of 4-dimethoxymethyl-pyridine-3-carbaldehyde. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.39 (d, <i>J</i> = 2.4 Hz, 1H), 9.21 (dd, <i>J</i> = 4.3, 1.9 Hz, 1H), 8.81 (s, 1H), 8.41–8.37 (m, 1H), 7.67 (ddd, <i>J</i> = 8.3, 4.1, 2.0 Hz, 1H), 4.09 (s, 3H).</div></div></div><div id="sec8_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime (<b>14</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (43%, overall yield), starting from pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic acid methyl ester.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.97 (s, 1H), 9.22 (s, 1H), 8.05 (s, 1H), 7.88 (dd, <i>J</i> = 7.9, 2.4 Hz, 1H), 7.82 (d, <i>J</i> = 2.4 Hz, 1H), 7.54–7.42 (m, 2H), 7.46 (s, 1H), 7.27 (t, <i>J</i> = 6.8 Hz, 1H), 6.97 (dd, <i>J</i> = 3.7, 2.9 Hz, 1H), 6.74 (d, <i>J</i> = 3.7 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.0, 151.0, 142.1, 139.5, 132.1, 130.5, 130.1, 124.8, 122.2, 118.8, 117.6, 117.0, 114.2, 109.7, 103.4, 93.6 ppm. MS (ESI+): 278.1 [C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 260–263 °C.</div></div><div id="sec8_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Thieno[2,3-<i>c</i>]pyridin-5-yl-chromen-4-one Oxime (<b>15</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (21%, overall yield), starting from thieno[2,3-<i>c</i>]pyridin-5-carboxylic acid methyl ester.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (s, 1H), 9.38 (s, 1H), 8.52 (s, 1H), 8.24 (d, <i>J</i> = 5.3 Hz, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.72 (d, <i>J</i> = 5.3 Hz, 1H), 7.71 (s, 1H), 7.58–7.45 (m, 2H), 7.30 (t, <i>J</i> = 7.4 Hz, 1H). MS (ESI+): 295.0 [C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 243–245 °C.</div></div><div id="sec8_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime (<b>16</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (43%, overall yield), starting from thieno[3,2-<i>c</i>]pyridin-6-carboxylic acid methyl ester.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.05 (s, 1H), 9.25 (s, 1H), 8.76 (s, 1H), 8.03 (d, <i>J</i> = 5.3 Hz, 1H), 7.91 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.72 (d, <i>J</i> = 5.3 Hz, 1H), 7.71 (s, 1H), 7.58–7.46 (m, 2H), 7.30 (t, <i>J</i> = 7.5 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.4, 148.8, 145.2, 143.5, 140.5, 139.9, 134.2, 129.0, 128.3, 122.7, 120.6, 120.0, 116.6, 115.5, 111.9, 92.6 ppm. MS (ESI+): 295.0 [C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 272–275 °C.</div></div><div id="sec8_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-Pyrrolo[1,2-<i>a</i>]pyrazin-3-yl-chromen-4-one Oxime (<b>17</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>11</b> (41% overall yield), starting from pyrrolo[1,2-<i>a</i>]pyrazine-3-carboxylic acid methyl ester. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.96 (s, 1H), 8.97 (s, 1H), 8.93 (s, 1H), 7.92 (s, 1H), 7.90 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.53 (td, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.48 (s, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (t, <i>J</i> = 7.5 Hz, 1H), 7.00 (dd, <i>J</i> = 3.9, 2.4 Hz, 1H), 6.96 (d, <i>J</i> = 3.9 Hz, 1H). MS (ESI+): 278.0 [C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 276–277 °C.</div><div id="sec8_1_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Pyrrolo[1,2-<i>a</i>]pyrazine-3-carboxylic Acid Methyl Ester</h5><div class="NLM_p last">Compound was prepared as follows: a suspension of methyl 2-{bis[(<i>tert</i>-butoxy)carbonyl]amino}prop-2-enoate<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (1.65 g, 4.5 mmol), potassium carbonate (3.7 g, 27.0 mmol), and pyrrole-2-formyl (428 mg, 4.5 mmol) in dry acetonitrile (45 mL) was stirred at room temperature for 16 h. The reaction mixture was filtered off, and the filtrate was concentrated under vacuum to give 1.8 g of a pale-yellow oil. The crude oil (500 mg, 1.26 mmol) was dissolved in TFA (4 mL), and the reaction mixture was stirred at room temperature for 1 h. The solution was poured onto ice–water, neutralized with sodium bicarbonate, and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. The residue was purified by column chromatography on silica gel (using 0–100% ethyl acetate in cyclohexane as eluent) to give 3,4-dihydro-pyrrolo[1,2-<i>a</i>]pyrazine-3-carboxylic acid methyl ester (169 mg, 75%) as an orange oil. The crude oil was dissolved in dichloromethane (5 mL), and manganese dioxide (800 mg, 9.2 mmol) was added in one portion. The reaction mixture was stirred at 40 °C for 1 h, filtered off, and the filtrate concentrated to dryness to give pyrrolo[1,2-<i>a</i>]pyrazine-3-carboxylic acid methyl ester (130 mg, 80%) as yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H), 8.76 (s, 1H), 7.55 (d, <i>J</i> = 2.4 Hz, 1H), 7.00 (dd, <i>J</i> = 4.0, 2.4 Hz, 1H), 6.89 (d, <i>J</i> = 4.0 Hz, 1H), 3.97 (s, 3H).</div></div></div><div id="sec8_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(1-Methyl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one Oxime (<b>18</b>)</h4><div class="NLM_p last">At 0 °C, sodium hydride (60% in mineral oil, 10 mg, 0.25 mmol) was slowly added to a solution of 2-(1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>19a</b>, 77 mg, 0.23 mmol) in dimethylformamide (5 mL), and the reaction mixture was stirred at room temperature for 1 h. At 0 °C, iodomethane (16 μL, 0.25 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 1 h before being poured into brine and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness to give crude 2-(1-methyl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime <b>18a</b> as a brown solid. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>11</b>, and purification by preparative HPLC afforded 2-(1-methyl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one oxime (<b>18</b>, 17 mg, 23%, 2 steps) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.00 (bs, 1H), 9.05 (s, 1H), 8.39 (s, 1H), 7.91 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.83 (s, 1H), 7.61 (s, 1H), 7.54 (ddd, <i>J</i> = 8.3, 6.9, 1.5 Hz, 1H), 7.49 (dd, <i>J</i> = 8.3, 1.3 Hz, 1H), 7.30 (ddd, <i>J</i> = 7.8, 6.9, 1.3 Hz, 1H), 6.76 (d, <i>J</i> = 2.6 Hz, 1H), 4.02 (s, 3H). MS (ESI+): 292.1 [C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 270–275 °C.</div></div><div id="sec8_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-(1<i>H</i>-Pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one Oxime (<b>19</b>)</h4><div class="NLM_p">Under argon, a solution of 2-hydroxyacetophenone (1.68 g, 12.4 mmol) in tetrahydrofuran (120 mL) was cooled to −78 °C and a 1 M solution of lithium hexamethyldisilazane in THF (2.25 mL, 2.25 mmol) was added dropwise. The reaction mixture was stirred at −78 °C for 1 h and at −10 °C for 2 h, then cooled again at −78 °C, before addition of a solution of 4-methyl-5-nitro-pyridine-2-carboxylic acid methyl ester<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (2.42 g, 12.4 mmol) in THF (60 mL). The resulting dark-red solution was stirred at −78 °C for 1 h then allowed to reach room temperature for 18 h. The reaction mixture was poured into an ice-cold 1 N solution of hydrochloric acid (200 mL) and extracted twice with ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated to dryness. The residue was dissolved in acetic acid (60 mL), treated with sulfuric acid (0.33 mL), and heated at 100 °C for 30 min. After cooling to room temperature, the mixture was concentrated under vacuum and the residue was neutralized with an aqueous solution of sodium bicarbonate. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum to give 2-(4-methyl-5-nitro-pyridin-2-yl)-chromen-4-one (2.33 g, 66%) as a brown solid. A mixture of the previous chromen-4-one (770 mg, 2.72 mmol) and <i>tert</i>-butyl-hydroxylamine hydrochloride (685 mg, 5.45 mmol) in methanol (20 mL) was subjected to microwave iradiation at 130 °C for 30 min. Methanol was removed under vacuum, and the crude solid was purified by column chromatography on silica gel (using a gradient of 0–20% dichloromethane in cyclohexane as eluent) to give 2-(4-methyl-5-nitro-pyridin-2-yl)-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (394 mg, 41%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.08 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 7.89 (s, 1H), 7.78 (s, 1H), 7.42 (td, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.32–7.19 (m, 2H), 2.76 (s, 3H), 1.42 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 354.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a suspension of 2-(4-methyl-5-nitro-pyridin-2-yl)-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (250 mg, 0.70 mmol) in dimethylformamide (6 mL) was added dimethylformamide-dimethylacetal (127 μL, 0.95 mmol), and the reaction mixture was stirred at 90 °C for 2.5 h. DMF was removed under vacuum, and the residue was dissolved in absolute ethanol. Then 10% palladium on charcoal (50 mg) was added, and the suspension was stirred under 1 atm of hydrogen at room temperature for 16 h. The catalyst was removed by filtration, and the filtrate was purified by column chromatography on silica gel (using a gradient of 0–20% ethyl acetate in cyclohexane as eluent) to give 2-(1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>19a</b>, 165 mg, 70%) as a yellow solid. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>11</b>, and purification by preparative HPLC afforded 2-(1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-5-yl)-chromen-4-one oxime (<b>19</b>, 39 mg, 70%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (bs, 1H), 10.80 (s, 1H), 8.84 (s, 1H), 8.25 (s, 1H), 7.89 (dd, <i>J</i> = 6.9, 1.5 Hz, 1H), 7.68 (dd, <i>J</i> = 2.5, 1.5 Hz, 1H), 7.57 (bs, 1H), 7.53–7.47 (m, 2H), 7.26 (ddd, <i>J</i> = 7.8, 6.9, 1.3 Hz, 1H), 6.67 (s, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.0, 151.2, 142.4, 138.4, 134.7, 133.3, 132.2, 130.4, 130.3, 124.7, 122.2, 119.0, 117.7, 111.9, 101.9, 93.0 ppm. MS (ESI+): 278.1 [C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 270–275 °C.</div></div><div id="sec8_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-Imidazo[1,2-<i>a</i>]pyridin-7-yl-chromen-4-one Oxime (<b>20</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (10%, overall yield), starting from imidazo[1,2-<i>a</i>]pyridine-7-carboxylic acid ethyl ester.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.09 (s, 1H), 8.61 (d, <i>J</i> = 7.3 Hz, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.87 (d, <i>J</i> = 7.8 Hz, 1H), 7.69 (s, 1H), 7.51–7.49 (m, 2H), 7.41 (dd, <i>J</i> = 7.3, 1.8 Hz, 1H), 7.29–7.24 (m, 1H), 7.21 (s, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.6, 149.1, 142.3, 140.0, 133.0, 128.7, 126.0, 125.3, 123.1, 120.3, 116.7, 116.0, 112.4, 111.7, 106.6, 92.5 ppm. MS (ESI+): 278.1 [C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 265–267 °C.</div></div><div id="sec8_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(5,7-Dimethyl-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl)-chromen-4-one Oxime (<b>21</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>11</b> (19% overall yield), starting from 5,7-dimethyl-pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic acid methyl ester. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H), 8.89 (s, 1H), 7.94 (d, <i>J</i> = 1.3 Hz, 1H), 7.88 (d, <i>J</i> = 7.9 Hz, 1H), 7.54–7.45 (m, 2H), 7.41 (s, 1H), 7.26–7.24 (m, 1H), 6.61 (s, 1H), 2.54 (s, 3H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.2, 151.0, 142.3, 136.9, 130.3, 129.3, 126.9, 124.6, 122.2, 122.0, 118.9, 117.7, 117.6, 112.2, 108.2, 92.8, 10.7, 10.0 ppm. MS (ESI+): 306.1 [C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div><div id="sec8_1_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 5,7-Dimethyl-pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic Acid Methyl Ester</h5><div class="NLM_p last">Compound was prepared as follows: a solution of 3,5-dimethylpyrrole-2-carbaldehyde (1.0 g, 8.1 mmol), 1.8-diazabicyclo[5.4.0]undec-7-ene (1.3 mL, 8.9 mmol), and ethyl isocyanoacetate (1.0 mL, 8.9 mmoL) in dioxane (18 mL) was stirred at room temperature for 24 h before being hydrolyzed with cold water, neutralized with acetic acid (5%), and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. The residue was purified by column chromatography on silica gel (using a gradient of 0–100% ethyl acetate in cyclohexane as eluent) to give 5,7-dimethyl-pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic acid methyl ester (522 mg, 29%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.51 (s, 1H), 8.12 (s, 1H), 6.55 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 1H), 2.51 (s, 3H), 2.34 (s, 3H), 1.41 (t, <i>J</i> = 7.1 Hz, 1H).</div></div></div><div id="sec8_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-Isoquinolin-3-yl-chromen-4-one (<b>22</b>)</h4><div class="NLM_p last">To a suspension of sodium hydride (60% in mineral oil, 227 mg, 5.70 mmol) in dry pyridine (4 mL) was added dropwise a solution of methyl isoquinoline-3-carboxylate (390 mg, 2.08 mmol) and 2-hydroxy-acetophenone (257 mg, 1.89 mmol) in dry pyridine (4 mL). The reaction mixture was heated at 90 °C for 15 min before being cooled to room temperature and poured into an ice-cooled 1 N aqueous solution of hydrochloric acid. The product was extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. The residue was dissolved in acetic acid (10 mL), and sulfuric acid (40 μL) was added. The resulting solution was heated at 100 °C for 30 min. The solvents were removed under vacuum, and the crude solid was triturated in water. The solid was collected by filtration, washed with an aqueous solution of sodium bicarbonate, and dried under vacuum to give 2-isoquinolin-3-yl-chromen-4-one (<b>22</b>, 459 mg, 89%) as a beige solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.32 (s, 1H), 8.49 (s, 1H), 8.27 (d, <i>J</i> = 7.2 Hz, 1H), 8.06 (d, <i>J</i> = 7.9 Hz, 1H), 8.01 (d, <i>J</i> = 7.9 Hz, 1H), 7.85–7.63 (m, 4H), 7.59 (s, 1H), 7.44 (t, <i>J</i> = 7.2 Hz, 1H); mp 170–175 °C.</div></div><div id="sec8_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Isoquinolin-3-yl-chromen-4-one <i>O</i>-Methyl-oxime, Mixture of Isomers <i>E</i> and <i>Z</i> (<b>23</b>)</h4><div class="NLM_p last">To a suspension of 2-isoquinolin-3-yl-chromen-4-one (<b>22</b>, 40 mg, 0.14 mmol) in methanol (2 mL) was added methoxylamine hydrochloride (24 mg, 0.29 mmol). The reaction mixture was subjected to microwave irradiation at 130 °C for 30 min. Methanol was removed under vacuum, and the residue was purified by column chromatography on silica gel (using a gradient of 0–20% ethyl acetate in cyclohexane as eluent) to give a 1:3 mixture of <i>Z</i>/<i>E</i> 2-isoquinolin-3-yl-chromen-4-one <i>O</i>-methyl-oxime (28 mg, 66%) as a yellow solid. <sup>1</sup>H NMR of the main isomer (300 MHz, CDCl<sub>3</sub>) δ 9.26 (s, 1H), 8.30 (s, 1H), 8.04 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 8.00 (d, <i>J</i> = 7.9 Hz, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (s, 1H), 7.76–7.71 (m, 1H), 7.67–7.62 (m, 1H), 7.46–7.39 (m, 1H), 7.35 (dd, <i>J</i> = 8.3, 1.2 Hz, 1H), 7.24–7.18 (m, 1H), 4.03 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.7, 152.8, 151.2, 142.7, 142.6, 135.3, 131.5, 131.1, 128.9, 128.6, 127.9, 127.6, 125.2, 122.5, 117.8, 117.7, 117.2, 94.7, 61.7 ppm. MS (ESI+): 303.0 [C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 170–176 °C.</div></div><div id="sec8_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-Isoquinolin-3-yl-3-methyl-chromen-4-one Oxime (<b>24</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (4% overall yield), starting from 2-hydroxypropiophenone instead of 2-hydroxyacetophenone. It was purified by preparative HPLC. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 9.49 (s, 1H), 8.44 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.88 (t, <i>J</i> = 7.2 Hz, 1H), 7.79 (t, <i>J</i> = 7.2 Hz, 1H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (d, <i>J</i> = 8.0 Hz, 1H), 6.98 (t, <i>J</i> = 7.6 Hz, 1H), 2.27 (s, 3H). MS (ESI+): 303.1 [C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-Isoquinolin-3-yl-6-methyl-chromen-4-one Oxime (<b>25</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (21% overall yield), starting from 2-hydroxy-5-methyl-acetophenone instead of 2-hydroxyacetophenone. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (s, 1H), 9.42 (s, 1H), 8.48 (s, 1H), 8.22 (d, <i>J</i> = 8.1 Hz, 1H), 8.15 (d, <i>J</i> = 8.1 Hz, 1H), 7.88 (td, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.78 (td, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 1H), 7.36 (dd, <i>J</i> = 8.8, 1.7 Hz, 1H), 2.37 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.6, 151.5, 148.1, 142.0, 141.0, 134.2, 133.0, 130.3, 130.2, 127.5, 127.4, 126.7, 126.4, 120.9, 117.4, 116.3, 115.6, 93.7, 19.4 ppm. MS (ESI+): 303.4 [C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 260–264 °C.</div></div><div id="sec8_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Isoquinolin-3-yl-6-trifluoromethyl-chromen-4-one Oxime (<b>26</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>11</b> (10% overall yield), starting from 2-hydroxy-5-trifluoromethyl-acetophenone instead of 2-hydroxyacetophenone. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 9.43 (s, 1H), 8.54 (s, 1H), 8.23 (d, <i>J</i> = 7.9 Hz, 1H), 8.15 (m, 2H), 7.94–7.85 (m, 2H), 7.79 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.78 (s, 1H), 7.73 (d, <i>J</i> = 8.7 Hz, 1H). MS (ESI+): 357.1 [C<sub>19</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 245–247 °C.</div><div id="sec8_1_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 2-Hydroxy-5-trifluoromethyl-acetophenone</h5><div class="NLM_p last">Compound was prepared as follows: at −78 °C, to solution of 2-methoxy-5-trifluoromethyl-acetophenone (650 mg, 3.0 mmol) in dry dichloromethane (40 mL) was slowly added a 1 M solution of boron trichloride in dichloromethane (7.5 mL, 7.5 mmol), keeping the internal temperature below −70 °C. The brown–orange solution was slowly warmed up to room temperature within 2 h. At 0 °C, the reaction mixture was hydrolyzed with a 1 N aqueous hydrochloride solution (40 mL) and extracted with dichloromethane. The organic layer was washed with water, dried over sodium sulfate, and concentrated to dryness. The residue was purified by column chromatography on silica gel (using a gradient of 0–10% ethyl acetate in cyclohexane) to give 2-hydroxy-5-trifluoromethyl-acetophenone (467 mg, 77%) as a pale-yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 12.55 (s, 1H), 7.99 (d, <i>J</i> = 2.0 Hz, 1H), 7.70 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 2.69 (s, 3H).</div></div></div><div id="sec8_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-Isoquinolin-3-yl-6-trifluoromethoxy-chromen-4-one Oxime (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (15% overall yield), starting from 2-hydroxy-5-trifluoromethoxy-acetophenone instead of 2-hydroxyacetophenone. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.34 (s, 1H), 9.43 (s, 1H), 8.51 (s, 1H), 8.22 (d, <i>J</i> = 7.9 Hz, 1H),), 8.15 (d, <i>J</i> = 7.9 Hz, 1H), 7.89 (td, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.79 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.78–7.75 (m, 1H), 7.75 (s, 1H), 7.66 (d, <i>J</i> = 9.0 Hz, 1H), 7.57 (dd, <i>J</i> = 9.0, 2.5 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.9, 152.8, 149.5, 144.8, 142.6, 141.4, 135.3, 131.5, 128.8, 128.5, 127.9, 127.5, 123.5, 120.3, 120.0, 120.0 (q, <i>J</i> = 260 Hz, OCF<sub>3</sub>), 117.1, 113.9, 94.7 ppm. MS (ESI+): 373.1 [C<sub>19</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 250–254 °C.</div></div><div id="sec8_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-Bromo-2-isoquinolin-3-yl-chromen-4-one Oxime (<b>28</b>)</h4><div class="NLM_p last">To an ice-cooled solution of 6-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (<b>103</b>, 50 mg, 0.12 mmol) in dichloromethane (3 mL) was cautiously added a 1 M solution of titanium tetrachloride in dichloromethane (0.35 mL, 0.35 mmol). The reaction mixture was stirred at 0 °C for 2 h, then at room temperature for 2 more hours, before being poured onto ice-cold water (50 mL). The mixture was basified using a 6 N aqueous sodium hydroxide solution until pH 10, and the yellow precipitate was collected by filtration. Recrystallization in hot chloroform gave 6-bromo-2-isoquinolin-3-yl-chromen-4-one oxime (<b>28</b>, 37 mg, 85%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.31 (s, 1H), 9.41 (s, 1H), 8.49 (s, 1H), 8.22 (d, <i>J</i> = 7.9 Hz, 1H), 8.13 (d, <i>J</i> = 7.9 Hz, 1H), 7.97 (d, <i>J</i> = 2.4 Hz, 1H), 7.88 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.78 (td, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.75 (s, 1H), 7.72 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 1H). MS (ESI+): 369.3 [C<sub>18</sub>H<sub>11</sub>BrN<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 266–269 °C.</div></div><div id="sec8_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-Isoquinolin-3-yl-6-methoxy-chromen-4-one Oxime (<b>29</b>)</h4><div class="NLM_p last">At 0 °C, to a solution of 6-hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>203</b>, 80 mg, 0.22 mmol) in DMF (2.5 mL) was added sodium hydride (60% in mineral oil, 13 mg, 0.33 mmol), and the reaction mixture was stirred at room temperature for 1 h. At 0 °C, iodomethane (15 μL, 0.24 mmol) was added dropwise. The resulting solution was stirred at room temperature for 20 h before being hydrolyzed and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum. Purification by column chromatography on silica gel (using a gradient of 0–20% ethyl acetate in cyclohexane as eluent) afforded 2-isoquinolin-3-yl-6-methoxy-chromen-4-one oxime <i>O</i>-<i>tert</i>-butyl oxime (59 mg, 67%) as a yellow solid. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>11</b>. Purification by column chromatography on silica gel (using a gradient of 0–10% methanol in dichloromethane as eluent) afforded 2-isoquinolin-3-yl-6-methoxy-chromen-4-one oxime (<b>29</b>, 31 mg, 62%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (s, 1H), 9.41 (s, 1H), 8.47 (s, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.87 (t, <i>J</i> = 7.7 Hz, 1H), 7.77 (t, <i>J</i> = 7.7 Hz, 1H), 7.75 (s, 1H), 7.47 (d, <i>J</i> = 9.0 Hz, 1H), 7.34 (d, <i>J</i> = 3.0 Hz, 1H), 7.15 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 3.81 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.1, 152.7, 152.6, 145.4, 143.7, 142.2, 135.3, 131.4, 128.6, 128.5, 127.9, 127.5, 119.4, 119.0, 118.1, 116.8, 104.2, 94.2, 55.4 ppm. MS (ESI+): 319.0 [C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 250–255 °C.</div></div><div id="sec8_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 7-Bromo-2-isoquinolin-3-yl-chromen-4-one Oxime (<b>30</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>28</b> (37%) starting from 7-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>106</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (s, 1H), 9.42 (s, 1H), 8.52 (s, 1H), 8.22 (d, <i>J</i> = 8.1 Hz, 1H), 8.10 (d, <i>J</i> = 7.9 Hz, 1H), 7.89 (td, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.86–7.75 (m, 3H), 7.74 (s, 1H), 7.49 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H). MS (ESI+): 369.3 [C<sub>18</sub>H<sub>11</sub>BrN<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 279–283 °C.</div></div><div id="sec8_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-Isoquinolin-3-yl-7-methoxy-chromen-4-one Oxime (<b>31</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>29</b> (18%, two steps), starting from 7-hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>206</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85 (s, 1H), 9.42 (s, 1H), 8.48 (s, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 8.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.88 (t, <i>J</i> = 6.9 Hz, 1H), 7.85–7.75 (m, 2H), 7.75 (s, 1H), 7.09 (d, <i>J</i> = 2.9 Hz, 1H), 6.91 (dd, <i>J</i> = 8.8, 2.9 Hz, 1H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.0, 152.8, 152.7, 152.3, 143.1, 142.0, 135.4, 131.4, 128.6, 128.5, 127.9, 127.4, 123.4, 116.7, 113.2, 111.6, 101.3, 95.0, 55.6 ppm. MS (ESI+): 319.0 [C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 246–248 °C.</div></div><div id="sec8_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 8-Chloro-2-isoquinolin-3-yl-chromen-4-one Oxime (<b>32</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>11</b> (12% overall yield), starting from 3-chloro-2-hydroxyacetophenone instead of 2-hydroxyacetophenone. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.34 (s, 1H), 9.44 (s, 1H), 8.38 (s, 1H), 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 8.17 (d, <i>J</i> = 8.1 Hz, 1H), 7.89 (t, <i>J</i> = 7.4 Hz, 1H), 7.87 (d, <i>J</i> = 7.0 Hz, 1H), 7.79 (t, <i>J</i> = 7.4 Hz, 1H), 7.79 (s, 1H), 7.71 (d, <i>J</i> = 7.9 Hz, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.0, 152.2, 146.6, 142.7, 141.6, 135.2, 131.5, 130.6, 128.8, 128.5, 127.9, 127.6, 125.4, 121.7, 121.1, 120.7, 116.8, 95.3 ppm. MS (ESI+): 323.1 [C<sub>18</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 270–272 °C.</div></div><div id="sec8_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-Cyclopropyl-2-isoquinolin-3-yl-chromen-4-one Oxime (<b>33</b>)</h4><div class="NLM_p">A solution of 6-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (<b>103</b>, 100 mg, 0.24 mmol), palladium acetate (3 mg, 0.014 mmol), potassium phosphate (175 mg, 0.83 mmol), dicyclohexylbiphenylphosphine (8 mg, 0.024 mmol), and cyclopropylboronic acid pinacol ester (99 mg, 0.59 mmol) in toluene (3 mL) was degassed with argon for 10 min. The reactor was sealed and the reaction mixture was heated at 120 °C for 18 h before being poured onto a saturated aqueous solution of ammonium chloride and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum. The crude solid was purified by column chromatography on silica gel (using a gradient of 0–80% dichloromethane in cyclohexane as eluent) to give 6-cyclopropyl-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (18 mg, 20%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 385.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>28</b> (60%), and the title product was purified by preparative HPLC. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.48 (s, 1H), 9.38 (s, 1H), 8.36 (s, 1H), 8.19 (d, <i>J</i> = 8.1 Hz, 1H), 8.12 (d, <i>J</i> = 8.1 Hz, 1H), 7.90–7.65 (m, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 7.08 (s, 1H), 2.02–1.98 (m, 1H), 1.00–0.96 (m, 2H), 0.69–0.65 (m, 2H). MS (ESI+): 329.2 [C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Isoquinolin-3-yl-6-(2-methoxy-ethoxy)-chromen-4-one Oxime (<b>34</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>29</b> (67%, two steps), starting from 6-hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>203</b>) and 2-bromoethylmethyl ether instead of iodomethane. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (s, 1H), 9.41 (s, 1H), 8.47 (s, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.87 (t, <i>J</i> = 7.7 Hz, 1H), 7.77 (t, <i>J</i> = 7.9 Hz, 1H), 7.73 (s, 1H), 7.46 (d, <i>J</i> = 8.9 Hz, 1H), 7.34 (d, <i>J</i> = 3.0 Hz, 1H), 7.16 (dd, <i>J</i> = 8.9, 3.0 Hz, 1H), 4.16–4.12 (m, 2H), 3.41–3.37 (m, 2H) 3.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.3, 152.8, 152.7, 145.5, 143.2, 142.2, 135.3, 131.4, 128.6, 128.5, 127.9, 127.5, 119.4, 119.0, 118.6, 116.8, 104.9, 94.2, 70.3, 67.4, 58.2 ppm. MS (ESI+): 363.2 [C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 198–204 °C.</div></div><div id="sec8_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-Isoquinolin-3-yl-6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-chromen-4-one Oxime (<b>35</b>)</h4><div class="NLM_p last">At 0 °C, to a mixture of 6-hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>203</b>, 110 mg, 0.33 mmol), 1-(2-hydroxyethyl)-4-methylpiperazine (50 mg, 0.34 mmol), and triphenylphosphine (130 mg, 0.49 mmol) in THF (3 mL) was added dropwise a 40% solution of diethyl azodicarboxylate in toluene (225 μL, 0.49 mmol). The reaction mixture was stirred at room temperature for 3 days before being poured onto a 1 N aqueous solution of HCl. The aqueous phase was washed twice with dichloromethane, neutralized by addition of a 6 N solution of NaOH, and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum to give 2-isoquinolin-3-yl-6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (51 mg, 31%) as a yellow solid. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>11</b>. Purification by column chromatography on silica gel (using a gradient of 0–10% methanol in dichloromethane as eluent) afforded 2-isoquinolin-3-yl-6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-chromen-4-one oxime (<b>35</b>, 21 mg, 53%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.03 (s, 1H), 9.41 (s, 1H), 8.47 (s, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.87 (t, <i>J</i> = 7.5 Hz, 1H), 7.77 (t, <i>J</i> = 7.5 Hz, 1H), 7.73 (s, 1H), 7.46 (d, <i>J</i> = 9.2 Hz, 1H), 7.33 (d, <i>J</i> = 2.5 Hz, 1H), 7.15 (dd, <i>J</i> = 9.2, 2.5 Hz, 1H), 4.11 (t, <i>J</i> = 5.6 Hz, 2H), 2.70 (t, <i>J</i> = 5.6 Hz, 2H), 2.60–2.40 (m, 4H), 2.40–2.20 (m, 4H), 2.14 (s, 3H). MS (ESI+): 431.3 [C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 233–236 °C.</div></div><div id="sec8_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-Isoquinolin-3-yl-6-[3-(4-methyl-piperazin-1-yl)-propylamino]-chromen-4-one Oxime (<b>36</b>)</h4><div class="NLM_p last">Under inert atmosphere, a mixture of 6-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>103</b>, 150 mg, 0.35 mmol), 3-(4-methylpiperazin-1-yl)propylamine (83 mg, 0.53 mmol), potassium <i>tert</i>-butoxide (59 mg, 0.53 mmol), and [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride (5 mg, 0.01 mmol) in 1,2-dimethoxyethane (2 mL) was heated at 110 °C for 3 days. The solvent was removed under vacuum, and the crude mixture was purified by column chromatography on silica gel (using a gradient of 5–20% methanol in dichloromethane as eluent) to give 2-isoquinolin-3-yl-6-[3-(4-methyl-piperazin-1-yl)-propylamino]-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (159 mg, 90%) as a yellow solid. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>11</b>. Purification by column chromatography on silica gel (using a gradient of 20–30% methanol in dichloromethane and 5% ammonium hydroxide as eluent) afforded 2-isoquinolin-3-yl-6-[3-(4-methyl-piperazin-1-yl)-propylamino]-chromen-4-one oxime (<b>36</b>, 100 mg, 75%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 9.40 (s, 1H), 8.43 (s, 1H), 8.20 (d, <i>J</i> = 8.1 Hz, 1H), 8.13 (d, <i>J</i> = 8.1 Hz, 1H), 7.85 (t, <i>J</i> = 7.3 Hz, 1H), 7.76 (t, <i>J</i> = 7.3 Hz, 1H), 7.69 (s, 1H), 7.28 (d, <i>J</i> = 8.9 Hz, 1H), 6.94 (d, <i>J</i> = 3.0 Hz, 1H), 6.82 (dd, <i>J</i> = 8.9, 3.0 Hz, 1H), 5.88 (m, 1H), 3.04 (m, 2H) 2.45–2.20 (m, 10H), 2.14 (s, 3H), 1.70 (m, 2H). MS (ESI+): 444.5 [C<sub>26</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 208–211 °C.</div></div><div id="sec8_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-Isoquinolin-3-yl-7-(2-methoxy-ethoxy)-chromen-4-one Oxime (<b>37</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>29</b> (22%, two steps), starting from 7-hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>206</b>) and 2-bromoethylmethyl ether instead of iodomethane. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.84 (s, 1H), 9.42 (s, 1H), 8.50 (s, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.89 (t, <i>J</i> = 7.0 Hz, 1H), 7.85–7.75 (m, 2H), 7.75 (s, 1H), 7.11 (d, <i>J</i> = 2.9 Hz, 1H), 6.91 (dd, <i>J</i> = 8.8, 2.9 Hz, 1H), 4.24–4.20 (m, 2H), 3.74–3.70 (m, 2H), 3.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.3, 152.8, 152.6, 152.2, 143.1, 142.0, 135.3, 131.5, 128.6, 128.5, 127.9, 127.4, 123.4, 116.7, 113.6, 111.7, 101.8, 95.0, 70.2, 67.4, 58.2 ppm. MS (ESI+): 363.2 [C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 223–225 °C.</div></div><div id="sec8_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Isoquinolin-3-yl-7-phenethyl-chromen-4-one Oxime (<b>38</b>)</h4><div class="NLM_p last">Under inert atmosphere, a mixture of 7-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>106</b>, 100 mg, 0.24 mmol), phenylacetylene (31 μL, 0.28 mmol), triethylamine (49 μL, 0.35 mmol), copper iodide (9 mg, 0.05 mmol), and bis(triphenylphosphine)palladium(II) dichloride (17 mg, 0.02 mmol) in DMF (5 mL) was heated at 90 °C for 18 h. The reaction mixture was cooled, neutralized with a 0.5N aqueous solution of HCl, and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. Purification by column chromatography on silica gel (using a gradient of 20–60% dichloromethane in cyclohexane) afforded the phenylethynyl intermediate (62 mg, 59%) as a beige solid. LCMS, <i>m</i>/<i>z</i> = 445.0 [M + H]<sup>+</sup>. The solid was dissolved in methanol (2 mL) and THF (9 mL), and the solution was degassed with argon. Lindlar’s catalyst (22 mg) was added, and the suspension was placed under 1 atm of hydrogen. The reaction mixture was stirred at room temperature for 5 h before being filtered off. The filtrate was concentrated under vacuum to give the crude phenethyl product (61% purity) as a greenish oil. LCMS, <i>m</i>/<i>z</i> = 449.0 [M + H]<sup>+</sup>. <i>tert</i>-Butyl removal was perfomed in a manner analogous to <b>11</b>, and purification by preparative HPLC afforded 2-isoquinolin-3-yl-7-phenethyl-chromen-4-one oxime (<b>38</b>, 13 mg, 14% overall yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (s, 1H), 9.50 (s, 1H), 8.56 (s, 1H), 8.30 (d, <i>J</i> = 8.0 Hz, 1H), 8.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.97 (t, <i>J</i> = 7.2 Hz, 1H), 7.90–7.80 (m, 3H), 7.49 (s, 1H), 7.40–7.35 (m, 4H), 7.35–7.20 (m, 2H), 3.06 (s, 4H). MS (ESI+): 393.1 [C<sub>26</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>).</div></div><div id="sec8_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 6-(2-Methoxy-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one oxime (<b>39</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>29</b> (45%, two steps), starting from 6-hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>204</b>) and 2-bromoethylmethyl ether instead of iodomethane. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.93 (s, 1H), 9.21 (s, 1H), 8.03 (s, 1H), 7.81 (d, <i>J</i> = 2.8 Hz, 1H), 7.43 (s, 1H), 7.40 (d, <i>J</i> = 9.0 Hz, 1H), 7.30 (d, <i>J</i> = 3.0 Hz, 1H), 7.13 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.98 (dd, <i>J</i> = 3.8, 2.8 Hz, 1H), 6.73 (d, <i>J</i> = 3.8 Hz, 1H), 4.16–4.11 (m, 2H), 3.69–3.64 (m, 2H), 3.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.2, 152.1, 145.3, 142.2, 139.5, 132.2, 130.2, 119.3, 118.9, 118.5, 116.9, 114.2, 109.6, 104.9, 103.3, 92.9, 70.3, 67.3, 58.2 ppm. MS (ESI+): 352.1 [C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 212–215 °C.</div></div><div id="sec8_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 6-(2-Morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one oxime Hydrochloride (<b>40</b>)</h4><div class="NLM_p">A mixture of 6-hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>204</b>, 100 mg, 0.29 mmol), 4-(2-chloroethyl)morpholine hydrochloride (80 mg, 0.43 mmol), and potassium carbonate (119 mg, 0.86 mmol) in dry acetone (2.5 mL) was heated at 60 °C for 20 h. Acetone was removed under vacuum, and the crude residue was treated with water and extracted twice with ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated under vacuum. Purification by column chromatography on silica gel (using a gradient of 20–100% ethyl acetate in cyclohexane as eluent) afforded 6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (89 mg, 67%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 463.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">At 0 °C, to a stirred solution of 6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2,-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (80 mg, 0.17 mmol) in dichloromethane (1.0 mL) was added a 1 M solution of titanium tetrachloride in dichloromethane (0.5 mL, 0.52 mmol). The reaction mixture was stirred at 0 °C for 2 h then at room temperature for 24 h before being neutralized to pH = 10 by addition of a 6N aqueous solution of NaOH. The resulting yellow precipitate was collected by filtration, washed with water, and dried under vacuum before being treated with a 1.2 N solution of HCl in methanol. Concentration to dryness and trituration in diethyl ether gave 6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one oxime hydrochloride (<b>40</b>, 38 mg, 51%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.99 (bs, 1H), 10.67 (bs, 1H), 9.22 (s, 1H), 8.05 (s, 1H), 7.82 (d, <i>J</i> = 2.8 Hz, 1H), 7.46 (d, <i>J</i> = 9.0 Hz, 1H), 7.44 (s, 1H), 7.39 (d, <i>J</i> = 3.0 Hz, 1H), 7.20 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.98 (dd, <i>J</i> = 3.6, 2.8 Hz, 1H), 6.74 (d, <i>J</i> = 3.6 Hz, 1H), 4.46–4.43 (m, 2H), 3.99–3.96 (m, 2H), 3.90–3.70 (m, 2H), 3.65–3.45 (m, 4H), 3.30–3.12 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.2, 152.1, 145.3, 142.2, 139.5, 132.7, 130.2, 119.3, 118.8, 118.5, 117.0, 114.2, 109.6, 105.1, 103.3, 92.9, 66.2 (2C), 65.8, 56.9, 53.6 (2C) ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub> [(M + H)<sup>+</sup>] 406.1641, found 406.1639; mp >270 °C.</div></div><div id="sec8_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 6-[2-(4,4-Difluoro-piperidin-1-yl)-ethoxy]-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime Hydrochloride (<b>41</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>42</b> (48%, two steps), using 4,4-difluoropiperidine instead of pyrrolidine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.27 (bs, 1H), 10.99 (bs, 1H), 9.23 (s, 1H), 8.06 (s, 1H), 7.82 (d, <i>J</i> = 2.8 Hz, 1H), 7.47 (d, <i>J</i> = 9.0 Hz, 1H), 7.45 (s, 1H), 7.41 (d, <i>J</i> = 3.0 Hz, 1H), 7.22 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.99 (dd, <i>J</i> = 3.7, 2.8 Hz, 1H), 6.74 (d, <i>J</i> = 3.7 Hz, 1H), 4.52–4.47 (m, 2H), 3.90–3.70 (m, 2H), 3.66–3.62 (m, 2H), 3.29–3.33 (m, 2H), 2.60–2.30 (m, 4H). MS (ESI+): 441.1 [C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 6-(2-Pyrrolydin-1-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime Hydrochloride (<b>42</b>)</h4><div class="NLM_p">A suspension of 6-hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>204</b>, 140 mg, 0.40 mmol), potassium carbonate (277 mg, 2.0 mmol), and 1,2-dichloroethane (1.0 mL, 12.6 mmol) in dry DMF (6.5 mL) was subjected to microwave irradiation at 130 °C for 90 min. The reaction mixture was poured onto a saturated aqueous solution of ammonium chloride and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. Purification by column chromatography on silica gel (using a gradient of 0–20% ethyl acetate in cyclohexane as eluent) gave 6-(2-chloro-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (48 mg, 29%) as a yellow solid. This reaction was realized twice and the products were combined. LCMS, <i>m</i>/<i>z</i> = 412.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">A mixture of 6-(2-chloro-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (64 mg, 0.16 mmol), potassium carbonate (64 mg, 0.46 mmol), and pyrrolidine (19 μL, 0.24 mmol) in acetonitrile (1.5 mL) was heated in a sealed reactor at 100 °C for 18 h. The reaction mixture was cooled to room temperature, and the precipitate was filtered off and washed with ethyl acetate. The filtrate was concentrated to dryness and purified by column chromatography on silica gel (using a gradient of 0–2% methanol in ethyl acetate as eluent) to give 6-(2-pyrrolydin-1-yl-ethoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (49 mg, 71%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 447.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>40</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.94 (bs, 1H), 10.16 (bs, 1H), 9.22 (s, 1H), 8.04 (s, 1H), 7.82 (d, <i>J</i> = 2.8 Hz, 1H), 7.46 (d, <i>J</i> = 9.0 Hz, 1H), 7.44 (s, 1H), 7.38 (d, <i>J</i> = 3.0 Hz, 1H), 7.20 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.99 (dd, <i>J</i> = 3.6, 2.8 Hz, 1H), 6.74 (d, <i>J</i> = 3.6 Hz, 1H), 4.40–4.25 (m, 2H), 3.45–3.69 (m, 4H), 3.11–3.22 (m, 2H), 2.00–2.08 (m, 2H), 1.88–1.95 (m, 2H). MS (ESI+): 391.2 [C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >260 °C.</div></div><div id="sec8_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 6-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime Dihydrochloride (<b>43</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>42</b> (26%, two steps), using 4-methylpiperazine instead of pyrrolidine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (bs, 1H), 10.98 (bs, 1H), 9.22 (s, 1H), 8.05 (s, 1H), 7.82 (d, <i>J</i> = 2.8 Hz, 1H), 7.46 (d, <i>J</i> = 9.0 Hz, 1H), 7.45 (s, 1H), 7.39 (d, <i>J</i> = 3.0 Hz, 1H), 7.21 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.99 (dd, <i>J</i> = 3.7, 2.8 Hz, 1H), 6.74 (d, <i>J</i> = 3.7 Hz, 1H), 4.46–4.42 (m, 2H), 4.00–3.20 (m, 10H), 2.84 (s, 3H). MS (ESI+): 420.2 [C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >230 °C.</div></div><div id="sec8_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 6-[2-(4-Dimethylaminopiperidin-1-yl)-ethoxy]-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime Dihydrochloride (<b>44</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>42</b> (14%, two steps), using 4-dimethylaminopiperidine instead of pyrrolidine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (s, 1H), 7.99 (s, 1H), 7.73 (m, 1H), 7.42 (m, 3H), 7.41 (s, 1H), 7.17 (m, 1H), 6.95 (s, 1H), 6.71 (m, 1H), 4.36 (m, 2H), 3.70 (m, 2H), 3.53 (m, 2H), 3.16 (m, 2H), 2.78 (s, 6H), 2.50 (m, 1H), 2.28 (m, 2H), 2.03 (m, 2H). Two exchangeable protons were not observed. MS (ESI+): 448.3 [C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >255 °C.</div></div><div id="sec8_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 6-(1-Acetyl-piperidin-4-yloxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime (<b>45</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>58</b> (22%, four steps), starting from 6-iodo-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>105</b>) and using 1-boc-4-hydroxypiperidine instead of 1-boc-3-hydroxyazetidine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (bs, 1H), 9.22 (s, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.43–7.37 (m, 3H), 7.17 (dd, <i>J</i> = 9.0, 2.9 Hz, 1H), 6.99–6.98 (m, 1H), 6.75–6.73 (m, 1H), 4.66–4.57 (m, 1H), 3.89–3.81 (m, 1H), 3.72–3.64 (m, 1H), 3.39–3.30 (m, 1H), 3.28–3.19 (m, 1H), 2.02 (s, 3H), 1.99–1.86 (m, 2H), 1.71–1.59 (m, 1H), 1.57–1.48 (m, 1H). MS (ESI+): 419.1 [C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3-(4-Hydroxyimino-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-4<i>H</i>-chromen-6-yloxy)-azetidine-1-carboxylic Acid Dimethylamide (<b>46</b>)</h4><div class="NLM_p">6-(1-Boc-azetidin-3-yloxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime was prepared in a manner analogous to <b>58</b> (first step, 40%), starting from 6-iodo-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime <b>105</b>. LCMS, <i>m</i>/<i>z</i> = 505.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">To a solution of 6-(1-boc-azetidin-3-yloxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (235 mg, 0.47 mmol) in dichloromethane (23 mL) was added trifluoroacetic acid (0.5 mL), and the reaction mixture was stirred at room temperature for 30 min. The reddish solution was carefully neutralized by addition of a saturated aqueous solution of potassium carbonate at 0 °C and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness to give 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (195 mg, quant) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 405.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>58</b> (84%, 2 steps), starting from 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime and using dimethylcarbamyl chloride instead of acetyl chloride. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.93 (s, 1H), 9.09 (s, 1H), 7.92 (s, 1H), 7.69 (d, <i>J</i> = 2.5 Hz, 1H), 7.32–7.30 (m, 2H), 7.04 (d, <i>J</i> = 3.0 Hz, 1H), 6.98 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 6.85 (dd, <i>J</i> = 3.7, 2.5 Hz, 1H), 6.61 (d, <i>J</i> = 3.7 Hz, 1H), 4.90 (m, 1H), 4.18 (dd, <i>J</i> = 9.1, 6.5 Hz, 2H), 3.76 (dd, <i>J</i> = 9.1, 3.8 Hz, 2H), 2.60 (s, 6H). MS (ESI+): 420.3 [C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(3-Pyridin-3-yl-propoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime (<b>47</b>)</h4><div class="NLM_p">A mixture of 6-hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>204</b>, 300 mg, 0.86 mmol), 3-(3-chloropropyl)-pyridine hydrochloride<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (422 mg, 1.89 mmol), and potassium carbonate (475 mg, 3.43 mmol) in dry acetonitrile (8.5 mL) was heated at 85 °C for 3 days. Acetonitrile was removed under vacuum, and the crude residue was treated with water and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum. Purification by column chromatography on silica gel (using a gradient of 0–50% ethyl acetate in cyclohexane as eluent) afforded 6-(3-pyridin-3-yl-propoxy)-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (320 mg, 80%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 469.4 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>60</b>. The title compound was purified by preparative HPLC and isolated as a free base after neutralization of the collected tubes with potassium carbonate and collection by filtration (9%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.95 (bs, 1H), 9.22 (s, 1H), 8.87 (s, 1H), 8.78 (d, <i>J</i> = 5.6 Hz, 1H), 8.50 (d, <i>J</i> = 7.8 Hz, 1H), 8.04 (s, 1H), 7.99 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 7.82 (d, <i>J</i> = 2.5 Hz, 1H), 7.44 (s, 1H), 7.41 (d, <i>J</i> = 9.1 Hz, 1H), 7.30 (d, <i>J</i> = 3.0 Hz, 1H), 7.08 (dd, <i>J</i> = 9.1, 3.0 Hz, 1H), 6.98 (dd, <i>J</i> = 3.5, 2.5 Hz, 1H), 6.74 (d, <i>J</i> = 3.5 Hz, 1H), 4.06 (t, <i>J</i> = 6.1 Hz, 2H), 3.00 (t, <i>J</i> = 7.5 Hz, 2H), 2.19–2.12 (m, 2H). MS (ESI+): 413.3 [C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 6-[3-(2-Methyl-pyridin-4-yl)-propoxy]-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one Oxime, Hydrochloride (<b>48</b>)</h4><div class="NLM_p">At 0 °C, to a solution of 3-(2-methyl-pyridin-4-yl)-propan-1-ol (230 mg, 1.52 mmol) in dichloromethane (7.6 mL) and triethylamine (0.25 mL, 1.82 mmol), methanesulfonyl chloride (118 μL, 1.52 mmol) was slowly added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane, washed with a saturated aqueous solution of potassium carbonate and brine, and then dried over sodium sulfate and concentrated under vacuum. The crude methanesulfonic acid 3-(2-methyl-pyridin-4-yl)-propyl ester (350 mg) was directly engaged in the next step. LCMS, <i>m</i>/<i>z</i> = not detected.</div><div class="NLM_p">To a solution of 6-hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>204</b>, 150 mg, 0.43 mmol) in acetonitrile (9.0 mL) were added potassium carbonate (180 mg, 1.28 mmol) and methanesulfonic acid 3-(2-methyl-pyridin-4-yl)-propyl ester (147 mg, 0.64 mmol). The reaction mixture was stirred at 100 °C overnight before being cooled to room temperature, neutralized with water, and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum. The crude yellow solid was purified by column chromatography on silica gel (using a gradient of 20–50% ethyl acetate in cyclohexane as eluent) to afford 6-[3-(2-methyl-pyridin-4-yl)-propoxy]-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (100 mg, 32%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 483.3 [M + H]<sup>+</sup>.</div><div class="NLM_p"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>60</b>. The title compound was purified by preparative HPLC and isolated as a free base after neutralization of the collected tubes with potassium carbonate and collection by filtration (61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.93 (s, 1H), 9.24 (s, 1H), 8.68 (d, <i>J</i> = 6.2 Hz, 1H), 8.07 (s, 1H), 7.88 (s, 1H), 7.84–7.81 (m, 2H), 7.46 (s, 1H), 7.44 (d, <i>J</i> = 9.1 Hz, 1H), 7.36 (d, <i>J</i> = 3.0 Hz, 1H), 7.12 (dd, <i>J</i> = 9.1, 3.0 Hz, 1H), 7.00 (dd, <i>J</i> = 3.8, 2.8 Hz, 1H), 6.76 (d, <i>J</i> = 3.8 Hz, 1H), 4.08 (t, <i>J</i> = 6.2 Hz, 2H), 3.04 (t, <i>J</i> = 7.2 Hz, 2H), 2.72 (s, 3H), 2.21–2.14 (m, 2H). One exchangeable proton was not observed. MS (ESI+): 427.3 [C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div><div id="sec8_1_48_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 3-(2-Methyl-pyridin-4-yl)-propan-1-ol</h5><div class="NLM_p last">Compound was prepared as follows: To a solution of 2-methyl-pyridine-4-carbaldehyde (100 mg, 1.03 mmol) in toluene (4.0 mL) was added (carbethoxymethylene)triphenylphosphorane (431 mg, 1.24 mmol), and the reaction mixture was stirred at room temperature overnight. Toluene was removed under vacuum, and petroleum ether (20 mL) was added. The solid was triturated and filtered off. The filtrate was concentrated under vacuum to give 3-(2-methyl-pyridin-4-yl)-acrylic acid ethyl ester as a colorless oil. LCMS, <i>m</i>/<i>z</i> = 192.1 [M + H]<sup>+</sup>. To a solution of crude 3-(2-methyl-pyridin-4-yl)-acrylic acid ethyl ester in absolute ethanol (9.0 mL), sodium borohydride (1.56 g, 41.2 mmol) was slowly added and the suspension was stirred at room temperature for 3 days. The reaction mixture was neutralized by addition of a 1 N aqueous solution of HCl at 0 °C, diluted with water, and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under vacuum to give 3-(2-methyl-pyridin-4-yl)-propan-1-ol (230 mg, 74%) as a pale-yellow oil. LCMS, <i>m</i>/<i>z</i> = 152.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec8_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 6-(2-Morpholin-4-yl-ethoxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>49</b>)</h4><div class="NLM_p">A mixture of 6-hydroxy-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>201</b>, 100 mg, 0.27 mmol), 4-(2-chloroethyl)morpholine hydrochloride (62 mg, 0.41 mmol), and potassium carbonate (113 mg, 0.82 mmol) in dry acetonitrile (5.5 mL) was heated under reflux for 16 h. The reaction mixture was poured into ice–water, and the resulting precipitate was collected by filtration and dried under vacuum to give 6-(2-morpholin-4-yl-ethoxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (108 mg, 82%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 480.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>40</b> (77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.14 (bs, 2H), 9.27 (s, 1H), 8.78 (s, 1H), 8.06 (d, <i>J</i> = 5.4 Hz, 1H), 7.74 (d, <i>J</i> = 5.4 Hz, 1H), 7.70 (s, 1H), 7.52 (d, <i>J</i> = 9.0 Hz, 1H), 7.43 (d, <i>J</i> = 2.9 Hz, 1H), 7.25 (dd, <i>J</i> = 9.0, 2.9 Hz, 1H), 4.52–4.49 (m, 2H), 4.00–3.97 (m, 2H), 3.87–3.81 (m, 2H), 3.60–3.51 (m, 4H), 3.26–3.18 (m, 2H). MS (ESI+): 424.3 [C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >230 °C.</div></div><div id="sec8_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 6-[2-(4,4-Difluoro-piperidin-1-yl)-ethoxy]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>50</b>)</h4><div class="NLM_p">The title compound was prepared in a manner analogous to <b>49</b> (42%, two steps), starting from 6-hydroxy-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>201</b>) and 1-(2-chloroethyl)-4,4-difluoropiperidine hydrochloride instead of 4-(2-chloroethyl)-morpholine hydrochloride. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.36 (bs, 1H), 11.06 (bs, 1H), 9.26 (s, 1H), 8.77 (s, 1H), 8.05 (d, <i>J</i> = 5.4 Hz, 1H), 7.73 (d, <i>J</i> = 5.4 Hz, 1H), 7.69 (s, 1H), 7.49 (d, <i>J</i> = 9.0 Hz, 1H), 7.42 (d, <i>J</i> = 2.9 Hz, 1H), 7.24 (dd, <i>J</i> = 9.0, 2.9 Hz, 1H), 4.51–4.48 (m, 2H), 3.92–3.88 (m, 2H), 3.74–3.69 (m, 2H), 3.65–3.63 (m, 2H), 3.45–3.26 (m, 2H), 2.43–2.33 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.4, 152.6, 147.4, 145.8, 145.7, 142.8, 142.1, 137.4, 136.4, 131.2, 122.9 (t, <i>J</i> = 247 Hz, CF<sub>2</sub>), 119.5, 119.1, 118.6, 114.1, 105.7, 94.0, 62.8, 55.9, 53.9 (2C), 49.2 (2C) ppm. MS (ESI+): 458.3 [C<sub>23</sub>H<sub>21</sub> F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 225–230 °C.</div><div id="sec8_1_50_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 1-(2-Chloroethyl)-4,4-difluoropiperidine Hydrochloride</h5><div class="NLM_p last">Compound was prepared as follows: a suspension of 4,4-difluoropiperidine hydrochloride (1.1 g, 6.98 mmol), 2-bromo-1-ethanol (470 μL, 6.63 mmol), and potassium carbonate (780 mg, 5.65 mmol) in dry acetonitrile (20 mL) was heated at 90 °C for 20 h. After cooling, the suspension was filtered off and the filtrate was concentrated under vacuum. The residue was taken in chloroform, filtered off, and the filtrate concentrated to dryness to give 2-(4,4-difluoro-piperidin-1-yl)-ethanol (1.1 g, 95%) as a yellow oil. The alcohol was dissolved in dry toluene (10 mL) and thionyl chloride (580 μL, 7.25 mmol) was added. The solution was heated at 120 °C for 2 h before being cooled with an ice bath. The resulting precipitate was collected by filtration and washed with diethyl ether. The residue was recrystallized in hot 1-butanol and triturated in diethyl ether to give 1-(2-chloroethyl)-4,4-difluoropiperidine hydrochloride (685 mg, 64%) as colorless crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.25 (bs, 1H), 4.05–4.03 (m, 2H), 3.26–3.16 (m, 2H), 3.73–3.60 (m, 4H), 2.45–2.32 (m, 4H).</div></div></div><div id="sec8_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 6-[3-(4,4-Difluoro-piperidin-1-yl)-propyl]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>51</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>60</b> (39%, two steps), starting from 3-(4-<i>tert</i>-butoxyimino-2-thieno[3,2-<i>c</i>]pyridin-6-yl-4<i>H</i>-chromen-6-yl)-propionaldehyde (<b>301</b>) and 4,4-difluoropiperidine instead of morpholine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.30 (bs, 1H), 11.02 (bs, 1H), 9.25 (s, 1H), 8.75 (s, 1H), 8.04 (d, <i>J</i> = 5.4 Hz, 1H), 7.78–7.68 (m, 3H), 7.44 (s, 2H), 3.66–3.55 (m, 2H), 3.20–3.05 (m, 6H), 2.76–2.66 (m, 2H), 2.38–2.24 (m, 2H), 2.16–2.02 (m, 2H). MS (ESI+): 456.0 [C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>F<sub>2</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 201–206 °C.</div></div><div id="sec8_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 6-[3-(3,3-Difluoro-pyrrolidin-1-yl)-propyl]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>52</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>60</b> (25%, two steps), starting from 3-(4-<i>tert</i>-butoxyimino-2-thieno[3,2-<i>c</i>]pyridin-6-yl-4<i>H</i>-chromen-6-yl)-propionaldehyde (<b>301</b>) and 3,3-difluoropyrrolidine instead of morpholine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.50 (bs, 1H), 11.01 (bs, 1H), 9.26 (s, 1H), 8.76 (s, 1H), 8.05 (d, <i>J</i> = 5.4 Hz, 1H), 7.78–7.70 (m, 3H), 7.48–7.40 (m, 2H), 4.20–4.00 (m, 2H), 3.45–3.30 (m, 2H), 3.30–3.20 (m, 2H), 2.75–2.65 (m, 2H), 2.08–1.90 (m, 2H), 1.55–1.30 (m, 2H). MS (ESI+): 444.2 [C<sub>22</sub>H<sub>19</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 226–229 °C.</div></div><div id="sec8_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>R</i>)-6-(1-Pyrimidin-4-yl-pyrrolidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>53</b>)</h4><div class="NLM_p">(<i>R</i>)-6-(Pyrrolidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime hydrochloride was prepared in a manner analogous to <b>58</b> (99%, two steps), starting from 6-iodo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>102</b>) and using (<i>R</i>)-(−)-<i>N</i>-boc-3-pyrrolidinol instead of 1-boc-3-hydroxyazetidine. LCMS, <i>m</i>/<i>z</i> = 436.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">A mixture of (<i>R</i>)-6-(pyrrolidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime hydrochloride (100 mg, 0.21 mmol), 4-bromopyrimidine hydrochloride (83 mg, 0.42 mmol), and diisopropylethylamine (0.11 mL, 0.64 mmol) in ethanol (1.0 mL) was stirred at room temperature for 16 h. The reaction mixture was concentrated under vacuum, and the crude residue was purified by column chromatography on silica gel (using a gradient of 0–2% of methanol in dichloromethane as eluent) to give (<i>R</i>)-6-(1-pyrimidin-4-yl-pyrrolidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (95 mg, 87%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 514.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>58</b> (39%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.13 (bs, 1H), 9.32 (s, 1H), 8.92 (s, 1H), 8.83 (s, 1H), 8.42 (d, <i>J</i> = 6.9 Hz, 1H), 8.11 (d, <i>J</i> = 5.4 Hz, 1H), 7.79 (d, <i>J</i> = 5.4 Hz, 1H), 7.75 (s, 1 H), 7.56 (d, <i>J</i> = 9.0 Hz, 1H), 7.45 (d, <i>J</i> = 3.0 Hz, 1H), 7.28 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 7.05 (d, <i>J</i> = 6.9 Hz, 1H), 5.39–5.36 (m, 1H), 4.07–4.03 (m, 1H), 3.98–3.93 (m, 2H), 3.76–3.71 (m, 1H), 2.44–2.40 (m, 2H). One exchangeable proton was not observed. MS (ESI+): 458.0 [C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 6-(1-Pyrimidin-4-yl-piperidin-4-ylamino)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>54</b>)</h4><div class="NLM_p">Under inert atmosphere, a mixture of 6-iodo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>102</b>, 500 mg, 1.05 mmol), 1-boc-4-aminopiperidine (420 mg, 2.10 mmol), potassium phosphate (668 mg, 3.15 mmol), copper iodide (40 mg, 0.21 mmol), and ethylene glycol (0.12 mL, 2.10 mmol) in <i>n</i>-butanol (2.5 mL) was heated at 100 °C for 2 days. The reaction mixture was cooled to room temperature, filtered off, and the residue washed with ethyl acetate. The filtrate was washed with water and brine. The organic phase was dried over sodium sulfate, filtered, and concentrated under vacuum. The crude solid was purified by flash column chromatography on silica gel (using 10–30% ethyl acetate in cyclohexane as eluent) to afford 6-(1-boc-piperidin-4-ylamino)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (390 mg, 68%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 549.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>53</b> (76%, three steps) starting from 6-(1-boc-piperidin-4-ylamino)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.12 (bs, 1H), 9.27 (s, 1H), 8.83 (s, 1H), 8.79 (s, 1H), 8.35 (d, <i>J</i> = 7.5 Hz, 1H), 8.07 (d, <i>J</i> = 5.4 Hz, 1H), 7.75 (d, <i>J</i> = 5.4 Hz, 1H), 7.71 (s, 1H), 7.50–7.44 (m, 2H); 7.30–7.18 (m, 2H), 4.96–4.68 (m, 2H), 3.79 (bs, 1H), 3.54–3.35 (m, 2H), 2.19–2.11 (m, 2H), 1.52–1.68 (m, 2H). Two exchangeable protons were not observed. MS (ESI+): 471.0 [C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 6-(1-Pyridin-3-yl-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime (<b>55</b>)</h4><div class="NLM_p">Under inert atmosphere, a mixture of 6-(azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime hydrochloride obtained in example <b>58</b> (100 mg, 0.22 mmol), 3-bromopyridine (31 μL, 0.33 mmol), palladium(II) acetate (5 mg, 0.02 mmol), (±)-2,2′-bis(diphenylphosphino)-1,1′-binaphthalene (27 mg, 0.04 mmol), and sodium <i>tert</i>-butoxide (63 mg, 0.65 mmol) in toluene (3.5 mL) was heated at 120 °C for 2 h. The reaction mixture was poured onto ice–water and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness. The resulting yellow oil was purified by column chromatography on silica gel (using 0–10% methanol in dichloromethane as eluent) to afford 6-[1-(pyridin-4-yl)-azetidin-3-yloxy]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one-<i>O</i>-<i>tert</i>-butyl oxime (70 mg, 60%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 499.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>58</b>. The title compound was purified by preparative HPLC and isolated as a free base after neutralization of the collected tubes with potassium carbonate and extraction with dichloromethane (21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.08 (bs, 1H), 9.23 (s, 1H), 8.74 (s, 1H), 8.02 (d, <i>J</i> = 5.4 Hz, 1H), 7.92–7.88 (m, 2H), 7.72 (d, <i>J</i> = 5.4 Hz, 1H), 7.66 (s, 1H), 7.50 (d, <i>J</i> = 8.9 Hz, 1H), 7.21 (d, <i>J</i> = 2.9 Hz, 1H), 7.19–7.11 (m, 2H), 6.94–6.87 (m, 1H), 5.31–5.29 (m, 1H), 4.34 (dd, <i>J</i> = 6.5, 8.6 Hz, 2H), 3.89 (dd, <i>J</i> = 3.8, 8.6 Hz, 2H). MS (ESI+): 443.0 [C<sub>24</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >250 °C.</div></div><div id="sec8_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 6-(2′-Methyl-3,4,5,6-tetrahydro-2<i>H</i>-[1,3′]bipyridinyl-4-ylmethyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime, Hydrochloride (<b>56</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>55</b> (63%), starting from 6-piperidin-4-ylmethyl-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime hydrochloride (<b>401</b>) and using 3-bromo-2-methyl-pyridine instead of 3-bromopyridine. <i>tert</i>-Butyl removal was performed in a manner analogous to <b>60</b> (40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.98 (bs, 1H), 9.26 (s, 1H), 8.76 (s, 1H), 8.36 (d, <i>J</i> = 5.4 Hz, 1H), 8.08 (d, <i>J</i> = 8.0 Hz, 1H), 8.04 (d, <i>J</i> = 5.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.0, 5.6 Hz, 1H), 7.74–7.71 (m, 3H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.40 (d, <i>J</i> = 8.3, 2.0 Hz, 1H), 3.24–3.21 (m, 2H), 2.77–2.71 (m, 2H), 2.68–2.65 (m, 2H), 2.65 (s, 3H), 1.79–1.69 (m, 3H), 1.49–1.36 (m, 2H). One exchangeable proton was not observed. MS (ESI+): 485.3 [C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >210 °C.</div></div><div id="sec8_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 6-(1-Acetyl-piperidin-4-ylmethoxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime (<b>57</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>58</b> (30%, 4 steps), using 1-boc-4-piperidinemethanol instead of 1-boc-3-hydroxyazetidine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (bs, 1H), 9.25 (s, 1H), 8.76 (s, 1H), 8.03 (d, <i>J</i> = 5.4 Hz, 1H), 7.72 (d, <i>J</i> = 5.4 Hz, 1H), 7.68 (s, 1H), 7.45 (d, <i>J</i> = 9.1 Hz, 1H), 7.33 (d, <i>J</i> = 3.1 Hz, 1H), 7.15 (dd, <i>J</i> = 9.1, 3.1 Hz, 1H), 4.43–4.38 (m, 1H), 4.00–3.85 (m, 3H), 3.15–3.00 (m, 1H), 2.57–2.51 (m, 1H), 2.05–2.00 (m, 1H), 1.99 (s, 3H), 1.86–1.74 (m, 2H), 1.34–1.06 (m, 2H). MS (ESI+): 450.1 [C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >235 °C.</div></div><div id="sec8_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 6-(1-Acetyl-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime (<b>58</b>)</h4><div class="NLM_p">Under inert atmosphere, a mixture of 6-iodo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>102</b>, 255 mg, 0.52 mmol), 1-boc-3-hydroxyazetidine (456 mg, 2.62 mmol), copper iodide (20 mg, 0.10 mmol), 1,10-phenanthroline (38 mg, 0.21 mmol), and cesium carbonate (513 mg, 1.57 mmol) in toluene (1.0 mL) was heated at 120 °C for 24 h. The reaction mixture was cooled to room temperature, and the precipitate was filtered off and washed with ethyl acetate. The filtrate was concentrated to dryness and purified by column chromatography on silica gel (using a gradient of 0–40% ethyl acetate in cyclohexane as eluent) to give 6-(1-boc-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (185 mg, 68%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 522.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">To a solution of 6-(1-boc-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (182 mg, 0.35 mmol) in dichloromethane (1.8 mL), was added dropwise a 2N solution of HCl in Et<sub>2</sub>O (1.8 mL, 3.5 mmol), and the reaction mixture was stirred at room temperature for 30 min. The yellow precipitate was collected by filtration, washed with a little amount of diethyl ether, and dried under vacuum to give 6-(azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime hydrochloride (159 mg, 99%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (bs, 1H), 9.29 (bs, 1H), 9.27 (s, 1H), 8.79 (s, 1H), 8.06 (d, <i>J</i> = 5.4 Hz, 1H), 7.74 (d, <i>J</i> = 5.4 Hz, 1H), 7.59 (s, 1H), 7.52 (d, <i>J</i> = 9.0 Hz, 1H), 7.29 (d, <i>J</i> = 3.0 Hz, 1H), 7.15 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 5.22–5.18 (m, 1H), 4.44–4.04 (m, 2H), 4.08–4.02 (m, 2H), 1.40 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 422.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">At 0 °C, to a solution of 6-(azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime hydrochloride (159 mg, 0.35 mmol) in triethylamine (0.2 mL) and dichloromethane (3.2 mL) was added acetyl chloride (60 μL, 0.84 mmol). The reaction mixture was stirred at 0 °C for 6 h before being poured onto a saturated aqueous solution of ammonium chloride and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated to dryness. Purification by column chromatography on silica gel (using a gradient of 0–10% methanol in dichloromethane as eluent) gave 6-(1-acetyl-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (100 mg, 62%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 464.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">At 0 °C, to a solution 6-(1-acetyl-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl oxime (97 mg, 0.21 mmol) and 2,2,2-trifluoroethanol (11 μL, 0.15 mmol) in dichloromethane (10 mL) was added dropwise a 1 M solution of titanium chloride in dichloromethane (0.4 mL, 0.42 mmol). The reaction mixture was stirred at room temperature for 16 h before being treated with an anhydrous solution of 2-propanol (25 mL) to give an orange solution. The mixture was concentrated under vacuum until an orange precipitate formed in 2–3 mL of remaining solvent. The precipitate was collected by filtration, washed with a little amount of 2-propanol and Et<sub>2</sub>O, and dried under vacuum to give 6-(1-acetyl-azetidin-3-yloxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one oxime (<b>58</b>, 80 mg, 94%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.10 (bs, 1H), 9.26 (s, 1H), 8.78 (s, 1H), 8.05 (d, <i>J</i> = 5.4 Hz, 1H), 7.73 (d, <i>J</i> = 5.4 Hz, 1H), 7.69 (s, 1H), 7.50 (d, <i>J</i> = 9.0 Hz, 1H), 7.20 (d, <i>J</i> = 3.0 Hz, 1H), 7.12 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 5.12–5.07 (m, 1H), 4.54 (dd, <i>J</i> = 9.5, 6.5 Hz, 1H), 4.27 (dd, <i>J</i> = 10.6, 6.5 Hz, 1H), 4.13 (dd, <i>J</i> = 9.5, 3.6 Hz, 1H), 3.82 (dd, <i>J</i> = 10.6, 3.6 Hz, 1H), 1.81 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 153.2, 152.7, 147.7, 145.9, 145.4, 142.4, 142.2, 136.5, 131.6, 122.9, 119.5, 118.9, 114.5, 105.4, 94.2, 67.5, 65.6, 56.9, 54.3, 52.0 ppm. MS (ESI+): 408.2 [C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp 230–246 °C.</div></div><div id="sec8_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 6-[2-(1-Methyl-1,8-diaza-spiro[4.5]dec-8-yl)-ethoxy]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Dihydrochloride (<b>59</b>)</h4><div class="NLM_p">A suspension of 6-hydroxy-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>201</b>, 200 mg, 0.55 mmol), potassium carbonate (453 mg, 3.28 mmol), and 2-bromoethanol (174 μL, 2.45 mmol) in dry acetonitrile (5.5 mL) was heated at 100 °C for 3 days. The reaction mixture was concentrated under vacuum and purified by column chromatography on silica gel (using a gradient of 0–40% ethyl acetate in cyclohexane as eluent) to give 6-(2-hydroxy-ethoxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (187 mg, 83%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 411.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">At 0 °C, to a solution of 6-(2-hydroxy-ethoxy)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (185 mg, 0.45 mmol) in dichloromethane (4.5 mL) and triethylamine (75 μL, 0.54 mmol), methanesulfonyl chloride (42 μL, 0.54 mmol) was slowly added and the reaction mixture was stirred at room temperature for 3 h. The resulting solution was diluted with dichloromethane, washed with a saturated aqueous solution of potassium carbonate and brine, and then dried over sodium sulfate and concentrated o dryness. The crude methane sulfonic ester was obtained as a yellow solid and engaged in the next step without purification. LCMS, <i>m</i>/<i>z</i> = 489.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">A suspension of the freshly obtained methane sulfonic ester (100 mg, 0.20 mmol), potassium carbonate (85 mg, 0.61 mmol), and 1-methyl-1.8-diazaspiro(4.5)decane dihydrochloride (70 mg, 0.31 mmol) in dry acetonitrile (2.0 mL) was heated at 100 °C for 16 h. The reaction mixture was partitioned between ethyl acetate and water and extracted twice with ethyl acetate. The combined organic extracts were washed brine, dried over sodium sulfate, and concentrated to dryness to give 6-[2-(1-methyl-1,8-diaza-spiro[4.5]dec-8-yl)-ethoxy]-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (66 mg, 59%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 447.5 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl removal was performed in a manner analogous to <b>40</b>. The title compound was purified by preparative HPLC, and salt formation was realized in a manner analogous to <b>40</b> (26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.32 (bs, 1H), 11.21 (bs, 1H), 11.13 (bs, 1H), 9.23 (s, 1H), 8.85–8.82 (m, 1H), 8.11 (d, <i>J</i> = 5.4 Hz, 1H), 7.79 (d, <i>J</i> = 5.4 Hz, 1H), 7.75 (s, 1H), 7.57 (d, <i>J</i> = 9.0 Hz, 1H), 7.48 (d, <i>J</i> = 3.0 Hz, 1H), 7.31 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 4.60–4.51 (m, 2H), 3.82–3.71 (m, 2H), 3.66–3.57 (m, 3H), 3.39–3.12 (m, 3H), 2.85–2.67 (m, 3H), 2.49–2.31 (m, 3H), 2.22–1.90 (m, 5H). MS (ESI+): 491.4 [C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>S + H]<sup>+</sup> (<i>m</i>/<i>z</i>); mp >200 °C.</div></div><div id="sec8_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 6-(3-Morpholin-4-yl-propyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one Oxime Hydrochloride (<b>60</b>)</h4><div class="NLM_p">A mixture of 3-(4-<i>tert</i>-butoxyimino-2-thieno[3,2-<i>c</i>]pyridin-6-yl-4<i>H</i>-chromen-6-yl)-propionaldehyde (<b>301</b>, 360 mg, 0.89 mmol), morpholine (116 mg, 1.33 mmol), sodium triacetoxyborohydride (283 mg, 1.33 mmol), and 1 drop of acetic acid in THF (4.0 mL) was stirred at room temperature for 16 h. The reaction mixture was poured onto ice–water and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated under vacuum. The resulting crude yellow oil was purified by column chromatography on silica gel (using 10–100% ethyl acetate in cyclohexane as eluent) to give 6-(3-morpholin-4-yl-propyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (300 mg, 70%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 478.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a solution of 6-(3-morpholin-4-yl-propyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (80 mg, 0.17 mmol) in dichloromethane (8 mL) was slowly added TFA (8 mL). The reaction mixture was heated at 45 °C for 24 h before being carefully neutralized by an aqueous solution of sodium bicarbonate at 0 °C and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated under vacuum. The crude yellow solid was purified by preparative HPLC and treated with a 1.2 M solution of HCl in methanol. Concentration to dryness and trituration in diethyl ether afforded 6-(3-morpholin-4-yl-propyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one oxime hydrochloride (<b>60</b>, 42 mg, 55%) as a yellow powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.04 (bs, 1H), 10.72 (bs, 1H), 9.26 (s, 1H), 8.77 (s, 1H), 8.05 (d, <i>J</i> = 5.4 Hz, 1H), 7.76–7.70 (m, 3H), 7.47–7.41 (m, 2H), 3.95 (m, 2H), 3.76 (m, 2H), 2.42, (m, 2H), 3.06 (m, 4H), 2.71 (m, 2H), 2.10 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.5, 149.6, 147.9, 145.3, 142.4, 142.1, 137.5, 136.4, 131.7, 130.9, 123.0, 121.6, 118.4, 117.8, 114.5, 94.9, 63.1(2C), 55.5, 50.9(2C), 31.5, 24.4 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S [(M + H)<sup>+</sup>] 421.1460, found 421.1454; mp 193–200 °C.</div></div><div id="sec8_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 6-Bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>101</b>)</h4><div class="NLM_p">To a suspension of sodium hydride (5.5 g, 60% in mineral oil, 139.4 mmol) in anhydrous pyridine (50 mL) was added a solution of 5-bromo-2-hydroxyacetophenone (10.0 g, 46.50 mmol) in pyridine (50 mL) followed by a solution of thieno[3,2-<i>c</i>]pyridine-6-carboxylic acid methyl ester (10.7 g, 55.80 mmol) in pyridine (50 mL). After complete addition, the reaction mixture was heated at 90 °C for 1 h before it was cooled to room temperature. The reaction mixture was poured into a cold aqueous HCl solution (3N, 625 mL). The resulting solid was collected by filtration, washed with water, and dried under suction. The solid was suspended in glacial acetic acid (100 mL), and 0.5 mL of concentrated H<sub>2</sub>SO<sub>4</sub> was added. The resulting suspension was heated at 110 °C for 1 h, before it was cooled to room temperature and concentrated to dryness under reduced pressure. The resulting residue was suspended in ice–water (200 mL) and neutralized with an aqueous NaOH solution (10%). The resulting precipitate was collected by filtration, washed with water, hexane, and dried under suction to give 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one (13 g, 78%) as a green solid. LCMS, <i>m</i>/<i>z</i> = 358.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">In a sealed tube, a suspension of 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one (9.0 g, 25.28 mmol) and <i>O</i>-(<i>tert</i>-butyl)hydroxylamine hydrochloride (6.3 g, 50.56 mmol) in anhydrous EtOH (90 mL) was heated at 120 °C for 12 h. The reaction mixture was cooled to room temperature, and the resulting precipitate was collected by filtration, washed with cold EtOH (50 mL), and dried under vacuum to give 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>101</b>, 6.8 g, 57%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>,) δ 9.27 (s, 1H), 8.78 (s, 1H), 8.07–8.03 (m, 2H), 7.75–7.71 (m, 2H), 7.61 (s, 1H), 7.53–7.49 (m, 1H), 1.39 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 430.9 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 6-Iodo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>102</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>101</b> (50%), starting from 5-iodo-2-hydroxyacetophenone<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> instead of 5-bromo-2-hydroxyacetophenone. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 8.77 (s, 1H), 8.22 (s, 1 H), 8.06 (d, <i>J</i> = 5.2 Hz, 1H), 7.87 (d, <i>J</i> = 8.3 Hz, 1H), 7.73 (d, <i>J</i> = 5.2 Hz, 1H), 7.61 (s, 1 H), 7.34 (d, <i>J</i> = 8.3 Hz, 1H), 1.39 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 476.9 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 6-Bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>103</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>101</b> (76%), starting from isoquinoline-3-carboxylic acid methyl ester. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.28 (s, 1H), 8.27 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 1H), 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.78 (s, 1H), 7.76 (td, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.67 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.50 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 1H), 1.43 (s, 9H).</div></div><div id="sec8_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 6-Bromo-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>104</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>101</b> (42%) starting from pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic acid ethyl ester instead of thieno[3,2-<i>c</i>]pyridine-6-carboxylic acid methyl ester. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (s, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.83 (d, <i>J</i> = 2.4 Hz, 1H), 7.70–7.67 (m, 1H), 7.44 (d, <i>J</i> = 8.8 Hz, 1H), 7.34 (s, 1H), 6.99 (d, <i>J</i> = 3.7 Hz, 1H), 6.75 (d, <i>J</i> = 3.7 Hz, 1H), 1.36 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 413.1 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 6-Iodo-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>105</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>101</b> (50%), starting from pyrrolo[1,2-<i>c</i>]pyrimidine-3-carboxylic acid ethyl ester and 5-iodo-2-hydroxyacetophenone instead of 5-bromo-2-hydroxyacetophenone. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 8.20 (d, <i>J</i> = 2.3 Hz, 1H), 8.07 (s, 1H), 7.86–7.83 (m, 2H), 7.37 (s, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 1H), 7.00 (dd, <i>J</i> = 3.8, 2.9 Hz, 1H), 6.76 (d, <i>J</i> = 3.8 Hz, 1H), 1.38 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 460.1 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 7-Bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>106</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>101</b> (77%), starting from isoquinoline-3-carboxylic acid methyl ester and 4-bromo-2-hydroxyacetophenone instead of 5-bromo-2-hydroxyacetophenone. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.28 (s, 1H), 8.26 (s, 1H), 8.02 (d, <i>J</i> = 8.1 Hz, 1H), 7.94 (d, <i>J</i> = 8.5 Hz, 1H), 7.93 (d, <i>J</i> = 8.1 Hz, 1H), 7.78 (s, 1H), 7.76 (td, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.66 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.53 (d, <i>J</i> = 1.9 Hz, 1H), 7.31 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 1.42 (s, 9H).</div></div><div id="sec8_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 6-Hydroxy-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>201</b>)</h4><div class="NLM_p last">A suspension of 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>101</b>, 400 mg, 1.16 mmol), tris(dibenzylideneacetone)dipalladium (60 mg, 0.06 mmol), 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-triisopropylbiphenyl (51 mg, 0.12 mmol), and potassium hydroxide (390 mg, 6.96 mmol) in dioxane (2.5 mL) was degassed with argon for 10 min. Water (2.5 mL) was added, and the reaction mixture was further degassed for 10 min. The tube was sealed, and the reaction mixture was heated at 100 °C for 12 h under vigorous stirring. The reaction mixture was cooled to room temperature, dioxane was removed under vacuum, and the aqueous layer was neutralized with a 1.5 N aqueous solution of HCl. The mixture was extracted twice with ethyl acetate, and the combined organic extracts were dried with brine, sodium sulfate, and concentrated under vacuum. Purification by column chromatography on silica gel (using a gradient of 10–40% ethyl acetate in cyclohexane as eluent) afforded 6-hydroxy-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>201</b>, 376 mg, 88%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.15 (s, 1H), 8.45 (s, 1H), 7.69 (s, 1 H), 7.58 (d, <i>J</i> = 5.4 Hz, 1H), 7.50–7.48 (m, 2H), 7.20 (d, <i>J</i> = 9.0 Hz, 1H), 6.92 (dd, <i>J</i> = 9.0, 3.6 Hz, 1 H), 5.42 (s, 1H), 1.40 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 367.2 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 6-Hydroxy-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>203</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>201</b> (89%) starting from 6-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>103</b>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.28 (s, 1H), 8.29 (s, 1H), 8.01 (d, <i>J</i> = 7.7 Hz, 1H), 7.94 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (t, <i>J</i> = 7.4 Hz, 1H), 7.75 (s, 1H), 7.65 (t, <i>J</i> = 7.5 Hz, 1H), 7.50 (d, <i>J</i> = 3.0 Hz, 1H), 7.28–7.22 (m, 1H), 6.90 (dd, <i>J</i> = 8.5, 3.0 Hz, 1H), 5.08 (s, 1H), 1.42 (s, 9H).</div></div><div id="sec8_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 6-Hydroxy-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime (<b>204</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>201</b> (57%) starting from 6-bromo-2-pyrrolo[1,2-<i>c</i>]pyrimidin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>104</b>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.79 (s, 1H), 7.90 (s, 1H), 7.52 (d, <i>J</i> = 2.9 Hz, 1H), 7.49 (s, 1H), 7.44 (d, <i>J</i> = 3.0 Hz, 1H), 7.17 (d, <i>J</i> = 8.8 Hz, 1H), 6.95–6.88 (m, 2H), 6.63 (d, <i>J</i> = 3.8 Hz, 1H), 5.56 (bs, 1H), 1.41 (s, 9H). LCMS, <i>m</i>/<i>z</i> = 350.3 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 7-Hydroxy-2-isoquinolin-3-yl-chromen-4-one O-<i>tert</i>-Butyl-oxime (<b>206</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner analogous to <b>201</b> (75%) starting from 7-bromo-2-isoquinolin-3-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>106</b>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.26 (s, 1H), 8.25 (s, 1H), 8.01–7.91 (m, 3H), 7.75 (s, 1H), 7.72 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.66–7.61 (m, 1H), 6.79 (d, <i>J</i> = 2.4 Hz, 1H), 6.69 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 5.45 (s, 1H), 1.39 (s, 9H).</div></div><div id="sec8_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 3-(4-<i>tert</i>-Butoxyimino-2-thieno[3,2-<i>c</i>]pyridin-6-yl-4<i>H</i>-chromen-6-yl)-propionaldehyde (<b>301</b>)</h4><div class="NLM_p">Under inert atmosphere, to a mixture of 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (<b>101</b>, 1.0 g, 2.3 mmol), palladium(II) acetate (51 mg, 0.23 mmol), and 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-triisopropylbiphenyl (195 mg, 0.46 mmol) in anhydrous THF (4 mL) was added a 0.5 M solution of 2-(1,3-dioxolan-2-yl)ethylzinc bromide in THF (9.2 mL, 4.6 mmol). The reaction mixture was subjected to microwave irradiation at 100 °C for 1 h. THF was removed under vacuum and the resulting crude yellow oil was purified by column chromatography on silica gel (using 10–30% ethyl acetate in cyclohexane as eluent) to give 6-(2-[1,3]dioxolan-2-yl-ethyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (0.87 g, 84%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 451.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a solution of 6-(2-[1,3]dioxolan-2-yl-ethyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-butyl-oxime (400 mg, 0.89 mmol) in THF (8.0 mL) was added a 3 N aqueous solution of HCl (2.5 mL). The resulting yellow mixture was stirred at room temperature for 24 h to give a thick-yellow emulsion. The reaction mixture was heated at 60 °C for 4 h before being cooled to room temperature. The resulting emulsion was neutralized by addition of an aqueous saturated solution of sodium bicarbonate and extracted twice with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated under vacuum to give 3-(4-<i>tert</i>-butoxyimino-2-thieno[3,2-<i>c</i>]pyridin-6-yl-4<i>H</i>-chromen-6-yl)-propionaldehyde (<b>301</b>, 360 mg, quant) as a yellow solid. The product was used in the next step without purification. LCMS, <i>m</i>/<i>z</i> = 407.3 [M + H]<sup>+</sup>.</div></div><div id="sec8_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 6-Piperidin-4-ylmethyl-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one <i>O</i>-<i>tert</i>-Butyl-oxime Hydrochloride (<b>401</b>)</h4><div class="NLM_p last">Under inert atmosphere, to a suspension of zinc dust (223 mg, 3.41 mmol) in anhydrous DMA (0.5 mL) was added 1,2-dibromoethane (32 μL) and trimethylsilyl chloride (49 μL). The resulting slurry was stirred at room temperature for 15 min. A solution of 1-boc-4-iodomethylpiperidine (738 mg, 2.27 mmol) in anhydrous DMA (2.0 mL) was added dropwise, and the reaction mixture was stirred at room temperature for 1 h. After decantation, the supernatant was collected by syringe and added to a mixture of 6-bromo-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one-<i>O</i>-<i>tert</i>-butyl-oxime (<b>101</b>, 325 mg, 0.76 mmol), copper iodide (9 mg, 0.045 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (19 mg, 0.023 mmol) in anhydrous DMA (2.0 mL). The reaction mixture was sealed under inert atmosphere and heated at 80 °C for 24 h before being filtered off on Celite and washed with ethyl acetate. The filtrate was concentrated to dryness, and the crude residue was purified by column chromatography on silica gel (using a gradient of 0–10% of ethyl acetate in cyclohexane as eluent) to afford 6-(1-boc-piperidin-4-ylmethyl)-2-thieno[3,2-<i>c</i>]pyridin-6-yl-chromen-4-one-<i>O</i>-<i>tert</i>-butyl-oxime (330 mg, 79%) as a yellow solid. LCMS, <i>m</i>/<i>z</i> = 548.4 [M + H]<sup>+</sup>. Boc removal was performed in a manner analogous to <b>58</b> (quant). LCMS, <i>m</i>/<i>z</i> = 448.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Calcium Functional Assay on Human mGluRs</h3><div class="NLM_p">Compounds were tested successively for their agonist and allosteric modulator activities on HEK-293 cells transiently overexpressing one of the eight subtypes of human or rat mGlu receptors. Compounds exerted agonist activity if, by themselves in absence of glutamate, they were able to activate the tested mGluR subtype and they exerted positive (PAM) or negative (NAM) allosteric modulator activity if they increased or decreased the effect of glutamate (or L-AP4 for mGluR7), respectively.</div><div class="NLM_p">HEK-293 cells were cultured in Modified Eagle’s Medium (MEM) supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin and 1% nonessential amino acids at 37 °C/5% CO<sub>2</sub> and transfected by electroporation as previously described.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> Plasmids encoding human mGluRs were constructed from a pRK backbone and human mGluR cDNAs (either cloned from SK-NSH or human cerebellum mRNA extract or purchased from BioXTal or Genecopoeia). Plasmids encoding the promiscuous G protein Gα15 or the chimeric Gqi9 or Gi/Gq (GqTOP) G proteins (used to deviate the natural coupling of the group II and group III mGluRs from inhibition of cAMP production to Ca<sup>2+</sup> release pathway) were described previously.<a onclick="showRef(event, 'ref47 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref47 ref49 ref50">(47, 49, 50)</a> Receptor activity was detected by changes in intracellular calcium, as measured using the fluorescent Ca<sup>2+</sup> sensitive dye, Fluo4-AM (Molecular Probes). Cells were cultured for 24 h after electrotransfection. The day of the screening, cells were first deprived from FCS for 3 h, then washed with freshly prepared assay buffer (1× HBSS supplemented with 20 mM HEPES, 1 mM MgSO<sub>4</sub>, 3.3 mM Na<sub>2</sub>CO<sub>3</sub>, 1.3 mM CaCl<sub>2</sub>, 2.5 mM Probenecid, and 0.1% BSA) and loaded for 1 h 30 min with assay buffer containing 1 μM Fluo4AM and 0.1 mg/mL pluronic acid. After washing, cells were incubated in assay buffer (50 or 20 μL for assay performed in 96 well-plate (WP) or 384 WP format, respectively), then agonist and allosteric modulator activities of compound were consecutively evaluated on the same cell plate. Agonist activity was first tested during 10 min with the addition of 50 μL (or 20 μL for 384 WP format) of 3× compound solution (prepared in buffer). Then, cells were stimulated by 50 μL (or 20 μL for 384 WP format) of 3× glutamate solution (prepared in buffer) at EC<sub>20</sub> or EC<sub>80</sub> for PAM and NAM tests, respectively, and fluorescence was recorded for additional 3 min; EC<sub>20</sub> and EC<sub>80</sub> glutamate concentrations are the concentrations resulting in 20% or 80% of the maximal glutamate response, respectively. Successive compound additions and measurement of fluorescence signals (excitation, 485 nm; emission, 525 nm) at sampling intervals of 1 s were performed using microplate reader FLIPRTetra (Molecular Devices).</div><div class="NLM_p">For potency determination, a concentration–response test was performed using 20 concentrations (ranging over 6 logs) of each compound. Concentration–response curves were fitted using the sigmoidal dose–response (variable slope) analysis in XLfit Scientific Curve Fitting for Excel (IDBS). Potency and efficacy (expressed in percentage of maximal glutamate response) of agonist/positive allosteric modulator effects were calculated. Experiments were performed in duplicate, three times independently.</div><div class="NLM_p last">For experiments of shift in glutamate concentration–response curve, 10 or 20 concentrations of glutamate (ranging over 4.5 logs) were tested alone or in the presence of various concentrations (typically 0.1, 0.3, 1, 3, 10 μM) of each compound. Concentration–response curves were fitted using the sigmoidal dose–response (variable slope) analysis in XLfit Scientific Curve Fitting for Excel (IDBS). Potency of glutamate alone or in the presence of compound was determined and used to calculate fold increase in the apparent affinity for glutamate. Experiments were performed in duplicate, three times independently.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00991">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00991" class="ext-link">10.1021/acs.jmedchem.7b00991</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General methods for the synthesis of all compounds, and methods for the in vitro and in vivo DMPK protocols and supplemental figures (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and the associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf">jm7b00991_si_001.pdf (658.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_002.xlsx">jm7b00991_si_002.xlsx (42.12 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00991" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Delphine Charvin</span> - <span class="hlFld-Affiliation affiliation">Prexton
Therapeutics, 14 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4801-7800" title="Orcid link">http://orcid.org/0000-0002-4801-7800</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3175545d4159585f541f7259504347585f7141435449455e5f4559544350415444455852421f525e5c"><span class="__cf_email__" data-cfemail="6226070e120a0b0c074c210a0310140b0c221210071a160d0c160a071003120717160b01114c010d0f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephan Schann</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f48787979c959a9ab4909b99959d9a809c918695849181809d9787da979b99"><span class="__cf_email__" data-cfemail="354646565d545b5b75515a58545c5b415d504754455040415c56461b565a58">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincent Pomel</span> - <span class="hlFld-Affiliation affiliation">Prexton
Therapeutics, 14 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Millan Ortiz</span> - <span class="hlFld-Affiliation affiliation">Prexton
Therapeutics, 14 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mélanie Frauli</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie Scheffler</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edith Steinberg</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luc Baron</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurène Deshons</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Rudigier</span> - <span class="hlFld-Affiliation affiliation">Prestwick
Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Delphine Thiarc</span> - <span class="hlFld-Affiliation affiliation">Prestwick
Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christophe Morice</span> - <span class="hlFld-Affiliation affiliation">Prestwick
Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baptiste Manteau</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanislas Mayer</span> - <span class="hlFld-Affiliation affiliation">Domain
Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danielle Graham</span> - <span class="hlFld-Affiliation affiliation">EMD
Serono, 45A Middlesex Turnpike, Billerica, Massachusetts 0182, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruno Giethlen</span> - <span class="hlFld-Affiliation affiliation">Prestwick
Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadia Brugger</span> - <span class="hlFld-Affiliation affiliation">EMD
Serono, 45A Middlesex Turnpike, Billerica, Massachusetts 0182, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaël Hédou</span> - <span class="hlFld-Affiliation affiliation">EMD
Serono, 45A Middlesex Turnpike, Billerica, Massachusetts 0182, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">François Conquet</span> - <span class="hlFld-Affiliation affiliation">Prexton
Therapeutics, 14 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written by D.C and S.S. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors of this manuscript are or were employees of the different institutions involved in this program (Prexton Therapeutics, Domain Therapeutics, Prestwick Chemical, EMD Serono). Prexton Therapeutics is actively developing mGluR4 PAMs as therapeutic agents.<br /></br></div></li></ul></div><div class="ack" id="ACK-d249e8553-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Jonathan Brotchie and Dr. Michael Hill for their contribution with animal modeling and data collection, Dr. Lakshindra Chetia and Dr. Vaidyanathan for their support during the Domain-Prexton collaboration, Dr. David Spalding, Dr. Nada Abla-Geiser, and Dr. Marc Lecomte for their help with animal PK studies. We also like thank Prof. Jean-Philippe Pin for kindly providing plasmids encoding the promiscuous G protein Gα15 and the chimeric Gqi9 or Gi/Gq (GqTOP) G proteins. This work was funded by Domain Therapeutics, EMD Serono, and Prexton Therapeutics. Domain Therapeutics received funding from the French government for the ARAMIS project (Fonds Unique Interministériel, FUI).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i100" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i100"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> Abbreviations Used</h2><tr><td class="NLM_term">AMPA</td><td class="NLM_def"><p class="first last">α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid</p></td></tr><tr><td class="NLM_term">BG</td><td class="NLM_def"><p class="first last">basal ganglia</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyltransferase</p></td></tr><tr><td class="NLM_term">L-DOPA</td><td class="NLM_def"><p class="first last">3,4-dihydroxy-<span class="smallcaps smallerCapital">l</span>-phenylalanine</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">mGluR</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulator</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic(s)</p></td></tr><tr><td class="NLM_term">6-OHDA</td><td class="NLM_def"><p class="first last">6-hydroxydopamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">World Health Organization</span><span class="NLM_x">. </span> <span class="citation_source-book">Neurological Disorders: Public Health Challenges</span>; <span class="NLM_publisher-name">World Health Organization Press</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=World+Health+Organization&title=Neurological+Disorders%3A+Public+Health+Challenges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DNeurological%2520Disorders%253A%2520Public%2520Health%2520Challenges%26pub%3DWorld%2520Health%2520Organization%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, K.</span><span> </span><span class="NLM_article-title">The scientific and clinical basis for the treatment of Parkinson disease (2009)</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1212/WNL.0b013e3181a1d44c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1212%2FWNL.0b013e3181a1d44c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2009&pages=S1-136&author=C.+W.+Olanowauthor=M.+B.+Sternauthor=K.+Sethi&title=The+scientific+and+clinical+basis+for+the+treatment+of+Parkinson+disease+%282009%29&doi=10.1212%2FWNL.0b013e3181a1d44c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1212%2FWNL.0b013e3181a1d44c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0b013e3181a1d44c%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DStern%26aufirst%3DM.%2BB.%26aulast%3DSethi%26aufirst%3DK.%26atitle%3DThe%2520scientific%2520and%2520clinical%2520basis%2520for%2520the%2520treatment%2520of%2520Parkinson%2520disease%2520%25282009%2529%26jtitle%3DNeurology%26date%3D2009%26volume%3D72%26spage%3DS1%26epage%3D136%26doi%3D10.1212%2FWNL.0b013e3181a1d44c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, W. C.</span><span> </span><span class="NLM_article-title">An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S88</span><span class="refDoi"> DOI: 10.1212/WNL.56.suppl_5.S1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1212%2FWNL.56.suppl_5.S1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2001&pages=S1-S88&author=C.+W.+Olanowauthor=R.+L.+Wattsauthor=W.+C.+Koller&title=An+algorithm+%28decision+tree%29+for+the+management+of+Parkinson%E2%80%99s+disease+%282001%29%3A+treatment+guidelines&doi=10.1212%2FWNL.56.suppl_5.S1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1212%2FWNL.56.suppl_5.S1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.56.suppl_5.S1%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DWatts%26aufirst%3DR.%2BL.%26aulast%3DKoller%26aufirst%3DW.%2BC.%26atitle%3DAn%2520algorithm%2520%2528decision%2520tree%2529%2520for%2520the%2520management%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520%25282001%2529%253A%2520treatment%2520guidelines%26jtitle%3DNeurology%26date%3D2001%26volume%3D56%26spage%3DS1%26epage%3DS88%26doi%3D10.1212%2FWNL.56.suppl_5.S1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Prashanth, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, W. G.</span><span> </span><span class="NLM_article-title">l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment</span> <span class="citation_source-journal">Int. Rev. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1016/B978-0-12-381328-2.00002-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FB978-0-12-381328-2.00002-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=21907082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWhsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2011&pages=31-54&author=L.+K.+Prashanthauthor=S.+Foxauthor=W.+G.+Meissner&title=l-Dopa-induced+dyskinesia-clinical+presentation%2C+genetics%2C+and+treatment&doi=10.1016%2FB978-0-12-381328-2.00002-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">L-dopa-induced dyskinesia-clinical presentation, genetics, and treatment</span></div><div class="casAuthors">Prashanth, L. K.; Fox, Susan; Meissner, Wassilios G.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia</span>),
    <span class="NLM_cas:pages">31-54</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Levodopa-induced dyskinesia (LID) has been recognized since the introduction of levodopa for the management of Parkinson's disease (PD) and continues to be one of the most clin. challenging factors in long-term management of patients with PD.  Most patients develop LID within 10 years of PD onset and the cause has been attributed to various factors including disease demographics, pharmacol., and possibly genetic causes.  The clin. pattern of LID varies and shows intra and inter-patient variability and has been classified based upon phenomenol. and relation to timing of levodopa.  The potential armamentarium to address and manage LID has significantly increased in the last decade.  This chapter addresses the current understanding of various clin. aspects and available therapeutics for LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfzKjt5Y4PQLVg90H21EOLACvtfcHk0ljXOcEjNc5ICg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWhsLzJ&md5=82fd0dcf23817bf6a927003553976a1b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381328-2.00002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381328-2.00002-X%26sid%3Dliteratum%253Aachs%26aulast%3DPrashanth%26aufirst%3DL.%2BK.%26aulast%3DFox%26aufirst%3DS.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26atitle%3Dl-Dopa-induced%2520dyskinesia-clinical%2520presentation%252C%2520genetics%252C%2520and%2520treatment%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2011%26volume%3D98%26spage%3D31%26epage%3D54%26doi%3D10.1016%2FB978-0-12-381328-2.00002-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fox, S. H.</span><span> </span><span class="NLM_article-title">Non-dopaminergic treatments for motor control in Parkinson’s disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1007/s40265-013-0105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1007%2Fs40265-013-0105-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1405-1415&author=S.+H.+Fox&title=Non-dopaminergic+treatments+for+motor+control+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40265-013-0105-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0105-4%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DS.%2BH.%26atitle%3DNon-dopaminergic%2520treatments%2520for%2520motor%2520control%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1405%26epage%3D1415%26doi%3D10.1007%2Fs40265-013-0105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.coph.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.coph.2005.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16368268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=98-102&author=M.+J.+Marinoauthor=P.+J.+Conn&title=Glutamate-based+therapeutic+approaches%3A+allosteric+modulators+of+metabotropic+glutamate+receptors&doi=10.1016%2Fj.coph.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors</span></div><div class="casAuthors">Marino, Michael J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate receptors (mGluRs) were proposed as novel targets for the treatment of a variety of disorders.  Recently, highly selective allosteric modulators of the mGluRs were developed by several groups.  These allosteric compds. provide an unprecedented degree of selectivity for individual mGluRs, allowing for more detailed functional studies on the roles of these receptors.  Furthermore, the allosteric approach avoids many of the hurdles assocd. with the development of direct agonists as drugs, and provides a clear path forward for clin. proof-of-concept studies.  Currently, both pos. allosteric modulators of mGluR2 and neg. allosteric modulators of mGluR5 hold promise as novel anxiolytics, and pos. allosteric modulators of mGluR4 appear to be an exciting new target for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9A6c0VveAl7Vg90H21EOLACvtfcHk0ljXOcEjNc5ICg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVynug%253D%253D&md5=819ca06118515c19c3f0047fb7fc420d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DGlutamate-based%2520therapeutic%2520approaches%253A%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D98%26epage%3D102%26doi%3D10.1016%2Fj.coph.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Amalric, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F. C.</span><span> </span><span class="NLM_article-title">Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson’s disease</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2012.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22664304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=53-64&author=M.+Amalricauthor=S.+Lopezauthor=C.+Goudetauthor=G.+Fisoneauthor=G.+Battagliaauthor=F.+Nicolettiauthor=J.+P.+Pinauthor=F.+C.+Acher&title=Group+III+and+subtype+4+metabotropic+glutamate+receptor+agonists%3A+discovery+and+pathophysiological+applications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuropharm.2012.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease</span></div><div class="casAuthors">Amalric, M.; Lopez, S.; Goudet, C.; Fisone, G.; Battaglia, G.; Nicoletti, F.; Pin, J.-P.; Acher, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-64</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the loss of dopaminergic (DA) neurons of the substantia nigra pars compacta, represents a major challenge to treat patients affected by Parkinson's disease (PD).  The imbalanced situation in favor of excitation in the disease state may also accelerate excitotoxic processes, thereby representing a potential target for neuroprotective therapies.  Reducing the excitatory action of glutamate, the major excitatory neurotransmitter in the basal ganglia, should lead to symptomatic improvement for PD patients and may promote the survival of DA neurons.  Recent studies have focused on the modulatory action of metabotropic glutamate (mGlu) receptors on neurodegenerative diseases including PD.  Group III mGlu receptors, including subtypes 4, 7, and 8, are largely expressed in the basal ganglia.  Recent studies highlight the use of selective mGlu4 receptor pos. allosteric modulators (PAMs) for the treatment of PD.  Here we review the effects of newly-designed group-III orthosteric agonists on neuroprotection, neurorestoration, and redn. of L-DOPA induced dyskinesia in animal models of PD.  The combination of orthosteric mGlu4 receptor selective agonists with PAMs may open new avenues for the symptomatic treatment of PD.  This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfNTiuwGkzrVg90H21EOLACvtfcHk0ljXOcEjNc5ICg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVKktbc%253D&md5=d55ec6e3b38b5f58db08a973dc6e76b0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DAmalric%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DAcher%26aufirst%3DF.%2BC.%26atitle%3DGroup%2520III%2520and%2520subtype%25204%2520metabotropic%2520glutamate%2520receptor%2520agonists%253A%2520discovery%2520and%2520pathophysiological%2520applications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D53%26epage%3D64%26doi%3D10.1016%2Fj.neuropharm.2012.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jane, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J.</span><span> </span><span class="NLM_article-title">Pharmacological agents acting at subtypes of metabotropic glutamate receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1476</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00092-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2899%2900092-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10530808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=1431-1476&author=D.+D.+Schoeppauthor=D.+E.+Janeauthor=J.+Monn&title=Pharmacological+agents+acting+at+subtypes+of+metabotropic+glutamate+receptors&doi=10.1016%2FS0028-3908%2899%2900092-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological agents acting at subtypes of metabotropic glutamate receptors</span></div><div class="casAuthors">Schoepp, D. D.; Jane, D. E.; Monn, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1431-1476</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with ∼270 refs.  Metabotropic (G-protein-coupled) glutamate (mGlu) receptors have now emerged as a recognized, but still relatively new area of excitatory amino acid research.  Current understanding of the roles and involvement of mGlu receptor subtypes in physiol./pathophysiol. functions of the central nervous system has been recently propelled by the emergence of various structurally novel, potent, and mGlu receptor selective pharmacol. agents.  This article reviews the evolution of pharmacol. agents that have been reported to target mGlu receptors, with a focus on the known receptor subtype selectivities of current agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1C80nlavsgrVg90H21EOLACvtfcHk0ljsNbtW3Kthhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWnsLc%253D&md5=08a832c7cab387bc096131bd2d916cab</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900092-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900092-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMonn%26aufirst%3DJ.%26atitle%3DPharmacological%2520agents%2520acting%2520at%2520subtypes%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D1999%26volume%3D38%26spage%3D1431%26epage%3D1476%26doi%3D10.1016%2FS0028-3908%2899%2900092-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors in the basal ganglia motor circuit</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1038/nrn1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fnrn1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16276355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=787-798&author=P.+J.+Connauthor=G.+Battagliaauthor=M.+J.+Marinoauthor=F.+Nicoletti&title=Metabotropic+glutamate+receptors+in+the+basal+ganglia+motor+circuit&doi=10.1038%2Fnrn1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors in the basal ganglia motor circuit</span></div><div class="casAuthors">Conn, P. Jeffrey; Battalglia, Giuseppe; Marino, Michael J.; Nicoletti, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In recent years there have been tremendous advances in our understanding of the circuitry of the basal ganglia and our ability to predict the behavioral effects of specific cellular changes in this circuit on voluntary movement.  These advances, combined with a new understanding of the rich distribution and diverse physiol. roles of metabotropic glutamate receptors in the basal ganglia, indicate that these receptors might have a key role in motor control and raise the exciting possibility that they might provide therapeutic targets for the treatment of Parkinson's disease and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAptgUy8Ve6rVg90H21EOLACvtfcHk0ljsNbtW3Kthhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsL3I&md5=f21bea466eee933e278c362a38d43227</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrn1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1763%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DNicoletti%26aufirst%3DF.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520in%2520the%2520basal%2520ganglia%2520motor%2520circuit%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D787%26epage%3D798%26doi%3D10.1038%2Fnrn1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turle-Lorenzo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Leonibus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalric, M.</span><span> </span><span class="NLM_article-title">Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6701</span><span class="NLM_x">–</span> <span class="NLM_lpage">6711</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0299-07.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.0299-07.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17581957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=6701-6711&author=S.+Lopezauthor=N.+Turle-Lorenzoauthor=F.+Acherauthor=E.+De+Leonibusauthor=A.+Meleauthor=M.+Amalric&title=Targeting+group+III+metabotropic+glutamate+receptors+produces+complex+behavioral+effects+in+rodent+models+of+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.0299-07.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease</span></div><div class="casAuthors">Lopez, Sebastien; Turle-Lorenzo, Nathalie; Acher, Francine; De Leonibus, Elvira; Mele, Andrea; Amalric, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6701-6711</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternatives to L-DOPA (L-3,4-dihydroxyphenylalanine) for the treatment of Parkinson's disease (PD).  Their presynaptic location at GABAergic and glutamatergic synapses within basal ganglia nuclei provide a crit. target to reduce abnormal activities assocd. with PD.  The effects of selective group III mGluR agonists (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) and L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) infused into the globus pallidus (GP) or the substantia nigra pars reticulata (SNr) were thus studied in rat models of PD.  Bilateral infusions of ACPT-I (1, 2.5, and 5 nmol/μl) into the GP fully reverse the severe akinetic deficits produced by 6-hydroxydopamine nitrostriatal dopamine lesions in a reaction-time task without affecting the performance of controls.  Similar results were obsd. after L-AP4 (1 nmol) or picrotoxin, a GABAA receptor antagonist, infused into the GP.  In addn., intrapallidal ACPT-I counteracts haloperidol-induced catalepsy.  This effect is reversed by concomitant administration of a selective group III receptor antagonist (RS)-α-cyclopropyl-4-phosphonophenylglycine.  In contrast, ACPT-I (0.05, 0.1, and 0.25 nmol) infusions into the SNr enhance the lesion-induced akinetic deficits in control and lesioned rats and do not reverse haloperidol-induced catalepsy.  L-AP4 (0.05 nmol) and picrotoxin in the SNr produce the same effects.  Together, these results show that activation of group III mGluRs in the GP provides benefits in parkinsonian rats, presumably by modulating GABAergic neurotransmission.  The opposite effects produced by group III mGluR activation in the SNr, also obsd. with a selective mGluR8 agonist, support the use of subtype-selective group III mGluR agonists as a potential antiparkinsonian strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRtwJhZxZ7rVg90H21EOLACvtfcHk0lg3-BgbwP0J4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVWqs7w%253D&md5=05a960ea9fb79233bc9c1bf69a8b3c73</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0299-07.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0299-07.2007%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DTurle-Lorenzo%26aufirst%3DN.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DDe%2BLeonibus%26aufirst%3DE.%26aulast%3DMele%26aufirst%3DA.%26aulast%3DAmalric%26aufirst%3DM.%26atitle%3DTargeting%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%2520produces%2520complex%2520behavioral%2520effects%2520in%2520rodent%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D6701%26epage%3D6711%26doi%3D10.1523%2FJNEUROSCI.0299-07.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Vernon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbarsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datla, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dexter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croucher, M. J.</span><span> </span><span class="NLM_article-title">Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1124/jpet.106.108159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.106.108159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17012606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=397-409&author=A.+C.+Vernonauthor=V.+Zbarskyauthor=K.+P.+Datlaauthor=D.+T.+Dexterauthor=M.+J.+Croucher&title=Selective+activation+of+group+III+metabotropic+glutamate+receptors+by+L-%28%2B%29-2-amino-4-phosphonobutryic+acid+protects+the+nigrostriatal+system+against+6-hydroxydopamine+toxicity+in+vivo&doi=10.1124%2Fjpet.106.108159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo</span></div><div class="casAuthors">Vernon, Anthony C.; Zbarsky, Virginia; Datla, Krishna P.; Dexter, David T.; Croucher, Martin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Evidence from several studies suggests that the progressive degeneration of dopaminergic (DA) neurons of the substantia nigra pars compacta (SNc) in Parkinson's disease (PD) may in part be due to excessive release of glutamate from subthalamic projections onto nigral DA neurons.  Previous in vitro studies have demonstrated that selective activation of Group III metabotropic glutamate receptors (mGluR) neg. modulates excitatory transmission in the SNc and is neuroprotective against glutamate-mediated toxicity.  Consistent with this, we have reported preliminary data indicating that the selective group III mGluR agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) can also protect the nigrostriatal system against 6-hydroxydopamine (6-OHDA) toxicity in vivo.  We have now extended these preliminary studies in this model and report here that both acute and subchronic intranigral injections of L-AP4 provide significant protection of the nigrostriatal system against 6-OHDA toxicity.  This neuroprotection displays a bell-shaped profile with a clear concn.-dependent relationship.  In contrast, when administered to animals 7 days post-6-OHDA lesioning, L-AP4 significantly protects the functionality but not the integrity of the nigrostriatal system.  We further demonstrate that neuroprotection by L-AP4 in vivo is reversed by coadministration of the selective Group III mGluR antagonist (RS)-α-methylserine-O-phosphate, confirming a receptor-mediated mechanism of action.  These data provide further compelling evidence that selective activation of Group III mGluR is neuroprotective in an in vivo exptl. model of PD, a finding that may have important implications for the future treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGx5qqmT7mP7Vg90H21EOLACvtfcHk0lg3-BgbwP0J4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFChtw%253D%253D&md5=7721f7e77ffc4c708575b7f206a59f5f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.108159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.108159%26sid%3Dliteratum%253Aachs%26aulast%3DVernon%26aufirst%3DA.%2BC.%26aulast%3DZbarsky%26aufirst%3DV.%26aulast%3DDatla%26aufirst%3DK.%2BP.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26aulast%3DCroucher%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%2520by%2520L-%2528%252B%2529-2-amino-4-phosphonobutryic%2520acid%2520protects%2520the%2520nigrostriatal%2520system%2520against%25206-hydroxydopamine%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D397%26epage%3D409%26doi%3D10.1124%2Fjpet.106.108159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Maj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inderbitzin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoehr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranesic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flor, P. J.</span><span> </span><span class="NLM_article-title">(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span><span class="refDoi"> DOI: 10.1016/S0028-3908(03)00271-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2803%2900271-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2003&pages=895-906&author=M.+Majauthor=V.+Brunoauthor=Z.+Dragicauthor=R.+Yamamotoauthor=G.+Battagliaauthor=W.+Inderbitzinauthor=N.+Stoehrauthor=T.+Steinauthor=F.+Gaspariniauthor=I.+Vranesicauthor=R.+Kuhnauthor=F.+Nicolettiauthor=P.+J.+Flor&title=%28%E2%88%92%29-PHCCC%2C+a+positive+allosteric+modulator+of+mGluR4%3A+characterization%2C+mechanism+of+action%2C+and+neuroprotection&doi=10.1016%2FS0028-3908%2803%2900271-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2803%2900271-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252803%252900271-5%26sid%3Dliteratum%253Aachs%26aulast%3DMaj%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DDragic%26aufirst%3DZ.%26aulast%3DYamamoto%26aufirst%3DR.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DInderbitzin%26aufirst%3DW.%26aulast%3DStoehr%26aufirst%3DN.%26aulast%3DStein%26aufirst%3DT.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DVranesic%26aufirst%3DI.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26atitle%3D%2528%25E2%2588%2592%2529-PHCCC%252C%2520a%2520positive%2520allosteric%2520modulator%2520of%2520mGluR4%253A%2520characterization%252C%2520mechanism%2520of%2520action%252C%2520and%2520neuroprotection%26jtitle%3DNeuropharmacology%26date%3D2003%26volume%3D45%26spage%3D895%26epage%3D906%26doi%3D10.1016%2FS0028-3908%2803%2900271-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charvin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessif, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koser, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLella, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, I. J.</span><span> </span><span class="NLM_article-title">A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1124/jpet.112.196063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.112.196063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22787118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=167-177&author=E.+Le+Poulauthor=C.+Boleaauthor=F.+Girardauthor=S.+Poliauthor=D.+Charvinauthor=B.+Campoauthor=J.+Bortoliauthor=A.+Bessifauthor=B.+Luoauthor=A.+J.+Koserauthor=L.+M.+Hodgeauthor=K.+M.+Smithauthor=A.+G.+DiLellaauthor=N.+Livertonauthor=F.+Hessauthor=S.+E.+Browneauthor=I.+J.+Reynolds&title=A+potent+and+selective+metabotropic+glutamate+receptor+4+positive+allosteric+modulator+improves+movement+in+rodent+models+of+Parkinson%E2%80%99s+disease&doi=10.1124%2Fjpet.112.196063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease</span></div><div class="casAuthors">Le Poul, Emmanuel; Bolea, Christelle; Girard, Francoise; Poli, Sonia; Charvin, Delphine; Campo, Brice; Bortoli, Julien; Bessif, Abdhelak; Luo, Bin; Koser, Amy Jo; Hodge, Lisa M.; Smith, Karen M.; DiLella, Anthony G.; Liverton, Nigel; Hess, Fred; Browne, Susan E.; Reynolds, Ian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">167-177</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) have been proposed as a novel therapeutic approach for the treatment of Parkinson's disease.  However, evaluation of this proposal has been limited by the availability of appropriate pharmacol. tools to interrogate the target.  In this study, we describe the properties of a novel mGluR4 PAM.  5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178) enhances glutamate-mediated activation of human and rat mGluR4 with EC50 values of 4 and 9 nM, resp.  The compd. is highly selective for mGluR4 with minimal activities at other mGluRs.  Oral administration of ADX88178 in rats is assocd. with high bioavailability and results in cerebrospinal fluid exposure of >50-fold the in vitro EC50 value.  ADX88178 reverses haloperidol-induced catalepsy in rats at 3 and 10 mg/kg.  It is noteworthy that this compd. alone has no impact on forelimb akinesia resulting from a bilateral 6-hydroxydopamine lesion in rats.  However, coadministration of a low dose of L-DOPA (6 mg/kg) enabled a robust, dose-dependent reversal of the forelimb akinesia deficit.  ADX88178 also increased the effects of quinpirole in lesioned rats and enhanced the effects of L-DOPA in MitoPark mice.  It is noteworthy that the enhancement of the actions of L-DOPA was not assocd. with an exacerbation of L-DOPA-induced dyskinesias in rats.  ADX88178 is a novel, potent, and selective mGluR4 PAM that is a valuable tool for exploring the therapeutic potential of mGluR4 modulation.  The use of this novel tool mol. supports the proposal that activation of mGluR4 may be therapeutically useful in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKn2sck-WjrVg90H21EOLACvtfcHk0lg3-BgbwP0J4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagsbvJ&md5=16472f6814708d33dd463fbdbf0c6fce</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.196063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.196063%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DCharvin%26aufirst%3DD.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBortoli%26aufirst%3DJ.%26aulast%3DBessif%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DKoser%26aufirst%3DA.%2BJ.%26aulast%3DHodge%26aufirst%3DL.%2BM.%26aulast%3DSmith%26aufirst%3DK.%2BM.%26aulast%3DDiLella%26aufirst%3DA.%2BG.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DHess%26aufirst%3DF.%26aulast%3DBrowne%26aufirst%3DS.%2BE.%26aulast%3DReynolds%26aufirst%3DI.%2BJ.%26atitle%3DA%2520potent%2520and%2520selective%2520metabotropic%2520glutamate%2520receptor%25204%2520positive%2520allosteric%2520modulator%2520improves%2520movement%2520in%2520rodent%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D167%26epage%3D177%26doi%3D10.1124%2Fjpet.112.196063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Kalinichev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer-Urios, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uslaner, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celanire, S.</span><span> </span><span class="NLM_article-title">Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span><span class="refDoi"> DOI: 10.1124/jpet.114.214437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.114.214437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=24947466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1artbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=495-505&author=M.+Kalinichevauthor=E.+Le+Poulauthor=C.+Boleaauthor=F.+Girardauthor=B.+Campoauthor=M.+Fonsiauthor=I.+Royer-Uriosauthor=S.+E.+Browneauthor=J.+M.+Uslanerauthor=M.+J.+Davisauthor=J.+Raberauthor=R.+Duvoisinauthor=S.+T.+Bateauthor=I.+J.+Reynoldsauthor=S.+Poliauthor=S.+Celanire&title=Characterization+of+the+novel+positive+allosteric+modulator+of+the+metabotropic+glutamate+receptor+4+ADX88178+in+rodent+models+of+neuropsychiatric+disorders&doi=10.1124%2Fjpet.114.214437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders</span></div><div class="casAuthors">Kalinichev, Mikhail; Le Poul, Emmanuel; Bolea, Christelle; Girard, Francoise; Campo, Brice; Fonsi, Massimiliano; Royer-Urios, Isabelle; Browne, Susan E.; Uslaner, Jason M.; Davis, Matthew J.; Raber, Jacob; Duvoisin, Robert; Bate, Simon T.; Reynolds, Ian J.; Poli, Sonia; Celanire, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-505, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">There is growing evidence that activation of metabotropic glutamate receptor 4 (mGlu4) leads to anxiolytic- and antipsychotic-like efficacy in rodent models, yet its relevance to depression-like reactivity remains unclear.  Here, we present the pharmacol. evaluation of ADX88178 [5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine], a novel potent, selective, and brain-penetrant pos. allosteric modulator of the mGlu4 receptor in rodent models of anxiety, obsessive compulsive disorder (OCD), fear, depression, and psychosis.  ADX88178 dose-dependently reduced the no. of buried marbles in the marble burying test and increased open-arm exploration in the elevated plus maze (EPM) test, indicative of anxiolytic-like efficacy.  Target specificity of the effect in the EPM test was confirmed using male and female mGlu4 receptor knockout mice.  In mice, ADX88178 reduced the likelihood of conditioned freezing in the acquisition phase of the fear conditioning test, yet had no carryover effect in the expression phase.  Also, ADX88178 dose-dependently reduced duration of immobility in the forced swim test, indicative of antidepressant-like efficacy.  ADX88178 reduced DOI (2,5-dimethoxy-4-iodoamphetamine)-mediated head twitches (albeit with no dose-dependency), and MK-801 [(5S,10R)-(1)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]-induced locomotor hyperactivity in mice, but was inactive in the conditioned avoidance response test in rats.  The compd. showed good specificity as it had no effect on locomotor activity in mice and rats at efficacious doses.  Thus, allosteric activation of mGlu4 receptors can be a promising new therapeutic approach for treatment of anxiety, OCD, fear-related disorders, and psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQGgfpSK4icbVg90H21EOLACvtfcHk0lgDWpsg82RiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1artbvI&md5=76c4ccefb15198f128ecced62cbec235</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.214437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.214437%26sid%3Dliteratum%253Aachs%26aulast%3DKalinichev%26aufirst%3DM.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DRoyer-Urios%26aufirst%3DI.%26aulast%3DBrowne%26aufirst%3DS.%2BE.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DDavis%26aufirst%3DM.%2BJ.%26aulast%3DRaber%26aufirst%3DJ.%26aulast%3DDuvoisin%26aufirst%3DR.%26aulast%3DBate%26aufirst%3DS.%2BT.%26aulast%3DReynolds%26aufirst%3DI.%2BJ.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DCelanire%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25204%2520ADX88178%2520in%2520rodent%2520models%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D495%26epage%3D505%26doi%3D10.1124%2Fjpet.114.214437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bennouar, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uberti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacolod, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerkerian-Le Goff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubellini, P.</span><span> </span><span class="NLM_article-title">Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson’s disease treatment and dyskinesia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2012.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22491024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFaiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=158-169&author=K.+E.+Bennouarauthor=M.+A.+Ubertiauthor=C.+Melonauthor=M.+D.+Bacolodauthor=H.+N.+Jimenezauthor=M.+Cajinaauthor=L.+Kerkerian-Le+Goffauthor=D.+Dollerauthor=P.+Gubellini&title=Synergy+between+L-DOPA+and+a+novel+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+4%3A+implications+for+Parkinson%E2%80%99s+disease+treatment+and+dyskinesia&doi=10.1016%2Fj.neuropharm.2012.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia</span></div><div class="casAuthors">Bennouar, Khaled-Ezaheir; Uberti, Michelle A.; Melon, Christophe; Bacolod, Maria D.; Jimenez, Hermogenes N.; Cajina, Manuel; Kerkerian-Le Goff, Lydia; Doller, Dario; Gubellini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to dopamine depletion in Parkinson's disease (PD).  For this reason, group III mGlu receptors, in particular mGlu4, were considered as key strategic targets for non-dopaminergic pharmacol. treatments aimed at modulating these synapses, without producing the well known side-effects of L-DOPA, in particular the highly disabling L-DOPA-induced dyskinesia (LID).  Herein we add physiol. and functional support to this hypothesis using Lu AF21934, a novel selective and brain-penetrant mGlu4 receptor pos. allosteric modulator (PAM) tool compd.  By in vitro electrophysiol. recordings we demonstrate that Lu AF21934 inhibits corticostriatal synaptic transmission and enhances the effect of the orthosteric mGlu4 receptor-preferred agonist LSP1-2111.  In naive rats, Lu AF21934 dose-dependently (10 and 30 mg/kg) alleviated haloperidol-induced catalepsy.  In hemiparkinsonian rats (unilateral 6-hydroxydopamine lesion of the substantia nigra pars compacta), Lu AF21934 alone did not affect akinesia at the doses tested (10 and 30 mg/kg).  However, when Lu AF21934 was combined with sub-threshold doses of L-DOPA (1 and 5 mg/kg), it acted synergistically in alleviating akinesia in a dose-dependent manner and, notably, also reduced the incidence of LID but not its severity.  Interestingly, these effects occurred at Lu AF21934 brain free concns. that showed functional activity in in vitro screens (calcium flux and electrophysiol. assays).  These results support the potential for antiparkinsonian clin. use of a combined treatment consisting in L-DOPA and a mGlu4 receptor PAM to reduce efficacious L-DOPA doses (generally known as L-DOPA sparing), while maintaining the same benefit on PD motor troubles, and at the same time minimizing the development of LID.  This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3jZln8IohrVg90H21EOLACvtfcHk0lgDWpsg82RiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFaiu78%253D&md5=7c98d8a74c9bb958b7b8cc95d5f0a113</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DBennouar%26aufirst%3DK.%2BE.%26aulast%3DUberti%26aufirst%3DM.%2BA.%26aulast%3DMelon%26aufirst%3DC.%26aulast%3DBacolod%26aufirst%3DM.%2BD.%26aulast%3DJimenez%26aufirst%3DH.%2BN.%26aulast%3DCajina%26aufirst%3DM.%26aulast%3DKerkerian-Le%2BGoff%26aufirst%3DL.%26aulast%3DDoller%26aufirst%3DD.%26aulast%3DGubellini%26aufirst%3DP.%26atitle%3DSynergy%2520between%2520L-DOPA%2520and%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25204%253A%2520implications%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520treatment%2520and%2520dyskinesia%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.neuropharm.2012.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engers, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loch, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Development and antiparkinsonian activity of VU0418506, a selective positive allosteric modulator of metabotropic glutamate receptor 4 homomers without activity at mGlu2/4 heteromers</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1211</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SmsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1201-1211&author=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=X.+Linauthor=M.+Bubserauthor=A.+Thompson+Grayauthor=A.+L.+Blobaumauthor=D.+W.+Engersauthor=A.+L.+Rodriguezauthor=M.+T.+Lochauthor=J.+S.+Danielsauthor=C.+W.+Lindsleyauthor=C.+R.+Hopkinsauthor=J.+A.+Javitchauthor=P.+J.+Conn&title=Development+and+antiparkinsonian+activity+of+VU0418506%2C+a+selective+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+4+homomers+without+activity+at+mGlu2%2F4+heteromers&doi=10.1021%2Facschemneuro.6b00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers</span></div><div class="casAuthors">Niswender, Colleen M.; Jones, Carrie K.; Lin, Xin; Bubser, Michael; Thompson Gray, Analisa; Blobaum, Anna L.; Engers, Darren W.; Rodriguez, Alice L.; Loch, Matthew T.; Daniels, J. Scott; Lindsley, Craig W.; Hopkins, Corey R.; Javitch, Jonathan A.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1201-1211</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD).  As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using pos. and neg. allosteric modulators (PAMs and NAMs, resp.) has become a common strategy.  We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion.  Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacol. profile in response to allosteric modulators.  For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compds. potentiate mGlu4 responses regardless of mGlu2 coexpression.  We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models.  Using pharmacol. approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technol., we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compds. without activity at mGlu2/4 heteromers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUg2gMmrP17Vg90H21EOLACvtfcHk0lifAM2Fhc8akQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SmsLfE&md5=99640d47aaa23bed5e1aba4bb380cb0a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00036%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DThompson%2BGray%26aufirst%3DA.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DLoch%26aufirst%3DM.%2BT.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDevelopment%2520and%2520antiparkinsonian%2520activity%2520of%2520VU0418506%252C%2520a%2520selective%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25204%2520homomers%2520without%2520activity%2520at%2520mGlu2%252F4%2520heteromers%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D1201%26epage%3D1211%26doi%3D10.1021%2Facschemneuro.6b00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Engers, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogliotti, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salovich, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barrantes, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macor, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Discovery, Synthesis and Pre-Clinical Characterization of N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4)</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">–</span> <span class="NLM_lpage">1200</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvF2ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1192-1200&author=D.+W.+Engersauthor=A.+L.+Blobaumauthor=R.+D.+Gogliottiauthor=Y.+Y.+Cheungauthor=J.+M.+Salovichauthor=P.+M.+Garcia-Barrantesauthor=J.+S.+Danielsauthor=R.+Morrisonauthor=C.+K.+Jonesauthor=M.+G.+Soarsauthor=X.+Zhuoauthor=J.+Hurleyauthor=J.+E.+Macorauthor=J.+J.+Bronsonauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=C.+M.+Niswenderauthor=C.+R.+Hopkins&title=Discovery%2C+Synthesis+and+Pre-Clinical+Characterization+of+N-%283-chloro-4-fluorophenyl%29-1H-pyrazolo%5B4%2C3-b%5Dpyridin-3-amine+%28VU0418506%29%2C+a+novel+positive+allosteric+modulator+of+the+metabotropic+glutamate+receptor+4+%28mGlu4%29&doi=10.1021%2Facschemneuro.6b00035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)</span></div><div class="casAuthors">Engers, Darren W.; Blobaum, Anna L.; Gogliotti, Rocco D.; Cheung, Yiu-Yin; Salovich, James M.; Garcia-Barrantes, Pedro M.; Daniels, J. Scott; Morrison, Ryan; Jones, Carrie K.; Soars, Matthew G.; Zhuo, Xiaoliang; Hurley, Jeremy; Macor, John E.; Bronson, Joanne J.; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1192-1200</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclin. rodent models of Parkinson's disease has been established by a no. of groups.  Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506).  We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a no. of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group.  VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclin. safety species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgxhaqdEiSvbVg90H21EOLACvtfcHk0lifAM2Fhc8akQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvF2ntbo%253D&md5=0ced736754a1b0ce24cca4d99daf0503</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00035%26sid%3Dliteratum%253Aachs%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DGogliotti%26aufirst%3DR.%2BD.%26aulast%3DCheung%26aufirst%3DY.%2BY.%26aulast%3DSalovich%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DDiscovery%252C%2520Synthesis%2520and%2520Pre-Clinical%2520Characterization%2520of%2520N-%25283-chloro-4-fluorophenyl%2529-1H-pyrazolo%255B4%252C3-b%255Dpyridin-3-amine%2520%2528VU0418506%2529%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25204%2520%2528mGlu4%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D1192%26epage%3D1200%26doi%3D10.1021%2Facschemneuro.6b00035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Charvin, D.; Manteau, B.; Pomel, V.; Conquet, F.</span><span> </span><span class="NLM_article-title">Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors</span>. WO2016030444,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Charvin&author=B.+Manteau&author=V.+Pomel&author=F.+Conquet&title=Novel+chromone+oxime+derivative+and+its+use+as+allosteric+modulator+of+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvin%26aufirst%3DD.%26atitle%3DNovel%2520chromone%2520oxime%2520derivative%2520and%2520its%2520use%2520as%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Schann, S.; Mayer, S.; Morice, C.; Giethlen, B.</span><span> </span><span class="NLM_article-title">Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors</span>. WO2011051478,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Schann&author=S.+Mayer&author=C.+Morice&author=B.+Giethlen&title=Novel+oxime+derivatives+and+their+use+as+allosteric+modulators+of+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchann%26aufirst%3DS.%26atitle%3DNovel%2520oxime%2520derivatives%2520and%2520their%2520use%2520as%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busceti, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biagioni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traficante, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span> </span><span class="NLM_article-title">Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">7222</span><span class="NLM_x">–</span> <span class="NLM_lpage">7229</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.1595-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.1595-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16822979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=7222-7229&author=G.+Battagliaauthor=C.+L.+Buscetiauthor=G.+Molinaroauthor=F.+Biagioniauthor=A.+Traficanteauthor=F.+Nicolettiauthor=V.+Bruno&title=Pharmacological+activation+of+mGlu4+metabotropic+glutamate+receptors+reduces+nigrostriatal+degeneration+in+mice+treated+with+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine&doi=10.1523%2FJNEUROSCI.1595-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span></div><div class="casAuthors">Battaglia, Giuseppe; Busceti, Carla L.; Molinaro, Gemma; Biagioni, Francesca; Traficante, Anna; Nicoletti, Ferdinando; Bruno, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7222-7229</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We examd. whether selective activation of mGlu4 metabotropic glutamate receptors attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage in mice.  C57BL mice were treated with a single dose of MPTP (30 mg/kg, i.p.) proceded, 30 min earlier, by a systemic injection of the mGlu4 receptor enhancer N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC).  PHCCC was injected either s.c. in cremophor EL or i.p. in saline contg. 50% DMSO.  PHCCC treatment (3 or 10 mg/kg) significantly reduced MPTP toxicity, as assessed by measurements of the striatal levels of dopamine and its metabolites and by tyrosine hydroxylase, dopamine transporter, and glial fibrillary acidic protein immunostaining in the corpus striatum and substantia nigra.  In another set of expts., a higher cumulative dose of MPTP (80 mg/kg divided into four injections with 2 h of interval) was injected to mGlu4-/- mice and their Sv129/CD1 wild-type controls.  A higher dose was used in these expts. because Sv129/CD1 mice are less sensitive to MPTP toxicity.  Systemic administration of PHCCC was protective in wild-type mice but failed to affect nigrostriatal damage in mGlu4-/- mice.  Finally, unilateral infusion of PHCCC in the external globus pallidus protected the ipsilateral nigrostriatal pathway against MPTP toxicity.  These data support the view that mGlu4 receptors are potential targets for the exptl. treatment of parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmpIXlBAH1PrVg90H21EOLACvtfcHk0lhzZSd69pfqSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFejsbw%253D&md5=a135bb61fee6ddd6e4b17caf1ca7eae6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1595-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1595-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DBusceti%26aufirst%3DC.%2BL.%26aulast%3DMolinaro%26aufirst%3DG.%26aulast%3DBiagioni%26aufirst%3DF.%26aulast%3DTraficante%26aufirst%3DA.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DBruno%26aufirst%3DV.%26atitle%3DPharmacological%2520activation%2520of%2520mGlu4%2520metabotropic%2520glutamate%2520receptors%2520reduces%2520nigrostriatal%2520degeneration%2520in%2520mice%2520treated%2520with%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D7222%26epage%3D7229%26doi%3D10.1523%2FJNEUROSCI.1595-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLella, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson’s disease treatment</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">13668</span><span class="NLM_x">–</span> <span class="NLM_lpage">13673</span><span class="refDoi"> DOI: 10.1073/pnas.1835724100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1073%2Fpnas.1835724100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13668-13673&author=M.+J.+Marinoauthor=D.+L.+Williamsauthor=J.+A.+O%E2%80%99Brienauthor=O.+Valentiauthor=T.+P.+McDonaldauthor=M.+K.+Clementsauthor=R.+Wangauthor=A.+G.+DiLellaauthor=J.+F.+Hessauthor=G.+G.+Kinneyauthor=P.+J.+Conn&title=Allosteric+modulation+of+group+III+metabotropic+glutamate+receptor+4%3A+a+potential+approach+to+Parkinson%E2%80%99s+disease+treatment&doi=10.1073%2Fpnas.1835724100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1835724100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1835724100%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DValenti%26aufirst%3DO.%26aulast%3DMcDonald%26aufirst%3DT.%2BP.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDiLella%26aufirst%3DA.%2BG.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DAllosteric%2520modulation%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptor%25204%253A%2520a%2520potential%2520approach%2520to%2520Parkinson%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D13668%26epage%3D13673%26doi%3D10.1073%2Fpnas.1835724100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Stachowicz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">498</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2004.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.ejphar.2004.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=15363989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFGksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=498&publication_year=2004&pages=153-156&author=K.+Stachowiczauthor=K.+Klakauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+Pilc&title=Anxiolytic-like+effects+of+PHCCC%2C+an+allosteric+modulator+of+mGlu4+receptors%2C+in+rats&doi=10.1016%2Fj.ejphar.2004.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats</span></div><div class="casAuthors">Stachowicz, Katarzyna; Klak, Kinga; Klodzinska, Aleksandra; Chojnacka-Wojcik, Ewa; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">498</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We examd. the potential anxiolytic-like activity of (-)-N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), an allosteric modulator of metabotropic glutamate4 receptors (mGlu4), after administration into the basolateral amygdala, using the conflict drinking Vogel test in rats as a model.  The results indicate that PHCCC, but not 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate Et ester (CPCCOEt), the selective antagonist of group mGlu1 receptors, showed significant, dose-dependent anticonflict effects without affecting the threshold current or water intake.  The results indicate that pos. allosteric modulation of mGlu4 receptors may be a useful therapeutic approach to anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokig2pRNX0-LVg90H21EOLACvtfcHk0lhzZSd69pfqSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFGksL8%253D&md5=33836a910beaa8bf8b11f6243a522d67</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DStachowicz%26aufirst%3DK.%26aulast%3DKlak%26aufirst%3DK.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DAnxiolytic-like%2520effects%2520of%2520PHCCC%252C%2520an%2520allosteric%2520modulator%2520of%2520mGlu4%2520receptors%252C%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D498%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.ejphar.2004.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Iacovelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazzaglia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronica, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinsanti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Smaele, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Onofrio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giangaspero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span> </span><span class="NLM_article-title">Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">8388</span><span class="NLM_x">–</span> <span class="NLM_lpage">8397</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.2285-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.2285-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16899734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28Xos1Kju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=8388-8397&author=L.+Iacovelliauthor=A.+Arcellaauthor=G.+Battagliaauthor=S.+Pazzagliaauthor=E.+Aronicaauthor=P.+Spinsantiauthor=A.+Carusoauthor=E.+De+Smaeleauthor=A.+Saranauthor=A.+Gulinoauthor=M.+D%E2%80%99Onofrioauthor=F.+Giangasperoauthor=F.+Nicoletti&title=Pharmacological+activation+of+mGlu4+metabotropic+glutamate+receptors+inhibits+the+growth+of+medulloblastomas&doi=10.1523%2FJNEUROSCI.2285-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas</span></div><div class="casAuthors">Iacovelli, Luisa; Arcella, Antonietta; Battaglia, Giuseppe; Pazzaglia, Simonetta; Aronica, Eleonora; Spinsanti, Paola; Caruso, Alessandra; De Smaele, Enrico; Saran, Anna; Gulino, Alberto; D'Onofrio, Mara; Giangaspero, Felice; Nicoletti, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8388-8397</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Moving from the evidence that activation of type 4 metabotropic glutamate (mGlu4) receptors inhibits proliferation and promotes differentiation of cerebellar granule cell neuroprogenitors, we examd. the expression and function of mGlu4 receptors in medulloblastoma cells.  MGlu4 receptors were expressed in 46 of 60 human medulloblastoma samples.  Expression varied in relation to the histotype (nodular desmoplastic>classic>>large-cell anaplastic) and was inversely related to tumor severity, spreading, and recurrence.  MGlu4 receptors were also found in D283med, D341med, and DAOY medulloblastoma cell lines, where receptor activation with the selective enhancer PHCCC inhibited adenylyl cyclase and the phosphatidylinositol-3-kinase pathway without affecting the mitogen-activated protein kinase, Sonic Hedgehog, and Wnt pathways.  Interestingly, mGlu4 receptor activation reduced DNA synthesis and cell proliferation in all three cell lines.  This effect was abrogated by the phosphatidylinositol-3-kinase inhibitor LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one].  In in vivo expts., repeated s.c. injections of N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) reduced the growth of D283med and DAOY cell xenografts in nude mice.  More remarkably, s.c. or intracranial injections of PHCCC during the first week of life prevented the development of medulloblastomas in mice lacking one Patched-1 allele and x-irradiated 1 d after birth.  These data suggest that mGlu4 receptor enhancers are promising drugs for the treatment of medulloblastomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwH_YpxJPttrVg90H21EOLACvtfcHk0ljECV8TwlkX-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xos1Kju70%253D&md5=98d72e960bdce899cabe1df422a2bb0e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2285-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2285-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DIacovelli%26aufirst%3DL.%26aulast%3DArcella%26aufirst%3DA.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DPazzaglia%26aufirst%3DS.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3DSpinsanti%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DDe%2BSmaele%26aufirst%3DE.%26aulast%3DSaran%26aufirst%3DA.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Onofrio%26aufirst%3DM.%26aulast%3DGiangaspero%26aufirst%3DF.%26aulast%3DNicoletti%26aufirst%3DF.%26atitle%3DPharmacological%2520activation%2520of%2520mGlu4%2520metabotropic%2520glutamate%2520receptors%2520inhibits%2520the%2520growth%2520of%2520medulloblastomas%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D8388%26epage%3D8397%26doi%3D10.1523%2FJNEUROSCI.2285-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Goudet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschalier, A.</span><span> </span><span class="NLM_article-title">Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.pain.2007.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.pain.2007.08.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2008&pages=112-124&author=C.+Goudetauthor=E.+Chapuyauthor=A.+Allouiauthor=F.+Acherauthor=J.+P.+Pinauthor=A.+Eschalier&title=Group+III+metabotropic+glutamate+receptors+inhibit+hyperalgesia+in+animal+models+of+inflammation+and+neuropathic+pain&doi=10.1016%2Fj.pain.2007.08.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2007.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2007.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DChapuy%26aufirst%3DE.%26aulast%3DAlloui%26aufirst%3DA.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DEschalier%26aufirst%3DA.%26atitle%3DGroup%2520III%2520metabotropic%2520glutamate%2520receptors%2520inhibit%2520hyperalgesia%2520in%2520animal%2520models%2520of%2520inflammation%2520and%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2008%26volume%3D137%26spage%3D112%26epage%3D124%26doi%3D10.1016%2Fj.pain.2007.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zussy, C.; Gomez-Santacana, X.; Rovira, X.; De Bundel, D.; Ferrazzo, S.; Bosch, D.; Asede, D.; Malhaire, F.; Acher, F.; Giraldo, J.; Valjent, E.; Ehrlich, I.; Ferraguti, F.; Pin, J. P.; Llebaria, A.; Goudet, C.</span><span> </span><span class="NLM_article-title">Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4</span>.  <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span>DOI <span class="refDoi"> DOI: 10.1038/mp.2016.223</span> , <a href="https://www.ncbi.nlm.nih.gov/pubmed/27994221" class="extLink">https://www.ncbi.nlm.nih.gov/pubmed/27994221</a> (accessed December 20, 2016).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fmp.2016.223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+Zussy&author=X.+Gomez-Santacana&author=X.+Rovira&author=D.+De+Bundel&author=S.+Ferrazzo&author=D.+Bosch&author=D.+Asede&author=F.+Malhaire&author=F.+Acher&author=J.+Giraldo&author=E.+Valjent&author=I.+Ehrlich&author=F.+Ferraguti&author=J.+P.+Pin&author=A.+Llebaria&author=C.+Goudet&title=Dynamic+modulation+of+inflammatory+pain-related+affective+and+sensory+symptoms+by+optical+control+of+amygdala+metabotropic+glutamate+receptor+4&doi=10.1038%2Fmp.2016.223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fmp.2016.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2016.223%26sid%3Dliteratum%253Aachs%26aulast%3DZussy%26aufirst%3DC.%26atitle%3DDynamic%2520modulation%2520of%2520inflammatory%2520pain-related%2520affective%2520and%2520sensory%2520symptoms%2520by%2520optical%2520control%2520of%2520amygdala%2520metabotropic%2520glutamate%2520receptor%25204%26jtitle%3DMol.%2520Psychiatry%26date%3D2016%26doi%3D10.1038%2Fmp.2016.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fallarino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notartomaso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busceti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicciato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioretti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohmann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, R.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">902</span><span class="refDoi"> DOI: 10.1038/nm.2183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fnm.2183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=20657581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1artr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=897-902&author=F.+Fallarinoauthor=C.+Volpiauthor=F.+Fazioauthor=S.+Notartomasoauthor=C.+Vaccaauthor=C.+Buscetiauthor=S.+Bicciatoauthor=G.+Battagliaauthor=V.+Brunoauthor=P.+Puccettiauthor=M.+C.+Fiorettiauthor=F.+Nicolettiauthor=U.+Grohmannauthor=R.+Di+Marco&title=Metabotropic+glutamate+receptor-4+modulates+adaptive+immunity+and+restrains+neuroinflammation&doi=10.1038%2Fnm.2183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation</span></div><div class="casAuthors">Fallarino, Francesca; Volpi, Claudia; Fazio, Francesco; Notartomaso, Serena; Vacca, Carmine; Busceti, Carla; Bicciato, Silvio; Battaglia, Giuseppe; Bruno, Valeria; Puccetti, Paolo; Fioretti, Maria C.; Nicoletti, Ferdinando; Grohmann, Ursula; Di Marco, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">897-902</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High amts. of glutamate are found in the brains of people with multiple sclerosis, an inflammatory disease marked by progressive demyelination.  Glutamate might affect neuroinflammation via effects on immune cells.  Knockout mice lacking metabotropic glutamate receptor-4 (mGluR4) were markedly vulnerable to exptl. autoimmune encephalomyelitis (EAE, a mouse model of multiple sclerosis) and developed responses dominated by interleukin-17-producing T helper (TH17) cells.  In dendritic cells (DCs) from those mice, defective mGluR4 signaling-which would normally decrease intracellular cAMP formation-biased TH cell commitment to the TH17 phenotype.  In wild-type mice, mGluR4 was constitutively expressed in all peripheral DCs, and this expression increased after cell activation.  Treatment of wild-type mice with a selective mGluR4 enhancer increased EAE resistance via regulatory T (Treg) cells.  The high amts. of glutamate in neuroinflammation might reflect a counterregulatory mechanism that is protective in nature and might be harnessed therapeutically for restricting immunopathol. in multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_TVkLsW3vDbVg90H21EOLACvtfcHk0ljECV8TwlkX-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1artr4%253D&md5=56b1aeff47dd2351eb63654c19a76dda</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.2183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2183%26sid%3Dliteratum%253Aachs%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFazio%26aufirst%3DF.%26aulast%3DNotartomaso%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBusceti%26aufirst%3DC.%26aulast%3DBicciato%26aufirst%3DS.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DDi%2BMarco%26aufirst%3DR.%26atitle%3DMetabotropic%2520glutamate%2520receptor-4%2520modulates%2520adaptive%2520immunity%2520and%2520restrains%2520neuroinflammation%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D897%26epage%3D902%26doi%3D10.1038%2Fnm.2183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebois, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchalski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5626</span><span class="NLM_x">–</span> <span class="NLM_lpage">5630</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.bmcl.2008.08.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5626-5630&author=C.+M.+Niswenderauthor=E.+P.+Leboisauthor=Q.+Luoauthor=K.+Kimauthor=H.+Muchalskiauthor=H.+Yinauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+subtype+4+%28mGluR4%29%3A+Part+I.+Discovery+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+as+novel+mGluR4+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2008.08.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.087%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLebois%26aufirst%3DE.%2BP.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DMuchalski%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25204%2520%2528mGluR4%2529%253A%2520Part%2520I.%2520Discovery%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520novel%2520mGluR4%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5626%26epage%3D5630%26doi%3D10.1016%2Fj.bmcl.2008.08.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlo, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Paulis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Days, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalywajko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1358</span><span class="refDoi"> DOI: 10.1124/mol.108.049551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fmol.108.049551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=18664603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCntrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1345-1358&author=C.+M.+Niswenderauthor=K.+A.+Johnsonauthor=C.+D.+Weaverauthor=C.+K.+Jonesauthor=Z.+Xiangauthor=Q.+Luoauthor=A.+L.+Rodriguezauthor=J.+E.+Marloauthor=T.+de+Paulisauthor=A.+D.+Thompsonauthor=E.+L.+Daysauthor=T.+Nalywajkoauthor=C.+A.+Austinauthor=M.+B.+Williamsauthor=J.+E.+Ayalaauthor=R.+Williamsauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Discovery%2C+characterization%2C+and+antiparkinsonian+effect+of+novel+positive+allosteric+modulators+of+metabotropic+glutamate+receptor+4&doi=10.1124%2Fmol.108.049551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4</span></div><div class="casAuthors">Niswender, Colleen M.; Johnson, Kari A.; Weaver, C. David; Jones, Carrie K.; Xiang, Zixiu; Luo, Qingwei; Rodriguez, Alice L.; Marlo, Joy E.; de Paulis, Tomas; Thompson, Analisa D.; Days, Emily L.; Nalywajko, Tasha; Austin, Cheryl A.; Williams, Michael Baxter; Ayala, Jennifer E.; Williams, Richard; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1345-1358</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is caused by the death of dopamine neurons in the basal ganglia and results in motor symptoms such as tremor and bradykinesia.  Activation of metabotropic glutamate receptor 4 (mGluR4) has been shown to modulate neurotransmission in the basal ganglia and results in antiparkinsonian effects in rodent PD models.  N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) is a pos. allosteric modulator (PAM) of mGluR4 that has been used to further validate the role of mGluR4 in PD, but the compd. suffers from a lack of selectivity, relatively low potency, and poor soly.  Via high-throughput screening, we discovered more than 400 novel PAMs of mGluR4.  Compds. derived from a novel chem. scaffold were characterized in vitro at both rat and human mGluR4 using two distinct assays of mGluR4 function.  The lead compd. was approx. 8-fold more potent than PHCCC, enhanced the potency of glutamate at mGluR4 by 8-fold, and did not show any significant potentiator or antagonist activity at other mGluR subtypes.  Resoln. of the regioisomers of the lead revealed that the cis regioisomer, (±)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041), contained the majority of the mGluR4 PAM activity and also exhibited partial agonist activity at mGluR4 at a site that was distinct from the glutamate binding site, suggesting that this compd. is a mixed allosteric agonist/PAM of mGluR4.  VU0155041 was sol. in an aq. vehicle, and intracerebroventricular administration of 31 to 316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats.  These exciting results provide continued support for mGluR4 as a therapeutic target in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfO7Oi9u7buLVg90H21EOLACvtfcHk0lgdjRXYn8uGHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCntrfE&md5=c6316915f428898340313b7003f2e605</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049551%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DMarlo%26aufirst%3DJ.%2BE.%26aulast%3Dde%2BPaulis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DNalywajko%26aufirst%3DT.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%2BB.%26aulast%3DAyala%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%252C%2520characterization%252C%2520and%2520antiparkinsonian%2520effect%2520of%2520novel%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptor%25204%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1345%26epage%3D1358%26doi%3D10.1124%2Fmol.108.049551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">962</span><span class="NLM_x">–</span> <span class="NLM_lpage">966</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.bmcl.2008.11.104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=962-966&author=R.+Williamsauthor=C.+M.+Niswenderauthor=Q.+Luoauthor=U.+Leauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+subtype+4+%28mGluR4%29.+Part+II%3A+Challenges+in+hit-to-lead&doi=10.1016%2Fj.bmcl.2008.11.104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.104%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DLe%26aufirst%3DU.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25204%2520%2528mGluR4%2529.%2520Part%2520II%253A%2520Challenges%2520in%2520hit-to-lead%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D962%26epage%3D966%26doi%3D10.1016%2Fj.bmcl.2008.11.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGluR4</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1021/cn9000318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn9000318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=411-419&author=R.+Williamsauthor=Y.+Zhouauthor=C.+M.+Niswenderauthor=Q.+Luoauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=C.+R.+Hopkins&title=Re-exploration+of+the+PHCCC+scaffold%3A+discovery+of+improved+positive+allosteric+modulators+of+mGluR4&doi=10.1021%2Fcn9000318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4</span></div><div class="casAuthors">Williams, Richard; Zhou, Ya; Niswender, Colleen M.; Luo, Qingwei; Conn, P. Jeffrey; Lindsley, Craig W.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes a detailed structure-activity relation (SAR) anal. of the metabotropic glutamate receptor 4 (mGluR4) pos. allosteric modulator, (-)-N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC).  The authors have now developed compds. with improved potency and efficacy; in addn., compds. are presented that show selectivity for mGluR4 vs. the other mGluR subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2WcP_RojsbVg90H21EOLACvtfcHk0lh_l44uIKyUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVOgu70%253D&md5=e2d43eefe332164e71002af710ba1fd8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fcn9000318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn9000318%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DRe-exploration%2520of%2520the%2520PHCCC%2520scaffold%253A%2520discovery%2520of%2520improved%2520positive%2520allosteric%2520modulators%2520of%2520mGluR4%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D411%26epage%3D419%26doi%3D10.1021%2Fcn9000318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Schann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span> </span><span class="NLM_article-title">Novel screening paradigms for the identification of allosteric modulators and/or biased ligands for challenging G-protein-coupled receptors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/B978-0-12-800167-7.00018-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FB978-0-12-800167-7.00018-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=285-300&author=S.+Schannauthor=P.+Neuvilleauthor=M.+Bouvier&title=Novel+screening+paradigms+for+the+identification+of+allosteric+modulators+and%2For+biased+ligands+for+challenging+G-protein-coupled+receptors&doi=10.1016%2FB978-0-12-800167-7.00018-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800167-7.00018-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800167-7.00018-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchann%26aufirst%3DS.%26aulast%3DNeuville%26aufirst%3DP.%26aulast%3DBouvier%26aufirst%3DM.%26atitle%3DNovel%2520screening%2520paradigms%2520for%2520the%2520identification%2520of%2520allosteric%2520modulators%2520and%252For%2520biased%2520ligands%2520for%2520challenging%2520G-protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2014%26volume%3D49%26spage%3D285%26epage%3D300%26doi%3D10.1016%2FB978-0-12-800167-7.00018-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwakabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigemoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, S.</span><span> </span><span class="NLM_article-title">Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">11868</span><span class="NLM_x">–</span> <span class="NLM_lpage">11873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=11868-11873&author=Y.+Nakajimaauthor=H.+Iwakabeauthor=C.+Akazawaauthor=H.+Nawaauthor=R.+Shigemotoauthor=N.+Mizunoauthor=S.+Nakanishi&title=Molecular+characterization+of+a+novel+retinal+metabotropic+glutamate+receptor+mGluR6+with+a+high+agonist+selectivity+for+L-2-amino-4-phosphonobutyrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DIwakabe%26aufirst%3DH.%26aulast%3DAkazawa%26aufirst%3DC.%26aulast%3DNawa%26aufirst%3DH.%26aulast%3DShigemoto%26aufirst%3DR.%26aulast%3DMizuno%26aufirst%3DN.%26aulast%3DNakanishi%26aufirst%3DS.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520novel%2520retinal%2520metabotropic%2520glutamate%2520receptor%2520mGluR6%2520with%2520a%2520high%2520agonist%2520selectivity%2520for%2520L-2-amino-4-phosphonobutyrate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D11868%26epage%3D11873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Duty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">–</span> <span class="NLM_lpage">1391</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01426.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%E2%80%99s+disease%3A+a+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease&doi=10.1111%2Fj.1476-5381.2011.01426.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lh_l44uIKyUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391%26doi%3D10.1111%2Fj.1476-5381.2011.01426.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Blandini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armentero, M. T.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">1156</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08491.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1111%2Fj.1742-4658.2012.08491.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2012&pages=1156-1166&author=F.+Blandiniauthor=M.+T.+Armentero&title=Animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1742-4658.2012.08491.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08491.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08491.x%26sid%3Dliteratum%253Aachs%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFEBS%2520J.%26date%3D2012%26volume%3D279%26spage%3D1156%26epage%3D1166%26doi%3D10.1111%2Fj.1742-4658.2012.08491.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Deumens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1006/exnr.2002.7891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1006%2Fexnr.2002.7891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=12061862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2002&pages=303-317&author=R.+Deumensauthor=A.+Bloklandauthor=J.+Prickaerts&title=Modeling+Parkinson%E2%80%99s+disease+in+rats%3A+an+evaluation+of+6-OHDA+lesions+of+the+nigrostriatal+pathway&doi=10.1006%2Fexnr.2002.7891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway</span></div><div class="casAuthors">Deumens, Ronald; Blokland, Arjan; Prickaerts, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-317</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Human idiopathic Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by degeneration of the dopaminergic neurons of the nigrostriatal pathway.  Different 6-OHDA rat models of PD were developed in which this toxin was injected into different parts of the nigrostriatal pathway: (a) the medial forebrain bundle which leads to extensive dopamine (DA) depletion; (b) the substantia nigra pars compacta, which leads to more specific and moderate DA depletions; and (c) subregions of the caudate-putamen complex (CPu), which also leads to specific DA depletions.  In this article we review the dopaminergic depletion and behavioral consequences of 6-OHDA lesions in the rat.  It was examd. whether the relation between DA depletion and behavioral deficits mimic idiopathic PD.  In addn., it was evaluated which model most closely approximates the human situation, esp. in relation to the stage of this progressive disease.  It was concluded that with respect to the site of the lesion, rats with partial lesions of the ventrolateral CPu are the most appropriate models to study early and late stages of PD.  The choice of the behavioral parameters dets. the use of unilateral or bilateral lesions, although it is obvious that the bilateral model mimics the human situation more closely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraF6nvJly4p7Vg90H21EOLACvtfcHk0lhiBmUPihC6Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVequr0%253D&md5=4489ac8336d1bedbe02f52fe3a1ac2bb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2002.7891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2002.7891%26sid%3Dliteratum%253Aachs%26aulast%3DDeumens%26aufirst%3DR.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DModeling%2520Parkinson%25E2%2580%2599s%2520disease%2520in%2520rats%253A%2520an%2520evaluation%2520of%25206-OHDA%2520lesions%2520of%2520the%2520nigrostriatal%2520pathway%26jtitle%3DExp.%2520Neurol.%26date%3D2002%26volume%3D175%26spage%3D303%26epage%3D317%26doi%3D10.1006%2Fexnr.2002.7891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carta, A. R.</span><span> </span><span class="NLM_article-title">The 6-hydroxydopamine model of Parkinson’s disease</span> <span class="citation_source-journal">Neurotoxic. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1007/BF03033565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1007%2FBF03033565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17449457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFymu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=151-167&author=N.+Simolaauthor=M.+Morelliauthor=A.+R.+Carta&title=The+6-hydroxydopamine+model+of+Parkinson%E2%80%99s+disease&doi=10.1007%2FBF03033565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The 6-hydroxydopamine model of Parkinson's disease</span></div><div class="casAuthors">Simola, Nicola; Morelli, Micaela; Carta, Anna R.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3,4</span>),
    <span class="NLM_cas:pages">151-167</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">F. P. Graham Publishing Co.</span>)
        </div><div class="casAbstract">A review.  The neurotoxin 6-hydroxydopamine (6-OHDA) continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease in the rat.  The classical method of intracerebral infusion of 6-OHDA, involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochem. dysfunctions in Parkinson's disease.  Subsequently, more subtle models of partial dopaminergic degeneration have been developed with the aim of revealing finer motor deficits.  The present review will examine the main features of 6-OHDA models, namely the mechanisms of neurotoxin-induced neurodegeneration as well as several behavioral deficits and motor dysfunctions, including the priming model, modeled by this means.  An overview of the most recent morphol. and biochem. findings obtained with the 6-OHDA model will also be provided, particular attention being focused on the newly investigated intracellular mechanisms at the striatal level (e.g., A2A and NMDA receptors, PKA, CaMKII, ERK kinases, as well as immediate early genes, GAD67 and peptides).  Thanks to studies performed in the 6-OHDA model, all these mechanisms have now been hypothesised to represent the site of pathol. dysfunction at cellular level in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkyWlIkKbjbVg90H21EOLACvtfcHk0lhiBmUPihC6Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFymu7c%253D&md5=61ddf5d5b32a7d12630a9416e5b9f401</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2FBF03033565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033565%26sid%3Dliteratum%253Aachs%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DA.%2BR.%26atitle%3DThe%25206-hydroxydopamine%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2007%26volume%3D11%26spage%3D151%26epage%3D167%26doi%3D10.1007%2FBF03033565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Jenkins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poutiainen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kil, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruppu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aytan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedeoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brownell, A. L.</span><span> </span><span class="NLM_article-title">Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2015.11.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=462-473&author=B.+Jenkinsauthor=A.+Zhuauthor=P.+Poutiainenauthor=J.+K.+Choiauthor=K.+E.+Kilauthor=Z.+Zhangauthor=D.+Kuruppuauthor=N.+Aytanauthor=A.+Dedeogluauthor=A.+L.+Brownell&title=Functional+modulation+of+G-protein+coupled+receptors+during+Parkinson+disease-like+neurodegeneration&doi=10.1016%2Fj.neuropharm.2015.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DPoutiainen%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DJ.%2BK.%26aulast%3DKil%26aufirst%3DK.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DKuruppu%26aufirst%3DD.%26aulast%3DAytan%26aufirst%3DN.%26aulast%3DDedeoglu%26aufirst%3DA.%26aulast%3DBrownell%26aufirst%3DA.%2BL.%26atitle%3DFunctional%2520modulation%2520of%2520G-protein%2520coupled%2520receptors%2520during%2520Parkinson%2520disease-like%2520neurodegeneration%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D108%26spage%3D462%26epage%3D473%26doi%3D10.1016%2Fj.neuropharm.2015.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desbois, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blache, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span> </span><span class="NLM_article-title">Synthesis of carbamoylpyridine and imidazo[1,5-a]pyridin-1,3-diones via ortho-acetalhydantoin intermediates</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2003.10.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.tetlet.2003.10.200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=553-556&author=J.+M.+Chezalauthor=E.+Moreauauthor=N.+Desboisauthor=Y.+Blacheauthor=O.+Chavignonauthor=J.+C.+Teulade&title=Synthesis+of+carbamoylpyridine+and+imidazo%5B1%2C5-a%5Dpyridin-1%2C3-diones+via+ortho-acetalhydantoin+intermediates&doi=10.1016%2Fj.tetlet.2003.10.200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2003.10.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2003.10.200%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DDesbois%26aufirst%3DN.%26aulast%3DBlache%26aufirst%3DY.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520of%2520carbamoylpyridine%2520and%2520imidazo%255B1%252C5-a%255Dpyridin-1%252C3-diones%2520via%2520ortho-acetalhydantoin%2520intermediates%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D553%26epage%3D556%26doi%3D10.1016%2Fj.tetlet.2003.10.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberknecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, J.</span><span> </span><span class="NLM_article-title">Amino acids and peptides. XLIII: Dehydroamino acids. XVIII: Synthesis of dehydroamino acids and amino acids from <i>N</i>-acyl-2-(dialkyloxyphosphinyl)-glycin esters: II</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">1984</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1055/s-1984-30730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1055%2Fs-1984-30730" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1984&publication_year=1984&pages=53-60&author=U.+Schmidtauthor=A.+Lieberknechtauthor=J.+Wild&title=Amino+acids+and+peptides.+XLIII%3A+Dehydroamino+acids.+XVIII%3A+Synthesis+of+dehydroamino+acids+and+amino+acids+from+N-acyl-2-%28dialkyloxyphosphinyl%29-glycin+esters%3A+II&doi=10.1055%2Fs-1984-30730"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1055%2Fs-1984-30730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1984-30730%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DLieberknecht%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DJ.%26atitle%3DAmino%2520acids%2520and%2520peptides.%2520XLIII%253A%2520Dehydroamino%2520acids.%2520XVIII%253A%2520Synthesis%2520of%2520dehydroamino%2520acids%2520and%2520amino%2520acids%2520from%2520N-acyl-2-%2528dialkyloxyphosphinyl%2529-glycin%2520esters%253A%2520II%26jtitle%3DSynthesis%26date%3D1984%26volume%3D1984%26spage%3D53%26epage%3D60%26doi%3D10.1055%2Fs-1984-30730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Minguez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaquero, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez-Builla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castano, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J. L.</span><span> </span><span class="NLM_article-title">Pyrrolodiazines. 5. Synthesis, structure, and chemistry of pyrrolo[1,2-<i>c</i>]pyrimidine. Dipolar cycloaddition of pyrrolo[1,2-<i>c</i>]pyrimidinium ylides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7788</span><span class="NLM_x">–</span> <span class="NLM_lpage">7801</span><span class="refDoi"> DOI: 10.1021/jo9907080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9907080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=7788-7801&author=J.+M.+Minguezauthor=J.+J.+Vaqueroauthor=J.+Alvarez-Buillaauthor=O.+Castanoauthor=J.+L.+Andr%C3%A9s&title=Pyrrolodiazines.+5.+Synthesis%2C+structure%2C+and+chemistry+of+pyrrolo%5B1%2C2-c%5Dpyrimidine.+Dipolar+cycloaddition+of+pyrrolo%5B1%2C2-c%5Dpyrimidinium+ylides&doi=10.1021%2Fjo9907080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo9907080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9907080%26sid%3Dliteratum%253Aachs%26aulast%3DMinguez%26aufirst%3DJ.%2BM.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DAlvarez-Builla%26aufirst%3DJ.%26aulast%3DCastano%26aufirst%3DO.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.%2BL.%26atitle%3DPyrrolodiazines.%25205.%2520Synthesis%252C%2520structure%252C%2520and%2520chemistry%2520of%2520pyrrolo%255B1%252C2-c%255Dpyrimidine.%2520Dipolar%2520cycloaddition%2520of%2520pyrrolo%255B1%252C2-c%255Dpyrimidinium%2520ylides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D7788%26epage%3D7801%26doi%3D10.1021%2Fjo9907080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Wishka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groppi, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanchar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornburgh, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Burgos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raub, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arneric, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B. N.</span><span> </span><span class="NLM_article-title">Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4425</span><span class="NLM_x">–</span> <span class="NLM_lpage">4436</span><span class="refDoi"> DOI: 10.1021/jm0602413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0602413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4425-4436&author=D.+G.+Wishkaauthor=D.+P.+Walkerauthor=K.+M.+Yatesauthor=S.+C.+Reitzauthor=S.+Jiaauthor=J.+K.+Myersauthor=K.+L.+Olsonauthor=E.+J.+Jacobsenauthor=M.+L.+Wolfeauthor=V.+E.+Groppiauthor=A.+J.+Hancharauthor=B.+A.+Thornburghauthor=L.+A.+Cortes-Burgosauthor=E.+H.+Wongauthor=B.+A.+Statonauthor=T.+J.+Raubauthor=N.+R.+Higdonauthor=T.+M.+Wallauthor=R.+S.+Hurstauthor=R.+R.+Waltersauthor=W.+E.+Hoffmannauthor=M.+Hajosauthor=S.+Franklinauthor=G.+Careyauthor=L.+H.+Goldauthor=K.+K.+Cookauthor=S.+B.+Sandsauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=A.+S.+Kalgutkarauthor=S.+P.+Arnericauthor=B.+N.+Rogers&title=Discovery+of+N-%5B%283R%29-1-azabicyclo%5B2.2.2%5Doct-3-yl%5Dfuro%5B2%2C3-c%5Dpyridine-5-carboxamide%2C+an+agonist+of+the+alpha7+nicotinic+acetylcholine+receptor%2C+for+the+potential+treatment+of+cognitive+deficits+in+schizophrenia%3A+synthesis+and+structure%2D%2Dactivity+relationship&doi=10.1021%2Fjm0602413"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm0602413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0602413%26sid%3Dliteratum%253Aachs%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DReitz%26aufirst%3DS.%2BC.%26aulast%3DJia%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%2BK.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DWolfe%26aufirst%3DM.%2BL.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DHanchar%26aufirst%3DA.%2BJ.%26aulast%3DThornburgh%26aufirst%3DB.%2BA.%26aulast%3DCortes-Burgos%26aufirst%3DL.%2BA.%26aulast%3DWong%26aufirst%3DE.%2BH.%26aulast%3DStaton%26aufirst%3DB.%2BA.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DHigdon%26aufirst%3DN.%2BR.%26aulast%3DWall%26aufirst%3DT.%2BM.%26aulast%3DHurst%26aufirst%3DR.%2BS.%26aulast%3DWalters%26aufirst%3DR.%2BR.%26aulast%3DHoffmann%26aufirst%3DW.%2BE.%26aulast%3DHajos%26aufirst%3DM.%26aulast%3DFranklin%26aufirst%3DS.%26aulast%3DCarey%26aufirst%3DG.%26aulast%3DGold%26aufirst%3DL.%2BH.%26aulast%3DCook%26aufirst%3DK.%2BK.%26aulast%3DSands%26aufirst%3DS.%2BB.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DArneric%26aufirst%3DS.%2BP.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26atitle%3DDiscovery%2520of%2520N-%255B%25283R%2529-1-azabicyclo%255B2.2.2%255Doct-3-yl%255Dfuro%255B2%252C3-c%255Dpyridine-5-carboxamide%252C%2520an%2520agonist%2520of%2520the%2520alpha7%2520nicotinic%2520acetylcholine%2520receptor%252C%2520for%2520the%2520potential%2520treatment%2520of%2520cognitive%2520deficits%2520in%2520schizophrenia%253A%2520synthesis%2520and%2520structure--activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4425%26epage%3D4436%26doi%3D10.1021%2Fjm0602413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Adams, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittingham, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, C. L.</span><span> </span><span class="NLM_article-title">Diastereoselective synthesis of cyclopropane amino acids using diazo compounds generated in situ</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9433</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span><span class="refDoi"> DOI: 10.1021/jo035060c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo035060c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVClsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=9433-9440&author=L.+A.+Adamsauthor=V.+K.+Aggarwalauthor=R.+V.+Bonnertauthor=B.+Bresselauthor=R.+J.+Coxauthor=J.+Shepherdauthor=J.+de+Vicenteauthor=M.+Walterauthor=W.+G.+Whittinghamauthor=C.+L.+Winn&title=Diastereoselective+synthesis+of+cyclopropane+amino+acids+using+diazo+compounds+generated+in+situ&doi=10.1021%2Fjo035060c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective Synthesis of Cyclopropane Amino Acids Using Diazo Compounds Generated in Situ</span></div><div class="casAuthors">Adams, Luke A.; Aggarwal, Varinder K.; Bonnert, Roger V.; Bressel, Bettina; Cox, Russell J.; Shepherd, Jon; De Vicente, Javier; Walter, Magnus; Whittingham, William G.; Winn, Caroline L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9433-9440</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A simple and high-yielding method for the prepn. of cyclopropane amino acids is described.  The novel method involves the one-pot cyclopropanation of readily available dehydroamino acids using aryl and unsatd. diazo compds. generated in situ from the corresponding tosylhydrazone salts.  It was found that thermal 1,3-dipolar cycloaddn. followed by nitrogen extrusion gave the cyclopropane amino acid derivs. with good trans selectivity, while reactions in the presence of catalyst meso-tetraphenylporphyrin iron chloride gave predominantly the corresponding cis isomers.  The synthetic utility of this process was demonstrated in the synthesis of (cis)-2,3-methanophenylalanine, (trans)-2,3-methano-m-tyrosine, and (±)-coronamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-ZBlJ1Q99LVg90H21EOLACvtfcHk0ljOViBLQZRY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVClsrw%253D&md5=3a84664f044b47afe42ec966efb8f75e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjo035060c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo035060c%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DL.%2BA.%26aulast%3DAggarwal%26aufirst%3DV.%2BK.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBressel%26aufirst%3DB.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3Dde%2BVicente%26aufirst%3DJ.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DWhittingham%26aufirst%3DW.%2BG.%26aulast%3DWinn%26aufirst%3DC.%2BL.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520cyclopropane%2520amino%2520acids%2520using%2520diazo%2520compounds%2520generated%2520in%2520situ%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D9433%26epage%3D9440%26doi%3D10.1021%2Fjo035060c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Plewe, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dress, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehler, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahavendran, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanis, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7211</span><span class="NLM_x">–</span> <span class="NLM_lpage">7219</span><span class="refDoi"> DOI: 10.1021/jm900862n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900862n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7211-7219&author=M.+B.+Pleweauthor=S.+L.+Butlerauthor=K.+R.+Dressauthor=Q.+Huauthor=T.+W.+Johnsonauthor=J.+E.+Kuehlerauthor=A.+Kukiauthor=H.+Lamauthor=W.+Liuauthor=D.+Nowlinauthor=Q.+Pengauthor=S.+V.+Rahavendranauthor=S.+P.+Tanisauthor=K.+T.+Tranauthor=H.+Wangauthor=A.+Yangauthor=J.+Zhang&title=Azaindole+hydroxamic+acids+are+potent+HIV-1+integrase+inhibitors&doi=10.1021%2Fjm900862n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm900862n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900862n%26sid%3Dliteratum%253Aachs%26aulast%3DPlewe%26aufirst%3DM.%2BB.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKuehler%26aufirst%3DJ.%2BE.%26aulast%3DKuki%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DNowlin%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DRahavendran%26aufirst%3DS.%2BV.%26aulast%3DTanis%26aufirst%3DS.%2BP.%26aulast%3DTran%26aufirst%3DK.%2BT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DAzaindole%2520hydroxamic%2520acids%2520are%2520potent%2520HIV-1%2520integrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7211%26epage%3D7219%26doi%3D10.1021%2Fjm900862n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delmas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueiffier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blache, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lartigue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span> </span><span class="NLM_article-title">Heterocyclization of functionalized vinylic derivatives of imidazo</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6576</span><span class="NLM_x">–</span> <span class="NLM_lpage">6584</span><span class="refDoi"> DOI: 10.1021/jo015582x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo015582x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=6576-6584&author=J.+M.+Chezalauthor=E.+Moreauauthor=G.+Delmasauthor=A.+Gueiffierauthor=Y.+Blacheauthor=G.+Grassyauthor=C.+Lartigueauthor=O.+Chavignonauthor=J.+C.+Teulade&title=Heterocyclization+of+functionalized+vinylic+derivatives+of+imidazo&doi=10.1021%2Fjo015582x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo015582x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo015582x%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DDelmas%26aufirst%3DG.%26aulast%3DGueiffier%26aufirst%3DA.%26aulast%3DBlache%26aufirst%3DY.%26aulast%3DGrassy%26aufirst%3DG.%26aulast%3DLartigue%26aufirst%3DC.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26atitle%3DHeterocyclization%2520of%2520functionalized%2520vinylic%2520derivatives%2520of%2520imidazo%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D6576%26epage%3D6584%26doi%3D10.1021%2Fjo015582x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Gao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikai, N.</span><span> </span><span class="NLM_article-title">Cobalt-catalyzed ortho alkylation of aromatic imines with primary and secondary alkyl halides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">9279</span><span class="NLM_x">–</span> <span class="NLM_lpage">9282</span><span class="refDoi"> DOI: 10.1021/ja403759x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja403759x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVehu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=9279-9282&author=K.+Gaoauthor=N.+Yoshikai&title=Cobalt-catalyzed+ortho+alkylation+of+aromatic+imines+with+primary+and+secondary+alkyl+halides&doi=10.1021%2Fja403759x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cobalt-Catalyzed Ortho Alkylation of Aromatic Imines with Primary and Secondary Alkyl Halides</span></div><div class="casAuthors">Gao, Ke; Yoshikai, Naohiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">9279-9282</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here cobalt-N-heterocyclic carbene catalytic systems for the ortho alkylation of arom. imines with alkyl chlorides and bromides, which allows the introduction of a variety of primary and secondary alkyl groups at room temp. [e.g., PhC(:N-PMP)Me + n-C8H17Cl in presence of CoBr2, preligand 1,3-diisopropylbenzimidazolium bromide, and tBuCH2MgBr → o-octylacetophenone].  The stereochem. outcomes of the reaction of secondary alkyl halides suggest that the present reaction involves single-electron transfer from a cobalt species to the alkyl halide to generate the corresponding alkyl radical.  A cycloalkylated product obtained by this method can be transformed into unique spirocycles through manipulation of the directing and cycloalkyl groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8dQ8iwElS8LVg90H21EOLACvtfcHk0lgs4oDJd60EXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVehu78%253D&md5=208c65ba47a73504224ee53485533ec9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja403759x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja403759x%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DK.%26aulast%3DYoshikai%26aufirst%3DN.%26atitle%3DCobalt-catalyzed%2520ortho%2520alkylation%2520of%2520aromatic%2520imines%2520with%2520primary%2520and%2520secondary%2520alkyl%2520halides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D9279%26epage%3D9282%26doi%3D10.1021%2Fja403759x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Bovonsombat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leykajarakul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pla-on, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanthapura, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doowa, N.</span><span> </span><span class="NLM_article-title">Regioselective iodination of phenol and analogues using <i>N</i>-iodosuccinimide and <i>p</i>-toluenesulfonic acid</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2664</span><span class="NLM_x">–</span> <span class="NLM_lpage">2667</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2009.03.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.tetlet.2009.03.128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=2664-2667&author=P.+Bovonsombatauthor=J.+Leykajarakulauthor=C.+Khanauthor=K.+Pla-onauthor=M.+M.+Krauseauthor=P.+Khanthapuraauthor=R.+Aliauthor=N.+Doowa&title=Regioselective+iodination+of+phenol+and+analogues+using+N-iodosuccinimide+and+p-toluenesulfonic+acid&doi=10.1016%2Fj.tetlet.2009.03.128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.03.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.03.128%26sid%3Dliteratum%253Aachs%26aulast%3DBovonsombat%26aufirst%3DP.%26aulast%3DLeykajarakul%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DC.%26aulast%3DPla-on%26aufirst%3DK.%26aulast%3DKrause%26aufirst%3DM.%2BM.%26aulast%3DKhanthapura%26aufirst%3DP.%26aulast%3DAli%26aufirst%3DR.%26aulast%3DDoowa%26aufirst%3DN.%26atitle%3DRegioselective%2520iodination%2520of%2520phenol%2520and%2520analogues%2520using%2520N-iodosuccinimide%2520and%2520p-toluenesulfonic%2520acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D2664%26epage%3D2667%26doi%3D10.1016%2Fj.tetlet.2009.03.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Colle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1016/S0028-3908(98)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2898%2900091-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=1043-1051&author=I.+Brabetauthor=M.+L.+Parmentierauthor=C.+De+Colleauthor=J.+Bockaertauthor=F.+Acherauthor=J.+P.+Pin&title=Comparative+effect+of+L-CCG-I%2C+DCG-IV+and+gamma-carboxy-L-glutamate+on+all+cloned+metabotropic+glutamate+receptor+subtypes&doi=10.1016%2FS0028-3908%2898%2900091-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2898%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252898%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DParmentier%26aufirst%3DM.%2BL.%26aulast%3DDe%2BColle%26aufirst%3DC.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DComparative%2520effect%2520of%2520L-CCG-I%252C%2520DCG-IV%2520and%2520gamma-carboxy-L-glutamate%2520on%2520all%2520cloned%2520metabotropic%2520glutamate%2520receptor%2520subtypes%26jtitle%3DNeuropharmacology%26date%3D1998%26volume%3D37%26spage%3D1043%26epage%3D1051%26doi%3D10.1016%2FS0028-3908%2898%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Frauli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vol, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Among the twenty classical L-amino acids, only glutamate directly activates metabotropic glutamate receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2005.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2005.09.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=245-253&author=M.+Frauliauthor=P.+Neuvilleauthor=C.+Volauthor=J.+P.+Pinauthor=L.+Prezeau&title=Among+the+twenty+classical+L-amino+acids%2C+only+glutamate+directly+activates+metabotropic+glutamate+receptors&doi=10.1016%2Fj.neuropharm.2005.09.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2005.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2005.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DFrauli%26aufirst%3DM.%26aulast%3DNeuville%26aufirst%3DP.%26aulast%3DVol%26aufirst%3DC.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DAmong%2520the%2520twenty%2520classical%2520L-amino%2520acids%252C%2520only%2520glutamate%2520directly%2520activates%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2006%26volume%3D50%26spage%3D245%26epage%3D253%26doi%3D10.1016%2Fj.neuropharm.2005.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Gomeza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restituito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=923-930&author=J.+Gomezaauthor=S.+Maryauthor=I.+Brabetauthor=M.+L.+Parmentierauthor=S.+Restituitoauthor=J.+Bockaertauthor=J.+P.+Pin&title=Coupling+of+metabotropic+glutamate+receptors+2+and+4+to+G+alpha+15%2C+G+alpha+16%2C+and+chimeric+G+alpha+q%2Fi+proteins%3A+characterization+of+new+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DMary%26aufirst%3DS.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DParmentier%26aufirst%3DM.%2BL.%26aulast%3DRestituito%26aufirst%3DS.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DCoupling%2520of%2520metabotropic%2520glutamate%2520receptors%25202%2520and%25204%2520to%2520G%2520alpha%252015%252C%2520G%2520alpha%252016%252C%2520and%2520chimeric%2520G%2520alpha%2520q%252Fi%2520proteins%253A%2520characterization%2520of%2520new%2520antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D923%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Tora, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovira, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dione, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Koninck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudet, C.</span><span> </span><span class="NLM_article-title">Allosteric modulation of metabotropic glutamate receptors by chloride ions</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4174</span><span class="NLM_x">–</span> <span class="NLM_lpage">4188</span><span class="refDoi"> DOI: 10.1096/fj.14-269746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1096%2Ffj.14-269746" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=4174-4188&author=A.+S.+Toraauthor=X.+Roviraauthor=I.+Dioneauthor=H.+O.+Bertrandauthor=I.+Brabetauthor=Y.+De+Koninckauthor=N.+Doyonauthor=J.+P.+Pinauthor=F.+Acherauthor=C.+Goudet&title=Allosteric+modulation+of+metabotropic+glutamate+receptors+by+chloride+ions&doi=10.1096%2Ffj.14-269746"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-269746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-269746%26sid%3Dliteratum%253Aachs%26aulast%3DTora%26aufirst%3DA.%2BS.%26aulast%3DRovira%26aufirst%3DX.%26aulast%3DDione%26aufirst%3DI.%26aulast%3DBertrand%26aufirst%3DH.%2BO.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DDe%2BKoninck%26aufirst%3DY.%26aulast%3DDoyon%26aufirst%3DN.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DGoudet%26aufirst%3DC.%26atitle%3DAllosteric%2520modulation%2520of%2520metabotropic%2520glutamate%2520receptors%2520by%2520chloride%2520ions%26jtitle%3DFASEB%2520J.%26date%3D2015%26volume%3D29%26spage%3D4174%26epage%3D4188%26doi%3D10.1096%2Ffj.14-269746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junfeng Wang, Xiying Qu, Timothy M. Shoup, Gengyang Yuan, Sepideh Afshar, Chuzhi Pan, Aijun Zhu, Ji-Kyung Choi, Hye Jin Kang, Pekka Poutiainen, Georges El Fakhri, Zhaoda Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Anna-Liisa Brownell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of Fluorine-18-Labeled N-(4-Chloro-3-((fluoromethyl-d2)thio)phenyl)picolinamide for Imaging of mGluR4 in Brain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3381-3389. <a href="https://doi.org/10.1021/acs.jmedchem.0c00201" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00201%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252BFluorine-18-Labeled%252BN-%2525284-Chloro-3-%252528%252528fluoromethyl-d2%252529thio%252529phenyl%252529picolinamide%252Bfor%252BImaging%252Bof%252BmGluR4%252Bin%252BBrain%26aulast%3DWang%26aufirst%3DJunfeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D04032020%26date%3D21022020%26volume%3D63%26issue%3D6%26spage%3D3381%26epage%3D3389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pankaj
V. Khairnar, Tsai-Hui Lung, Yi-Jung Lin, Chi-Yi Wu, Srinivasa Rao Koppolu, Athukuri Edukondalu, Praneeth Karanam, <span class="NLM_string-name hlFld-ContribAuthor">Wenwei Lin</span>. </span><span class="cited-content_cbyCitation_article-title">An Intramolecular Wittig Approach toward Heteroarenes: Synthesis of Pyrazoles, Isoxazoles, and Chromenone-oximes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (11)
                                     , 4219-4223. <a href="https://doi.org/10.1021/acs.orglett.9b01395" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01395%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAn%252BIntramolecular%252BWittig%252BApproach%252Btoward%252BHeteroarenes%25253A%252BSynthesis%252Bof%252BPyrazoles%25252C%252BIsoxazoles%25252C%252Band%252BChromenone-oximes%26aulast%3DKhairnar%26aufirst%3DPankaj%2BV.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23042019%26date%3D22052019%26volume%3D21%26issue%3D11%26spage%3D4219%26epage%3D4223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph
D. Panarese, Darren W. Engers, Yong-Jin Wu, Joanne J. Bronson, John E. Macor, Aspen Chun, Alice L. Rodriguez, Andrew S. Felts, Julie L. Engers, Matthew T. Loch, Kyle A. Emmitte, Arlindo L. Castelhano, Michael J. Kates, Michael A. Nader, Carrie K. Jones, Anna L. Blobaum, P. Jeffrey Conn, Colleen M. Niswender, Corey R. Hopkins, <span class="NLM_string-name hlFld-ContribAuthor">Craig W. Lindsley</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 255-260. <a href="https://doi.org/10.1021/acsmedchemlett.8b00426" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00426</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00426%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BVU2957%252B%252528Valiglurax%252529%25253A%252BAn%252BmGlu4%252BPositive%252BAllosteric%252BModulator%252BEvaluated%252Bas%252Ba%252BPreclinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DPanarese%26aufirst%3DJoseph%2BD.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14092018%26date%3D16102018%26date%3D17102018%26date%3D16102018%26volume%3D10%26issue%3D3%26spage%3D255%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Meng-Yang Chang, Han-Yu Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yu-Lin Tsai</span>. </span><span class="cited-content_cbyCitation_article-title">Temperature-Controlled Desulfonylative Condensation of α-Sulfonyl o-Hydroxyacetophenones and 2-Formyl Azaarenes: Synthesis of Azaaryl Aurones and Flavones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (1)
                                     , 326-337. <a href="https://doi.org/10.1021/acs.joc.8b02857" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02857</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02857%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTemperature-Controlled%252BDesulfonylative%252BCondensation%252Bof%252B%2525CE%2525B1-Sulfonyl%252Bo-Hydroxyacetophenones%252Band%252B2-Formyl%252BAzaarenes%25253A%252BSynthesis%252Bof%252BAzaaryl%252BAurones%252Band%252BFlavones%26aulast%3DChang%26aufirst%3DMeng-Yang%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D07112018%26date%3D21122018%26date%3D12122018%26volume%3D84%26issue%3D1%26spage%3D326%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexis St-Gelais, Jérôme Alsarraf, Jean Legault, Charles Gauthier, <span class="NLM_string-name hlFld-ContribAuthor">André Pichette</span>. </span><span class="cited-content_cbyCitation_article-title">Soft-enolization Baker–Venkataraman Rearrangement Enabled Total Synthesis of Dirchromones and Related 2-Substituted Chromones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (23)
                                     , 7424-7428. <a href="https://doi.org/10.1021/acs.orglett.8b03148" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03148%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSoft-enolization%252BBaker%2525E2%252580%252593Venkataraman%252BRearrangement%252BEnabled%252BTotal%252BSynthesis%252Bof%252BDirchromones%252Band%252BRelated%252B2-Substituted%252BChromones%26aulast%3DSt-Gelais%26aufirst%3DAlexis%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02102018%26date%3D29112018%26volume%3D20%26issue%3D23%26spage%3D7424%26epage%3D7428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isabelle  Waku</span>, <span class="hlFld-ContribAuthor ">Mylena S.  Magalhães</span>, <span class="hlFld-ContribAuthor ">Camila O.  Alves</span>, <span class="hlFld-ContribAuthor ">Amanda R.  de Oliveira</span>. </span><span class="cited-content_cbyCitation_article-title">Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Neuroscience</span><span> <strong>2021,</strong> <em>53 </em>
                                    (11)
                                     , 3743-3767. <a href="https://doi.org/10.1111/ejn.15222" title="DOI URL">https://doi.org/10.1111/ejn.15222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ejn.15222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fejn.15222%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Neuroscience%26atitle%3DHaloperidol%2525E2%252580%252590induced%252Bcatalepsy%252Bas%252Ban%252Banimal%252Bmodel%252Bfor%252Bparkinsonism%25253A%252BA%252Bsystematic%252Breview%252Bof%252Bexperimental%252Bstudies%26aulast%3DWaku%26aufirst%3DIsabelle%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D11%26spage%3D3743%26epage%3D3767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alshaima’a M.  Qunies</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Emmitte</span>. </span><span class="cited-content_cbyCitation_article-title">Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>7 </em>, 1-22. <a href="https://doi.org/10.1080/13543776.2021.1903431" title="DOI URL">https://doi.org/10.1080/13543776.2021.1903431</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1903431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1903431%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DNegative%252Ballosteric%252Bmodulators%252Bof%252Bgroup%252BII%252Bmetabotropic%252Bglutamate%252Breceptors%25253A%252BA%252Bpatent%252Breview%252B%2525282015%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DQunies%26aufirst%3DAlshaima%25E2%2580%2599a%2BM.%26date%3D2021%26date%3D2021%26volume%3D7%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karen J.  Gregory</span>, <span class="hlFld-ContribAuthor ">Cyril  Goudet</span>, . </span><span class="cited-content_cbyCitation_article-title">International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (1)
                                     , 521-569. <a href="https://doi.org/10.1124/pr.119.019133" title="DOI URL">https://doi.org/10.1124/pr.119.019133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.119.019133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.119.019133%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DInternational%252BUnion%252Bof%252BBasic%252Band%252BClinical%252BPharmacology.%252BCXI.%252BPharmacology%25252C%252BSignaling%25252C%252Band%252BPhysiology%252Bof%252BMetabotropic%252BGlutamate%252BReceptors%26aulast%3DGregory%26aufirst%3DKaren%2BJ.%26date%3D2021%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D521%26epage%3D569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dario  Doller</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Modulation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00057-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00057-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00057-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00057-8%26sid%3Dliteratum%253Aachs%26atitle%3DAllosteric%252BModulation%26aulast%3DDoller%26aufirst%3DDario%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dario  Doller</span>, <span class="hlFld-ContribAuthor ">Anton  Bespalov</span>, <span class="hlFld-ContribAuthor ">Rob  Miller</span>, <span class="hlFld-ContribAuthor ">Malgorzata  Pietraszek</span>, <span class="hlFld-ContribAuthor ">Mikhail  Kalinichev</span>. </span><span class="cited-content_cbyCitation_article-title">A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (12)
                                     , 1323-1338. <a href="https://doi.org/10.1080/13543784.2020.1839047" title="DOI URL">https://doi.org/10.1080/13543784.2020.1839047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1839047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1839047%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DA%252Bcase%252Bstudy%252Bof%252Bfoliglurax%25252C%252Bthe%252Bfirst%252Bclinical%252BmGluR4%252BPAM%252Bfor%252Bsymptomatic%252Btreatment%252Bof%252BParkinson%2525E2%252580%252599s%252Bdisease%25253A%252Btranslational%252Bgaps%252Bor%252Ba%252Bfailing%252Bindustry%252Binnovation%252Bmodel%25253F%26aulast%3DDoller%26aufirst%3DDario%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D12%26spage%3D1323%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Dan  Wang</span>, <span class="hlFld-ContribAuthor ">Bo  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhulin  Zhou</span>, <span class="hlFld-ContribAuthor ">Li  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (6)
                                     , 1074-1085. <a href="https://doi.org/10.1016/j.drudis.2020.04.001" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRegulation%252Bof%252Bmicroglia%252Bby%252Bglutamate%252Band%252Bits%252Bsignal%252Bpathway%252Bin%252Bneurodegenerative%252Bdiseases%26aulast%3DZhang%26aufirst%3DXinyue%26date%3D2020%26volume%3D25%26issue%3D6%26spage%3D1074%26epage%3D1085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veronika A.  Prikhodko</span>, <span class="hlFld-ContribAuthor ">Yuriy I.  Sysoev</span>, <span class="hlFld-ContribAuthor ">Sergey  Okovityi</span>. </span><span class="cited-content_cbyCitation_article-title">Morpholine derivatives as potential agents for neurological manifestations of nervous system diseases. </span><span class="cited-content_cbyCitation_journal-name">Pharmacy Formulas</span><span> <strong>2020,</strong> <em>2 </em>
                                    (1)
                                     , 16-35. <a href="https://doi.org/10.17816/phf21381" title="DOI URL">https://doi.org/10.17816/phf21381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.17816/phf21381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.17816%2Fphf21381%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacy%2520Formulas%26atitle%3DMorpholine%252Bderivatives%252Bas%252Bpotential%252Bagents%252Bfor%252Bneurological%252Bmanifestations%252Bof%252Bnervous%252Bsystem%252Bdiseases%26aulast%3DPrikhodko%26aufirst%3DVeronika%2BA.%26date%3D2020%26date%3D2020%26volume%3D2%26issue%3D1%26spage%3D16%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serena  Boccella</span>, <span class="hlFld-ContribAuthor ">Ida  Marabese</span>, <span class="hlFld-ContribAuthor ">Francesca  Guida</span>, <span class="hlFld-ContribAuthor ">Livio  Luongo</span>, <span class="hlFld-ContribAuthor ">Sabatino  Maione</span>, <span class="hlFld-ContribAuthor ">Enza  Palazzo</span>. </span><span class="cited-content_cbyCitation_article-title">The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum. </span><span class="cited-content_cbyCitation_journal-name">Current Neuropharmacology</span><span> <strong>2019,</strong> <em>18 </em>
                                    (1)
                                     , 34-50. <a href="https://doi.org/10.2174/1570159X17666190618121859" title="DOI URL">https://doi.org/10.2174/1570159X17666190618121859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570159X17666190618121859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570159X17666190618121859%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Neuropharmacology%26atitle%3DThe%252BModulation%252Bof%252BPain%252Bby%252BMetabotropic%252BGlutamate%252BReceptors%252B7%252Band%252B8%252Bin%252Bthe%252BDorsal%252BStriatum%26aulast%3DBoccella%26aufirst%3DSerena%26date%3D2019%26volume%3D18%26issue%3D1%26spage%3D34%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Shoup</span>, <span class="hlFld-ContribAuthor ">Anna-Liisa  Brownell</span>, <span class="hlFld-ContribAuthor ">Zhaoda  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Improved synthesis of the thiophenol precursor N-(4-chloro-3-mercaptophenyl)picolinamide for making the mGluR4 PET ligands. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (29)
                                     , 3917-3922. <a href="https://doi.org/10.1016/j.tet.2019.06.010" title="DOI URL">https://doi.org/10.1016/j.tet.2019.06.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.06.010%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DImproved%252Bsynthesis%252Bof%252Bthe%252Bthiophenol%252Bprecursor%252BN-%2525284-chloro-3-mercaptophenyl%252529picolinamide%252Bfor%252Bmaking%252Bthe%252BmGluR4%252BPET%252Bligands%26aulast%3DWang%26aufirst%3DJunfeng%26date%3D2019%26volume%3D75%26issue%3D29%26spage%3D3917%26epage%3D3922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio  Bello</span>, <span class="hlFld-ContribAuthor ">Mario  Giannella</span>, <span class="hlFld-ContribAuthor ">Gianfabio  Giorgioni</span>, <span class="hlFld-ContribAuthor ">Alessandro  Piergentili</span>, <span class="hlFld-ContribAuthor ">Wilma  Quaglia</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (4)
                                     , 142. <a href="https://doi.org/10.3390/biom9040142" title="DOI URL">https://doi.org/10.3390/biom9040142</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9040142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9040142%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DReceptor%252BLigands%252Bas%252BHelping%252BHands%252Bto%252BL-DOPA%252Bin%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DBello%26aufirst%3DFabio%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D4%26spage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph D.  Panarese</span>, <span class="hlFld-ContribAuthor ">Darren W.  Engers</span>, <span class="hlFld-ContribAuthor ">Yong-Jin  Wu</span>, <span class="hlFld-ContribAuthor ">Jason M.  Guernon</span>, <span class="hlFld-ContribAuthor ">Aspen  Chun</span>, <span class="hlFld-ContribAuthor ">Alison R.  Gregro</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Bender</span>, <span class="hlFld-ContribAuthor ">Rory A.  Capstick</span>, <span class="hlFld-ContribAuthor ">Joshua M.  Wieting</span>, <span class="hlFld-ContribAuthor ">Joanne J.  Bronson</span>, <span class="hlFld-ContribAuthor ">John E.  Macor</span>, <span class="hlFld-ContribAuthor ">Ryan  Westphal</span>, <span class="hlFld-ContribAuthor ">Matthew  Soars</span>, <span class="hlFld-ContribAuthor ">Julie E.  Engers</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Felts</span>, <span class="hlFld-ContribAuthor ">Alice L.  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Emmitte</span>, <span class="hlFld-ContribAuthor ">Carrie K.  Jones</span>, <span class="hlFld-ContribAuthor ">Anna L.  Blobaum</span>, <span class="hlFld-ContribAuthor ">P.  Jeffrey Conn</span>, <span class="hlFld-ContribAuthor ">Colleen M.  Niswender</span>, <span class="hlFld-ContribAuthor ">Corey R.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Craig W.  Lindsley</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (2)
                                     , 342-346. <a href="https://doi.org/10.1016/j.bmcl.2018.10.050" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.10.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.10.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.10.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bdiscovery%252Bof%252BVU0652957%252B%252528VU2957%25252C%252BValiglurax%252529%25253A%252BSAR%252Band%252BDMPK%252Bchallenges%252Ben%252Broute%252Bto%252Ban%252BmGlu4%252BPAM%252Bdevelopment%252Bcandidate%26aulast%3DPanarese%26aufirst%3DJoseph%2BD.%26date%3D2019%26volume%3D29%26issue%3D2%26spage%3D342%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delphine  Charvin</span>, <span class="hlFld-ContribAuthor ">Rossella  Medori</span>, <span class="hlFld-ContribAuthor ">Robert A.  Hauser</span>, <span class="hlFld-ContribAuthor ">Olivier  Rascol</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2018,</strong> <em>17 </em>
                                    (11)
                                     , 804-822. <a href="https://doi.org/10.1038/nrd.2018.136" title="DOI URL">https://doi.org/10.1038/nrd.2018.136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2018.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2018.136%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DTherapeutic%252Bstrategies%252Bfor%252BParkinson%252Bdisease%25253A%252Bbeyond%252Bdopaminergic%252Bdrugs%26aulast%3DCharvin%26aufirst%3DDelphine%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D11%26spage%3D804%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delphine  Charvin</span>. </span><span class="cited-content_cbyCitation_article-title">mGlu4 allosteric modulation for treating Parkinson's disease. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2018,</strong> <em>135 </em>, 308-315. <a href="https://doi.org/10.1016/j.neuropharm.2018.03.027" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2018.03.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2018.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2018.03.027%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DmGlu4%252Ballosteric%252Bmodulation%252Bfor%252Btreating%252BParkinson%252527s%252Bdisease%26aulast%3DCharvin%26aufirst%3DDelphine%26date%3D2018%26volume%3D135%26spage%3D308%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Volpi</span>, <span class="hlFld-ContribAuthor ">Francesca  Fallarino</span>, <span class="hlFld-ContribAuthor ">Giada  Mondanelli</span>, <span class="hlFld-ContribAuthor ">Antonio  Macchiarulo</span>, <span class="hlFld-ContribAuthor ">Ursula  Grohmann</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2018,</strong> <em>13 </em>
                                    (5)
                                     , 411-423. <a href="https://doi.org/10.1080/17460441.2018.1443076" title="DOI URL">https://doi.org/10.1080/17460441.2018.1443076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2018.1443076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2018.1443076%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DOpportunities%252Band%252Bchallenges%252Bin%252Bdrug%252Bdiscovery%252Btargeting%252Bmetabotropic%252Bglutamate%252Breceptor%252B4%26aulast%3DVolpi%26aufirst%3DClaudia%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D5%26spage%3D411%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Fazio</span>, <span class="hlFld-ContribAuthor ">Martina  Ulivieri</span>, <span class="hlFld-ContribAuthor ">Claudia  Volpi</span>, <span class="hlFld-ContribAuthor ">Marco  Gargaro</span>, <span class="hlFld-ContribAuthor ">Francesca  Fallarino</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting metabotropic glutamate receptors for the treatment of neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2018,</strong> <em>38 </em>, 16-23. <a href="https://doi.org/10.1016/j.coph.2018.01.010" title="DOI URL">https://doi.org/10.1016/j.coph.2018.01.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2018.01.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DTargeting%252Bmetabotropic%252Bglutamate%252Breceptors%252Bfor%252Bthe%252Btreatment%252Bof%252Bneuroinflammation%26aulast%3DFazio%26aufirst%3DFrancesco%26date%3D2018%26volume%3D38%26spage%3D16%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irene  Sebastianutto</span>, <span class="hlFld-ContribAuthor ">Maria Angela  Cenci</span>. </span><span class="cited-content_cbyCitation_article-title">mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2018,</strong> <em>38 </em>, 81-89. <a href="https://doi.org/10.1016/j.coph.2018.03.003" title="DOI URL">https://doi.org/10.1016/j.coph.2018.03.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2018.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2018.03.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DmGlu%252Breceptors%252Bin%252Bthe%252Btreatment%252Bof%252BParkinson%252527s%252Bdisease%252Band%252BL-DOPA-induced%252Bdyskinesia%26aulast%3DSebastianutto%26aufirst%3DIrene%26date%3D2018%26volume%3D38%26spage%3D81%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cyril  Goudet</span>, <span class="hlFld-ContribAuthor ">Xavier  Rovira</span>, <span class="hlFld-ContribAuthor ">Philippe  Rondard</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Pin</span>, <span class="hlFld-ContribAuthor ">Amadeu  Llebaria</span>, <span class="hlFld-ContribAuthor ">Francine  Acher</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of Metabotropic Glutamate Receptors by Orthosteric, Allosteric, and Light-Operated Ligands. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 253-284. <a href="https://doi.org/10.1007/7355_2017_32" title="DOI URL">https://doi.org/10.1007/7355_2017_32</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_32%26sid%3Dliteratum%253Aachs%26atitle%3DModulation%252Bof%252BMetabotropic%252BGlutamate%252BReceptors%252Bby%252BOrthosteric%25252C%252BAllosteric%25252C%252Band%252BLight-Operated%252BLigands%26aulast%3DGoudet%26aufirst%3DCyril%26date%3D2018%26date%3D2018%26spage%3D253%26epage%3D284%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DStructure%252Band%252BFunction%252Bof%252BGPCRs%26aulast%3DLebon%26aufirst%3DGuillaume%26date%3D2019%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of reference mGluR4 ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro properties of compound <b>40</b>. (A) Agonist and PAM activities of compound <b>40</b> were consecutively evaluated in HEK293 cells expressing human mGluR4. In these cell lines, compound <b>40</b> potentiated the increases in intracellular calcium concentrations induced by an EC<sub>20</sub> glutamate (PAM effect) but had a minor agonist activity in absence of glutamate. (B) Increasing concentrations of compound <b>40</b> induced a 10-fold leftward shift of the glutamate concentration–response curves in these cell lines. (A,B) Each point represents the mean (±SD) of duplicate determination from a representative experiment. (C) Selectivity profile of compound <b>40</b> among mGluRs. Compound <b>40</b> was tested at 1 μM on HEK293 cells expressing each of the human mGluR, alone or in the presence of either an EC<sub>20</sub> or an EC<sub>80</sub> glutamate. The corresponding glutamate concentrations were determined for each receptor subtype. L-AP4 has been used instead of glutamate on hmGluR7. Each bar represents the mean (+SEM) of activities measured in at least two (when not active) or three experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reversal of haloperidol-induced catalepsy in mice by compound <b>40</b>. Mice were administered haloperidol (0.5 mg/kg, ip), and 1 h later, when catalepsy was present, they received an ip dose of compound <b>40</b> or vehicle. Catalepsy was assessed 40 min after compound <b>40</b> dosing. (A) Each bar represents the mean (+SD) latency to move on a vertical grid (immobility time). *<i>p</i> < 0.05 when compared to Vehicle (one-way ANOVA followed by Dunn’s multiple comparison) (<i>n</i> = 8/group). (B) Relationship between efficacy in reversal of haloperidol-induced catalepsy and compound <b>40</b> unbound fraction exposed in the brain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiparkinsonian effect of stand-alone compound <b>40</b> treatment on locomotor activity of 6-OHDA-lesioned rats. (A) Time-course of spontaneous locomotor activity in adult male Sprague–Dawley rats before (“Presurgery, vehicle”, dotted line) or after 6-OHDA-induced striatal lesions. Lesioned rats were treated either with vehicle (“Postsurgery, vehicle”, gray curve) or with compound <b>40</b> at 30 mg/kg ip (“Postsurgery, <b>40</b>”, black curve). Each time-point represents the mean counts (±SEM) for every 5 min. Compound <b>40</b> was administered ip at T0. (<i>n</i> = 10). (B) Compound <b>40</b> plasma and brain exposures in rats dosed with 30 mg/kg ip. Brain exposure was measured 30 and 60 min after administration. Brain levels at 120 and 240 min (c) were extrapolated from measured plasma exposure by using an average brain/plasma ratio of 3.25 as determined at 30 and 60 min. Unbound fraction of compound <b>40</b> in brain (a) was calculated by using the brain protein binding previously measured (99.24%, i.e. 0.76% unbound fraction). Brain unbound over rEC<sub>50</sub> ratio (b) was then calculated by using the in vitro rat mGluR4 EC<sub>50</sub> obtained in HEK293 cells (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antiparkinsonian effect of the combined treatment with compound <b>40</b> and a low suboptimal dose of L-dopa on locomotor activity of 6-OHDA-lesioned rats. (A) Total spontaneous locomotor activity values are presented. Data are expressed as mean of group (+SEM) and analyzed using one-way analysis of variance (ANOVA) repeated measures followed by Dunnett’s multiple comparisons. ***<i>p</i> < 0.001, **<i>p</i> < 0.01, * <i>p</i> < 0.05 vs Post Veh. The dotted horizontal lines represent the mean locomotor activity of the control conditions in 6-OHDA-lesioned rats: optimal L-dopa (upper line) and vehicle (lower line). Pre Veh: rats activity before the surgery, after vehicle ip administration. Post Veh: activity of the same animals after the surgery and stabilization of the 6-OHDA-induced striatal lesion, after vehicle ip administration; compound <b>40</b> ip administration. (<i>n</i> = 10). (B) Time-course of spontaneous locomotor activity of 6-OHDA-lesioned rats treated either with a low suboptimal dose of L-dopa alone (“6 mg/kg L-dopa”, gray curve) or with addition of compound <b>40</b> at 10 mg/kg ip (“6 mg/kg L-dopa + 10 mg/kg compound <b>40</b>”, black curve). Each time-point represents the mean counts (±SEM) for every 5 min (<i>n</i> = 10).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/medium/jm-2017-00991r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK profile of compound <b>60</b> in plasma and brain following oral administration at 25 mg/kg (in water) to Sprague–Dawley rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00991/20171103/images/large/jm-2017-00991r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00991&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">World Health Organization</span><span class="NLM_x">. </span> <span class="citation_source-book">Neurological Disorders: Public Health Challenges</span>; <span class="NLM_publisher-name">World Health Organization Press</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=World+Health+Organization&title=Neurological+Disorders%3A+Public+Health+Challenges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DNeurological%2520Disorders%253A%2520Public%2520Health%2520Challenges%26pub%3DWorld%2520Health%2520Organization%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, K.</span><span> </span><span class="NLM_article-title">The scientific and clinical basis for the treatment of Parkinson disease (2009)</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1212/WNL.0b013e3181a1d44c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1212%2FWNL.0b013e3181a1d44c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2009&pages=S1-136&author=C.+W.+Olanowauthor=M.+B.+Sternauthor=K.+Sethi&title=The+scientific+and+clinical+basis+for+the+treatment+of+Parkinson+disease+%282009%29&doi=10.1212%2FWNL.0b013e3181a1d44c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1212%2FWNL.0b013e3181a1d44c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0b013e3181a1d44c%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DStern%26aufirst%3DM.%2BB.%26aulast%3DSethi%26aufirst%3DK.%26atitle%3DThe%2520scientific%2520and%2520clinical%2520basis%2520for%2520the%2520treatment%2520of%2520Parkinson%2520disease%2520%25282009%2529%26jtitle%3DNeurology%26date%3D2009%26volume%3D72%26spage%3DS1%26epage%3D136%26doi%3D10.1212%2FWNL.0b013e3181a1d44c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, W. C.</span><span> </span><span class="NLM_article-title">An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S88</span><span class="refDoi"> DOI: 10.1212/WNL.56.suppl_5.S1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1212%2FWNL.56.suppl_5.S1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2001&pages=S1-S88&author=C.+W.+Olanowauthor=R.+L.+Wattsauthor=W.+C.+Koller&title=An+algorithm+%28decision+tree%29+for+the+management+of+Parkinson%E2%80%99s+disease+%282001%29%3A+treatment+guidelines&doi=10.1212%2FWNL.56.suppl_5.S1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1212%2FWNL.56.suppl_5.S1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.56.suppl_5.S1%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DWatts%26aufirst%3DR.%2BL.%26aulast%3DKoller%26aufirst%3DW.%2BC.%26atitle%3DAn%2520algorithm%2520%2528decision%2520tree%2529%2520for%2520the%2520management%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520%25282001%2529%253A%2520treatment%2520guidelines%26jtitle%3DNeurology%26date%3D2001%26volume%3D56%26spage%3DS1%26epage%3DS88%26doi%3D10.1212%2FWNL.56.suppl_5.S1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Prashanth, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, W. G.</span><span> </span><span class="NLM_article-title">l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment</span> <span class="citation_source-journal">Int. Rev. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1016/B978-0-12-381328-2.00002-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FB978-0-12-381328-2.00002-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=21907082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWhsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2011&pages=31-54&author=L.+K.+Prashanthauthor=S.+Foxauthor=W.+G.+Meissner&title=l-Dopa-induced+dyskinesia-clinical+presentation%2C+genetics%2C+and+treatment&doi=10.1016%2FB978-0-12-381328-2.00002-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">L-dopa-induced dyskinesia-clinical presentation, genetics, and treatment</span></div><div class="casAuthors">Prashanth, L. K.; Fox, Susan; Meissner, Wassilios G.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia</span>),
    <span class="NLM_cas:pages">31-54</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Levodopa-induced dyskinesia (LID) has been recognized since the introduction of levodopa for the management of Parkinson's disease (PD) and continues to be one of the most clin. challenging factors in long-term management of patients with PD.  Most patients develop LID within 10 years of PD onset and the cause has been attributed to various factors including disease demographics, pharmacol., and possibly genetic causes.  The clin. pattern of LID varies and shows intra and inter-patient variability and has been classified based upon phenomenol. and relation to timing of levodopa.  The potential armamentarium to address and manage LID has significantly increased in the last decade.  This chapter addresses the current understanding of various clin. aspects and available therapeutics for LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfzKjt5Y4PQLVg90H21EOLACvtfcHk0lj3QBoVlRB0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWhsLzJ&md5=82fd0dcf23817bf6a927003553976a1b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381328-2.00002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381328-2.00002-X%26sid%3Dliteratum%253Aachs%26aulast%3DPrashanth%26aufirst%3DL.%2BK.%26aulast%3DFox%26aufirst%3DS.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26atitle%3Dl-Dopa-induced%2520dyskinesia-clinical%2520presentation%252C%2520genetics%252C%2520and%2520treatment%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2011%26volume%3D98%26spage%3D31%26epage%3D54%26doi%3D10.1016%2FB978-0-12-381328-2.00002-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fox, S. H.</span><span> </span><span class="NLM_article-title">Non-dopaminergic treatments for motor control in Parkinson’s disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1007/s40265-013-0105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1007%2Fs40265-013-0105-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1405-1415&author=S.+H.+Fox&title=Non-dopaminergic+treatments+for+motor+control+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40265-013-0105-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0105-4%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DS.%2BH.%26atitle%3DNon-dopaminergic%2520treatments%2520for%2520motor%2520control%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1405%26epage%3D1415%26doi%3D10.1007%2Fs40265-013-0105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.coph.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.coph.2005.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16368268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=98-102&author=M.+J.+Marinoauthor=P.+J.+Conn&title=Glutamate-based+therapeutic+approaches%3A+allosteric+modulators+of+metabotropic+glutamate+receptors&doi=10.1016%2Fj.coph.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors</span></div><div class="casAuthors">Marino, Michael J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate receptors (mGluRs) were proposed as novel targets for the treatment of a variety of disorders.  Recently, highly selective allosteric modulators of the mGluRs were developed by several groups.  These allosteric compds. provide an unprecedented degree of selectivity for individual mGluRs, allowing for more detailed functional studies on the roles of these receptors.  Furthermore, the allosteric approach avoids many of the hurdles assocd. with the development of direct agonists as drugs, and provides a clear path forward for clin. proof-of-concept studies.  Currently, both pos. allosteric modulators of mGluR2 and neg. allosteric modulators of mGluR5 hold promise as novel anxiolytics, and pos. allosteric modulators of mGluR4 appear to be an exciting new target for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9A6c0VveAl7Vg90H21EOLACvtfcHk0lj3QBoVlRB0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVynug%253D%253D&md5=819ca06118515c19c3f0047fb7fc420d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DGlutamate-based%2520therapeutic%2520approaches%253A%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D98%26epage%3D102%26doi%3D10.1016%2Fj.coph.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Amalric, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F. C.</span><span> </span><span class="NLM_article-title">Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson’s disease</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2012.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22664304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=53-64&author=M.+Amalricauthor=S.+Lopezauthor=C.+Goudetauthor=G.+Fisoneauthor=G.+Battagliaauthor=F.+Nicolettiauthor=J.+P.+Pinauthor=F.+C.+Acher&title=Group+III+and+subtype+4+metabotropic+glutamate+receptor+agonists%3A+discovery+and+pathophysiological+applications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuropharm.2012.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease</span></div><div class="casAuthors">Amalric, M.; Lopez, S.; Goudet, C.; Fisone, G.; Battaglia, G.; Nicoletti, F.; Pin, J.-P.; Acher, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-64</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the loss of dopaminergic (DA) neurons of the substantia nigra pars compacta, represents a major challenge to treat patients affected by Parkinson's disease (PD).  The imbalanced situation in favor of excitation in the disease state may also accelerate excitotoxic processes, thereby representing a potential target for neuroprotective therapies.  Reducing the excitatory action of glutamate, the major excitatory neurotransmitter in the basal ganglia, should lead to symptomatic improvement for PD patients and may promote the survival of DA neurons.  Recent studies have focused on the modulatory action of metabotropic glutamate (mGlu) receptors on neurodegenerative diseases including PD.  Group III mGlu receptors, including subtypes 4, 7, and 8, are largely expressed in the basal ganglia.  Recent studies highlight the use of selective mGlu4 receptor pos. allosteric modulators (PAMs) for the treatment of PD.  Here we review the effects of newly-designed group-III orthosteric agonists on neuroprotection, neurorestoration, and redn. of L-DOPA induced dyskinesia in animal models of PD.  The combination of orthosteric mGlu4 receptor selective agonists with PAMs may open new avenues for the symptomatic treatment of PD.  This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfNTiuwGkzrVg90H21EOLACvtfcHk0lj3QBoVlRB0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVKktbc%253D&md5=d55ec6e3b38b5f58db08a973dc6e76b0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DAmalric%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DAcher%26aufirst%3DF.%2BC.%26atitle%3DGroup%2520III%2520and%2520subtype%25204%2520metabotropic%2520glutamate%2520receptor%2520agonists%253A%2520discovery%2520and%2520pathophysiological%2520applications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D53%26epage%3D64%26doi%3D10.1016%2Fj.neuropharm.2012.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jane, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J.</span><span> </span><span class="NLM_article-title">Pharmacological agents acting at subtypes of metabotropic glutamate receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1476</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00092-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2899%2900092-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10530808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=1431-1476&author=D.+D.+Schoeppauthor=D.+E.+Janeauthor=J.+Monn&title=Pharmacological+agents+acting+at+subtypes+of+metabotropic+glutamate+receptors&doi=10.1016%2FS0028-3908%2899%2900092-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological agents acting at subtypes of metabotropic glutamate receptors</span></div><div class="casAuthors">Schoepp, D. D.; Jane, D. E.; Monn, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1431-1476</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with ∼270 refs.  Metabotropic (G-protein-coupled) glutamate (mGlu) receptors have now emerged as a recognized, but still relatively new area of excitatory amino acid research.  Current understanding of the roles and involvement of mGlu receptor subtypes in physiol./pathophysiol. functions of the central nervous system has been recently propelled by the emergence of various structurally novel, potent, and mGlu receptor selective pharmacol. agents.  This article reviews the evolution of pharmacol. agents that have been reported to target mGlu receptors, with a focus on the known receptor subtype selectivities of current agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1C80nlavsgrVg90H21EOLACvtfcHk0ljX2psP1zt2MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWnsLc%253D&md5=08a832c7cab387bc096131bd2d916cab</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900092-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900092-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMonn%26aufirst%3DJ.%26atitle%3DPharmacological%2520agents%2520acting%2520at%2520subtypes%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D1999%26volume%3D38%26spage%3D1431%26epage%3D1476%26doi%3D10.1016%2FS0028-3908%2899%2900092-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors in the basal ganglia motor circuit</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1038/nrn1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fnrn1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16276355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=787-798&author=P.+J.+Connauthor=G.+Battagliaauthor=M.+J.+Marinoauthor=F.+Nicoletti&title=Metabotropic+glutamate+receptors+in+the+basal+ganglia+motor+circuit&doi=10.1038%2Fnrn1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors in the basal ganglia motor circuit</span></div><div class="casAuthors">Conn, P. Jeffrey; Battalglia, Giuseppe; Marino, Michael J.; Nicoletti, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In recent years there have been tremendous advances in our understanding of the circuitry of the basal ganglia and our ability to predict the behavioral effects of specific cellular changes in this circuit on voluntary movement.  These advances, combined with a new understanding of the rich distribution and diverse physiol. roles of metabotropic glutamate receptors in the basal ganglia, indicate that these receptors might have a key role in motor control and raise the exciting possibility that they might provide therapeutic targets for the treatment of Parkinson's disease and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAptgUy8Ve6rVg90H21EOLACvtfcHk0lj3G4shBvOc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsL3I&md5=f21bea466eee933e278c362a38d43227</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrn1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1763%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DNicoletti%26aufirst%3DF.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520in%2520the%2520basal%2520ganglia%2520motor%2520circuit%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D787%26epage%3D798%26doi%3D10.1038%2Fnrn1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lopez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turle-Lorenzo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Leonibus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalric, M.</span><span> </span><span class="NLM_article-title">Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6701</span><span class="NLM_x">–</span> <span class="NLM_lpage">6711</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0299-07.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.0299-07.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17581957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=6701-6711&author=S.+Lopezauthor=N.+Turle-Lorenzoauthor=F.+Acherauthor=E.+De+Leonibusauthor=A.+Meleauthor=M.+Amalric&title=Targeting+group+III+metabotropic+glutamate+receptors+produces+complex+behavioral+effects+in+rodent+models+of+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.0299-07.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease</span></div><div class="casAuthors">Lopez, Sebastien; Turle-Lorenzo, Nathalie; Acher, Francine; De Leonibus, Elvira; Mele, Andrea; Amalric, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6701-6711</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternatives to L-DOPA (L-3,4-dihydroxyphenylalanine) for the treatment of Parkinson's disease (PD).  Their presynaptic location at GABAergic and glutamatergic synapses within basal ganglia nuclei provide a crit. target to reduce abnormal activities assocd. with PD.  The effects of selective group III mGluR agonists (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) and L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) infused into the globus pallidus (GP) or the substantia nigra pars reticulata (SNr) were thus studied in rat models of PD.  Bilateral infusions of ACPT-I (1, 2.5, and 5 nmol/μl) into the GP fully reverse the severe akinetic deficits produced by 6-hydroxydopamine nitrostriatal dopamine lesions in a reaction-time task without affecting the performance of controls.  Similar results were obsd. after L-AP4 (1 nmol) or picrotoxin, a GABAA receptor antagonist, infused into the GP.  In addn., intrapallidal ACPT-I counteracts haloperidol-induced catalepsy.  This effect is reversed by concomitant administration of a selective group III receptor antagonist (RS)-α-cyclopropyl-4-phosphonophenylglycine.  In contrast, ACPT-I (0.05, 0.1, and 0.25 nmol) infusions into the SNr enhance the lesion-induced akinetic deficits in control and lesioned rats and do not reverse haloperidol-induced catalepsy.  L-AP4 (0.05 nmol) and picrotoxin in the SNr produce the same effects.  Together, these results show that activation of group III mGluRs in the GP provides benefits in parkinsonian rats, presumably by modulating GABAergic neurotransmission.  The opposite effects produced by group III mGluR activation in the SNr, also obsd. with a selective mGluR8 agonist, support the use of subtype-selective group III mGluR agonists as a potential antiparkinsonian strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRtwJhZxZ7rVg90H21EOLACvtfcHk0lj3G4shBvOc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVWqs7w%253D&md5=05a960ea9fb79233bc9c1bf69a8b3c73</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0299-07.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0299-07.2007%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DTurle-Lorenzo%26aufirst%3DN.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DDe%2BLeonibus%26aufirst%3DE.%26aulast%3DMele%26aufirst%3DA.%26aulast%3DAmalric%26aufirst%3DM.%26atitle%3DTargeting%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%2520produces%2520complex%2520behavioral%2520effects%2520in%2520rodent%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D6701%26epage%3D6711%26doi%3D10.1523%2FJNEUROSCI.0299-07.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Vernon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbarsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datla, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dexter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croucher, M. J.</span><span> </span><span class="NLM_article-title">Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1124/jpet.106.108159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.106.108159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17012606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=397-409&author=A.+C.+Vernonauthor=V.+Zbarskyauthor=K.+P.+Datlaauthor=D.+T.+Dexterauthor=M.+J.+Croucher&title=Selective+activation+of+group+III+metabotropic+glutamate+receptors+by+L-%28%2B%29-2-amino-4-phosphonobutryic+acid+protects+the+nigrostriatal+system+against+6-hydroxydopamine+toxicity+in+vivo&doi=10.1124%2Fjpet.106.108159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo</span></div><div class="casAuthors">Vernon, Anthony C.; Zbarsky, Virginia; Datla, Krishna P.; Dexter, David T.; Croucher, Martin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Evidence from several studies suggests that the progressive degeneration of dopaminergic (DA) neurons of the substantia nigra pars compacta (SNc) in Parkinson's disease (PD) may in part be due to excessive release of glutamate from subthalamic projections onto nigral DA neurons.  Previous in vitro studies have demonstrated that selective activation of Group III metabotropic glutamate receptors (mGluR) neg. modulates excitatory transmission in the SNc and is neuroprotective against glutamate-mediated toxicity.  Consistent with this, we have reported preliminary data indicating that the selective group III mGluR agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) can also protect the nigrostriatal system against 6-hydroxydopamine (6-OHDA) toxicity in vivo.  We have now extended these preliminary studies in this model and report here that both acute and subchronic intranigral injections of L-AP4 provide significant protection of the nigrostriatal system against 6-OHDA toxicity.  This neuroprotection displays a bell-shaped profile with a clear concn.-dependent relationship.  In contrast, when administered to animals 7 days post-6-OHDA lesioning, L-AP4 significantly protects the functionality but not the integrity of the nigrostriatal system.  We further demonstrate that neuroprotection by L-AP4 in vivo is reversed by coadministration of the selective Group III mGluR antagonist (RS)-α-methylserine-O-phosphate, confirming a receptor-mediated mechanism of action.  These data provide further compelling evidence that selective activation of Group III mGluR is neuroprotective in an in vivo exptl. model of PD, a finding that may have important implications for the future treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGx5qqmT7mP7Vg90H21EOLACvtfcHk0lj3G4shBvOc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFChtw%253D%253D&md5=7721f7e77ffc4c708575b7f206a59f5f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.108159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.108159%26sid%3Dliteratum%253Aachs%26aulast%3DVernon%26aufirst%3DA.%2BC.%26aulast%3DZbarsky%26aufirst%3DV.%26aulast%3DDatla%26aufirst%3DK.%2BP.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26aulast%3DCroucher%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%2520by%2520L-%2528%252B%2529-2-amino-4-phosphonobutryic%2520acid%2520protects%2520the%2520nigrostriatal%2520system%2520against%25206-hydroxydopamine%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D397%26epage%3D409%26doi%3D10.1124%2Fjpet.106.108159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Maj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inderbitzin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoehr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranesic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flor, P. J.</span><span> </span><span class="NLM_article-title">(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span><span class="refDoi"> DOI: 10.1016/S0028-3908(03)00271-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2803%2900271-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2003&pages=895-906&author=M.+Majauthor=V.+Brunoauthor=Z.+Dragicauthor=R.+Yamamotoauthor=G.+Battagliaauthor=W.+Inderbitzinauthor=N.+Stoehrauthor=T.+Steinauthor=F.+Gaspariniauthor=I.+Vranesicauthor=R.+Kuhnauthor=F.+Nicolettiauthor=P.+J.+Flor&title=%28%E2%88%92%29-PHCCC%2C+a+positive+allosteric+modulator+of+mGluR4%3A+characterization%2C+mechanism+of+action%2C+and+neuroprotection&doi=10.1016%2FS0028-3908%2803%2900271-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2803%2900271-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252803%252900271-5%26sid%3Dliteratum%253Aachs%26aulast%3DMaj%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DDragic%26aufirst%3DZ.%26aulast%3DYamamoto%26aufirst%3DR.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DInderbitzin%26aufirst%3DW.%26aulast%3DStoehr%26aufirst%3DN.%26aulast%3DStein%26aufirst%3DT.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DVranesic%26aufirst%3DI.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26atitle%3D%2528%25E2%2588%2592%2529-PHCCC%252C%2520a%2520positive%2520allosteric%2520modulator%2520of%2520mGluR4%253A%2520characterization%252C%2520mechanism%2520of%2520action%252C%2520and%2520neuroprotection%26jtitle%3DNeuropharmacology%26date%3D2003%26volume%3D45%26spage%3D895%26epage%3D906%26doi%3D10.1016%2FS0028-3908%2803%2900271-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charvin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessif, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koser, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLella, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, I. J.</span><span> </span><span class="NLM_article-title">A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1124/jpet.112.196063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.112.196063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22787118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=167-177&author=E.+Le+Poulauthor=C.+Boleaauthor=F.+Girardauthor=S.+Poliauthor=D.+Charvinauthor=B.+Campoauthor=J.+Bortoliauthor=A.+Bessifauthor=B.+Luoauthor=A.+J.+Koserauthor=L.+M.+Hodgeauthor=K.+M.+Smithauthor=A.+G.+DiLellaauthor=N.+Livertonauthor=F.+Hessauthor=S.+E.+Browneauthor=I.+J.+Reynolds&title=A+potent+and+selective+metabotropic+glutamate+receptor+4+positive+allosteric+modulator+improves+movement+in+rodent+models+of+Parkinson%E2%80%99s+disease&doi=10.1124%2Fjpet.112.196063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease</span></div><div class="casAuthors">Le Poul, Emmanuel; Bolea, Christelle; Girard, Francoise; Poli, Sonia; Charvin, Delphine; Campo, Brice; Bortoli, Julien; Bessif, Abdhelak; Luo, Bin; Koser, Amy Jo; Hodge, Lisa M.; Smith, Karen M.; DiLella, Anthony G.; Liverton, Nigel; Hess, Fred; Browne, Susan E.; Reynolds, Ian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">167-177</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) have been proposed as a novel therapeutic approach for the treatment of Parkinson's disease.  However, evaluation of this proposal has been limited by the availability of appropriate pharmacol. tools to interrogate the target.  In this study, we describe the properties of a novel mGluR4 PAM.  5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178) enhances glutamate-mediated activation of human and rat mGluR4 with EC50 values of 4 and 9 nM, resp.  The compd. is highly selective for mGluR4 with minimal activities at other mGluRs.  Oral administration of ADX88178 in rats is assocd. with high bioavailability and results in cerebrospinal fluid exposure of >50-fold the in vitro EC50 value.  ADX88178 reverses haloperidol-induced catalepsy in rats at 3 and 10 mg/kg.  It is noteworthy that this compd. alone has no impact on forelimb akinesia resulting from a bilateral 6-hydroxydopamine lesion in rats.  However, coadministration of a low dose of L-DOPA (6 mg/kg) enabled a robust, dose-dependent reversal of the forelimb akinesia deficit.  ADX88178 also increased the effects of quinpirole in lesioned rats and enhanced the effects of L-DOPA in MitoPark mice.  It is noteworthy that the enhancement of the actions of L-DOPA was not assocd. with an exacerbation of L-DOPA-induced dyskinesias in rats.  ADX88178 is a novel, potent, and selective mGluR4 PAM that is a valuable tool for exploring the therapeutic potential of mGluR4 modulation.  The use of this novel tool mol. supports the proposal that activation of mGluR4 may be therapeutically useful in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKn2sck-WjrVg90H21EOLACvtfcHk0lg7lZyz76JS3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagsbvJ&md5=16472f6814708d33dd463fbdbf0c6fce</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.196063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.196063%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DCharvin%26aufirst%3DD.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBortoli%26aufirst%3DJ.%26aulast%3DBessif%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DKoser%26aufirst%3DA.%2BJ.%26aulast%3DHodge%26aufirst%3DL.%2BM.%26aulast%3DSmith%26aufirst%3DK.%2BM.%26aulast%3DDiLella%26aufirst%3DA.%2BG.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DHess%26aufirst%3DF.%26aulast%3DBrowne%26aufirst%3DS.%2BE.%26aulast%3DReynolds%26aufirst%3DI.%2BJ.%26atitle%3DA%2520potent%2520and%2520selective%2520metabotropic%2520glutamate%2520receptor%25204%2520positive%2520allosteric%2520modulator%2520improves%2520movement%2520in%2520rodent%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D167%26epage%3D177%26doi%3D10.1124%2Fjpet.112.196063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Kalinichev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer-Urios, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uslaner, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celanire, S.</span><span> </span><span class="NLM_article-title">Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span><span class="refDoi"> DOI: 10.1124/jpet.114.214437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fjpet.114.214437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=24947466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1artbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=495-505&author=M.+Kalinichevauthor=E.+Le+Poulauthor=C.+Boleaauthor=F.+Girardauthor=B.+Campoauthor=M.+Fonsiauthor=I.+Royer-Uriosauthor=S.+E.+Browneauthor=J.+M.+Uslanerauthor=M.+J.+Davisauthor=J.+Raberauthor=R.+Duvoisinauthor=S.+T.+Bateauthor=I.+J.+Reynoldsauthor=S.+Poliauthor=S.+Celanire&title=Characterization+of+the+novel+positive+allosteric+modulator+of+the+metabotropic+glutamate+receptor+4+ADX88178+in+rodent+models+of+neuropsychiatric+disorders&doi=10.1124%2Fjpet.114.214437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders</span></div><div class="casAuthors">Kalinichev, Mikhail; Le Poul, Emmanuel; Bolea, Christelle; Girard, Francoise; Campo, Brice; Fonsi, Massimiliano; Royer-Urios, Isabelle; Browne, Susan E.; Uslaner, Jason M.; Davis, Matthew J.; Raber, Jacob; Duvoisin, Robert; Bate, Simon T.; Reynolds, Ian J.; Poli, Sonia; Celanire, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-505, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">There is growing evidence that activation of metabotropic glutamate receptor 4 (mGlu4) leads to anxiolytic- and antipsychotic-like efficacy in rodent models, yet its relevance to depression-like reactivity remains unclear.  Here, we present the pharmacol. evaluation of ADX88178 [5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine], a novel potent, selective, and brain-penetrant pos. allosteric modulator of the mGlu4 receptor in rodent models of anxiety, obsessive compulsive disorder (OCD), fear, depression, and psychosis.  ADX88178 dose-dependently reduced the no. of buried marbles in the marble burying test and increased open-arm exploration in the elevated plus maze (EPM) test, indicative of anxiolytic-like efficacy.  Target specificity of the effect in the EPM test was confirmed using male and female mGlu4 receptor knockout mice.  In mice, ADX88178 reduced the likelihood of conditioned freezing in the acquisition phase of the fear conditioning test, yet had no carryover effect in the expression phase.  Also, ADX88178 dose-dependently reduced duration of immobility in the forced swim test, indicative of antidepressant-like efficacy.  ADX88178 reduced DOI (2,5-dimethoxy-4-iodoamphetamine)-mediated head twitches (albeit with no dose-dependency), and MK-801 [(5S,10R)-(1)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]-induced locomotor hyperactivity in mice, but was inactive in the conditioned avoidance response test in rats.  The compd. showed good specificity as it had no effect on locomotor activity in mice and rats at efficacious doses.  Thus, allosteric activation of mGlu4 receptors can be a promising new therapeutic approach for treatment of anxiety, OCD, fear-related disorders, and psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQGgfpSK4icbVg90H21EOLACvtfcHk0lg7lZyz76JS3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1artbvI&md5=76c4ccefb15198f128ecced62cbec235</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.214437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.214437%26sid%3Dliteratum%253Aachs%26aulast%3DKalinichev%26aufirst%3DM.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DRoyer-Urios%26aufirst%3DI.%26aulast%3DBrowne%26aufirst%3DS.%2BE.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DDavis%26aufirst%3DM.%2BJ.%26aulast%3DRaber%26aufirst%3DJ.%26aulast%3DDuvoisin%26aufirst%3DR.%26aulast%3DBate%26aufirst%3DS.%2BT.%26aulast%3DReynolds%26aufirst%3DI.%2BJ.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DCelanire%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25204%2520ADX88178%2520in%2520rodent%2520models%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D495%26epage%3D505%26doi%3D10.1124%2Fjpet.114.214437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bennouar, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uberti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacolod, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerkerian-Le Goff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubellini, P.</span><span> </span><span class="NLM_article-title">Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson’s disease treatment and dyskinesia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2012.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=22491024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFaiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=158-169&author=K.+E.+Bennouarauthor=M.+A.+Ubertiauthor=C.+Melonauthor=M.+D.+Bacolodauthor=H.+N.+Jimenezauthor=M.+Cajinaauthor=L.+Kerkerian-Le+Goffauthor=D.+Dollerauthor=P.+Gubellini&title=Synergy+between+L-DOPA+and+a+novel+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+4%3A+implications+for+Parkinson%E2%80%99s+disease+treatment+and+dyskinesia&doi=10.1016%2Fj.neuropharm.2012.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia</span></div><div class="casAuthors">Bennouar, Khaled-Ezaheir; Uberti, Michelle A.; Melon, Christophe; Bacolod, Maria D.; Jimenez, Hermogenes N.; Cajina, Manuel; Kerkerian-Le Goff, Lydia; Doller, Dario; Gubellini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to dopamine depletion in Parkinson's disease (PD).  For this reason, group III mGlu receptors, in particular mGlu4, were considered as key strategic targets for non-dopaminergic pharmacol. treatments aimed at modulating these synapses, without producing the well known side-effects of L-DOPA, in particular the highly disabling L-DOPA-induced dyskinesia (LID).  Herein we add physiol. and functional support to this hypothesis using Lu AF21934, a novel selective and brain-penetrant mGlu4 receptor pos. allosteric modulator (PAM) tool compd.  By in vitro electrophysiol. recordings we demonstrate that Lu AF21934 inhibits corticostriatal synaptic transmission and enhances the effect of the orthosteric mGlu4 receptor-preferred agonist LSP1-2111.  In naive rats, Lu AF21934 dose-dependently (10 and 30 mg/kg) alleviated haloperidol-induced catalepsy.  In hemiparkinsonian rats (unilateral 6-hydroxydopamine lesion of the substantia nigra pars compacta), Lu AF21934 alone did not affect akinesia at the doses tested (10 and 30 mg/kg).  However, when Lu AF21934 was combined with sub-threshold doses of L-DOPA (1 and 5 mg/kg), it acted synergistically in alleviating akinesia in a dose-dependent manner and, notably, also reduced the incidence of LID but not its severity.  Interestingly, these effects occurred at Lu AF21934 brain free concns. that showed functional activity in in vitro screens (calcium flux and electrophysiol. assays).  These results support the potential for antiparkinsonian clin. use of a combined treatment consisting in L-DOPA and a mGlu4 receptor PAM to reduce efficacious L-DOPA doses (generally known as L-DOPA sparing), while maintaining the same benefit on PD motor troubles, and at the same time minimizing the development of LID.  This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3jZln8IohrVg90H21EOLACvtfcHk0lhPi4L0pumD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFaiu78%253D&md5=7c98d8a74c9bb958b7b8cc95d5f0a113</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DBennouar%26aufirst%3DK.%2BE.%26aulast%3DUberti%26aufirst%3DM.%2BA.%26aulast%3DMelon%26aufirst%3DC.%26aulast%3DBacolod%26aufirst%3DM.%2BD.%26aulast%3DJimenez%26aufirst%3DH.%2BN.%26aulast%3DCajina%26aufirst%3DM.%26aulast%3DKerkerian-Le%2BGoff%26aufirst%3DL.%26aulast%3DDoller%26aufirst%3DD.%26aulast%3DGubellini%26aufirst%3DP.%26atitle%3DSynergy%2520between%2520L-DOPA%2520and%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25204%253A%2520implications%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520treatment%2520and%2520dyskinesia%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.neuropharm.2012.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engers, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loch, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Development and antiparkinsonian activity of VU0418506, a selective positive allosteric modulator of metabotropic glutamate receptor 4 homomers without activity at mGlu2/4 heteromers</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1211</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SmsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1201-1211&author=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=X.+Linauthor=M.+Bubserauthor=A.+Thompson+Grayauthor=A.+L.+Blobaumauthor=D.+W.+Engersauthor=A.+L.+Rodriguezauthor=M.+T.+Lochauthor=J.+S.+Danielsauthor=C.+W.+Lindsleyauthor=C.+R.+Hopkinsauthor=J.+A.+Javitchauthor=P.+J.+Conn&title=Development+and+antiparkinsonian+activity+of+VU0418506%2C+a+selective+positive+allosteric+modulator+of+metabotropic+glutamate+receptor+4+homomers+without+activity+at+mGlu2%2F4+heteromers&doi=10.1021%2Facschemneuro.6b00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers</span></div><div class="casAuthors">Niswender, Colleen M.; Jones, Carrie K.; Lin, Xin; Bubser, Michael; Thompson Gray, Analisa; Blobaum, Anna L.; Engers, Darren W.; Rodriguez, Alice L.; Loch, Matthew T.; Daniels, J. Scott; Lindsley, Craig W.; Hopkins, Corey R.; Javitch, Jonathan A.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1201-1211</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD).  As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using pos. and neg. allosteric modulators (PAMs and NAMs, resp.) has become a common strategy.  We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion.  Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacol. profile in response to allosteric modulators.  For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compds. potentiate mGlu4 responses regardless of mGlu2 coexpression.  We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models.  Using pharmacol. approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technol., we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compds. without activity at mGlu2/4 heteromers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUg2gMmrP17Vg90H21EOLACvtfcHk0lhPi4L0pumD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SmsLfE&md5=99640d47aaa23bed5e1aba4bb380cb0a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00036%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DThompson%2BGray%26aufirst%3DA.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DLoch%26aufirst%3DM.%2BT.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDevelopment%2520and%2520antiparkinsonian%2520activity%2520of%2520VU0418506%252C%2520a%2520selective%2520positive%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25204%2520homomers%2520without%2520activity%2520at%2520mGlu2%252F4%2520heteromers%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D1201%26epage%3D1211%26doi%3D10.1021%2Facschemneuro.6b00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Engers, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogliotti, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salovich, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barrantes, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macor, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Discovery, Synthesis and Pre-Clinical Characterization of N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4)</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">–</span> <span class="NLM_lpage">1200</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvF2ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1192-1200&author=D.+W.+Engersauthor=A.+L.+Blobaumauthor=R.+D.+Gogliottiauthor=Y.+Y.+Cheungauthor=J.+M.+Salovichauthor=P.+M.+Garcia-Barrantesauthor=J.+S.+Danielsauthor=R.+Morrisonauthor=C.+K.+Jonesauthor=M.+G.+Soarsauthor=X.+Zhuoauthor=J.+Hurleyauthor=J.+E.+Macorauthor=J.+J.+Bronsonauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=C.+M.+Niswenderauthor=C.+R.+Hopkins&title=Discovery%2C+Synthesis+and+Pre-Clinical+Characterization+of+N-%283-chloro-4-fluorophenyl%29-1H-pyrazolo%5B4%2C3-b%5Dpyridin-3-amine+%28VU0418506%29%2C+a+novel+positive+allosteric+modulator+of+the+metabotropic+glutamate+receptor+4+%28mGlu4%29&doi=10.1021%2Facschemneuro.6b00035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)</span></div><div class="casAuthors">Engers, Darren W.; Blobaum, Anna L.; Gogliotti, Rocco D.; Cheung, Yiu-Yin; Salovich, James M.; Garcia-Barrantes, Pedro M.; Daniels, J. Scott; Morrison, Ryan; Jones, Carrie K.; Soars, Matthew G.; Zhuo, Xiaoliang; Hurley, Jeremy; Macor, John E.; Bronson, Joanne J.; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1192-1200</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclin. rodent models of Parkinson's disease has been established by a no. of groups.  Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506).  We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a no. of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group.  VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclin. safety species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgxhaqdEiSvbVg90H21EOLACvtfcHk0lg9epcisoEwgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvF2ntbo%253D&md5=0ced736754a1b0ce24cca4d99daf0503</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00035%26sid%3Dliteratum%253Aachs%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DGogliotti%26aufirst%3DR.%2BD.%26aulast%3DCheung%26aufirst%3DY.%2BY.%26aulast%3DSalovich%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DDiscovery%252C%2520Synthesis%2520and%2520Pre-Clinical%2520Characterization%2520of%2520N-%25283-chloro-4-fluorophenyl%2529-1H-pyrazolo%255B4%252C3-b%255Dpyridin-3-amine%2520%2528VU0418506%2529%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25204%2520%2528mGlu4%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D1192%26epage%3D1200%26doi%3D10.1021%2Facschemneuro.6b00035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Charvin, D.; Manteau, B.; Pomel, V.; Conquet, F.</span><span> </span><span class="NLM_article-title">Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors</span>. WO2016030444,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Charvin&author=B.+Manteau&author=V.+Pomel&author=F.+Conquet&title=Novel+chromone+oxime+derivative+and+its+use+as+allosteric+modulator+of+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvin%26aufirst%3DD.%26atitle%3DNovel%2520chromone%2520oxime%2520derivative%2520and%2520its%2520use%2520as%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Schann, S.; Mayer, S.; Morice, C.; Giethlen, B.</span><span> </span><span class="NLM_article-title">Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors</span>. WO2011051478,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Schann&author=S.+Mayer&author=C.+Morice&author=B.+Giethlen&title=Novel+oxime+derivatives+and+their+use+as+allosteric+modulators+of+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchann%26aufirst%3DS.%26atitle%3DNovel%2520oxime%2520derivatives%2520and%2520their%2520use%2520as%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busceti, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biagioni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traficante, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span> </span><span class="NLM_article-title">Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">7222</span><span class="NLM_x">–</span> <span class="NLM_lpage">7229</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.1595-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.1595-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16822979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=7222-7229&author=G.+Battagliaauthor=C.+L.+Buscetiauthor=G.+Molinaroauthor=F.+Biagioniauthor=A.+Traficanteauthor=F.+Nicolettiauthor=V.+Bruno&title=Pharmacological+activation+of+mGlu4+metabotropic+glutamate+receptors+reduces+nigrostriatal+degeneration+in+mice+treated+with+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine&doi=10.1523%2FJNEUROSCI.1595-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span></div><div class="casAuthors">Battaglia, Giuseppe; Busceti, Carla L.; Molinaro, Gemma; Biagioni, Francesca; Traficante, Anna; Nicoletti, Ferdinando; Bruno, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7222-7229</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We examd. whether selective activation of mGlu4 metabotropic glutamate receptors attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage in mice.  C57BL mice were treated with a single dose of MPTP (30 mg/kg, i.p.) proceded, 30 min earlier, by a systemic injection of the mGlu4 receptor enhancer N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC).  PHCCC was injected either s.c. in cremophor EL or i.p. in saline contg. 50% DMSO.  PHCCC treatment (3 or 10 mg/kg) significantly reduced MPTP toxicity, as assessed by measurements of the striatal levels of dopamine and its metabolites and by tyrosine hydroxylase, dopamine transporter, and glial fibrillary acidic protein immunostaining in the corpus striatum and substantia nigra.  In another set of expts., a higher cumulative dose of MPTP (80 mg/kg divided into four injections with 2 h of interval) was injected to mGlu4-/- mice and their Sv129/CD1 wild-type controls.  A higher dose was used in these expts. because Sv129/CD1 mice are less sensitive to MPTP toxicity.  Systemic administration of PHCCC was protective in wild-type mice but failed to affect nigrostriatal damage in mGlu4-/- mice.  Finally, unilateral infusion of PHCCC in the external globus pallidus protected the ipsilateral nigrostriatal pathway against MPTP toxicity.  These data support the view that mGlu4 receptors are potential targets for the exptl. treatment of parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmpIXlBAH1PrVg90H21EOLACvtfcHk0lg9epcisoEwgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFejsbw%253D&md5=a135bb61fee6ddd6e4b17caf1ca7eae6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1595-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1595-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DBusceti%26aufirst%3DC.%2BL.%26aulast%3DMolinaro%26aufirst%3DG.%26aulast%3DBiagioni%26aufirst%3DF.%26aulast%3DTraficante%26aufirst%3DA.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DBruno%26aufirst%3DV.%26atitle%3DPharmacological%2520activation%2520of%2520mGlu4%2520metabotropic%2520glutamate%2520receptors%2520reduces%2520nigrostriatal%2520degeneration%2520in%2520mice%2520treated%2520with%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D7222%26epage%3D7229%26doi%3D10.1523%2FJNEUROSCI.1595-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLella, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson’s disease treatment</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">13668</span><span class="NLM_x">–</span> <span class="NLM_lpage">13673</span><span class="refDoi"> DOI: 10.1073/pnas.1835724100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1073%2Fpnas.1835724100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13668-13673&author=M.+J.+Marinoauthor=D.+L.+Williamsauthor=J.+A.+O%E2%80%99Brienauthor=O.+Valentiauthor=T.+P.+McDonaldauthor=M.+K.+Clementsauthor=R.+Wangauthor=A.+G.+DiLellaauthor=J.+F.+Hessauthor=G.+G.+Kinneyauthor=P.+J.+Conn&title=Allosteric+modulation+of+group+III+metabotropic+glutamate+receptor+4%3A+a+potential+approach+to+Parkinson%E2%80%99s+disease+treatment&doi=10.1073%2Fpnas.1835724100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1835724100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1835724100%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DValenti%26aufirst%3DO.%26aulast%3DMcDonald%26aufirst%3DT.%2BP.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDiLella%26aufirst%3DA.%2BG.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DKinney%26aufirst%3DG.%2BG.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DAllosteric%2520modulation%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptor%25204%253A%2520a%2520potential%2520approach%2520to%2520Parkinson%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D13668%26epage%3D13673%26doi%3D10.1073%2Fpnas.1835724100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Stachowicz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">498</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2004.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.ejphar.2004.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=15363989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFGksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=498&publication_year=2004&pages=153-156&author=K.+Stachowiczauthor=K.+Klakauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+Pilc&title=Anxiolytic-like+effects+of+PHCCC%2C+an+allosteric+modulator+of+mGlu4+receptors%2C+in+rats&doi=10.1016%2Fj.ejphar.2004.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats</span></div><div class="casAuthors">Stachowicz, Katarzyna; Klak, Kinga; Klodzinska, Aleksandra; Chojnacka-Wojcik, Ewa; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">498</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We examd. the potential anxiolytic-like activity of (-)-N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), an allosteric modulator of metabotropic glutamate4 receptors (mGlu4), after administration into the basolateral amygdala, using the conflict drinking Vogel test in rats as a model.  The results indicate that PHCCC, but not 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate Et ester (CPCCOEt), the selective antagonist of group mGlu1 receptors, showed significant, dose-dependent anticonflict effects without affecting the threshold current or water intake.  The results indicate that pos. allosteric modulation of mGlu4 receptors may be a useful therapeutic approach to anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokig2pRNX0-LVg90H21EOLACvtfcHk0lhXaak8TkPCcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFGksL8%253D&md5=33836a910beaa8bf8b11f6243a522d67</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DStachowicz%26aufirst%3DK.%26aulast%3DKlak%26aufirst%3DK.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DAnxiolytic-like%2520effects%2520of%2520PHCCC%252C%2520an%2520allosteric%2520modulator%2520of%2520mGlu4%2520receptors%252C%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D498%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.ejphar.2004.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Iacovelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazzaglia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronica, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinsanti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Smaele, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Onofrio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giangaspero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span> </span><span class="NLM_article-title">Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">8388</span><span class="NLM_x">–</span> <span class="NLM_lpage">8397</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.2285-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1523%2FJNEUROSCI.2285-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=16899734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28Xos1Kju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=8388-8397&author=L.+Iacovelliauthor=A.+Arcellaauthor=G.+Battagliaauthor=S.+Pazzagliaauthor=E.+Aronicaauthor=P.+Spinsantiauthor=A.+Carusoauthor=E.+De+Smaeleauthor=A.+Saranauthor=A.+Gulinoauthor=M.+D%E2%80%99Onofrioauthor=F.+Giangasperoauthor=F.+Nicoletti&title=Pharmacological+activation+of+mGlu4+metabotropic+glutamate+receptors+inhibits+the+growth+of+medulloblastomas&doi=10.1523%2FJNEUROSCI.2285-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas</span></div><div class="casAuthors">Iacovelli, Luisa; Arcella, Antonietta; Battaglia, Giuseppe; Pazzaglia, Simonetta; Aronica, Eleonora; Spinsanti, Paola; Caruso, Alessandra; De Smaele, Enrico; Saran, Anna; Gulino, Alberto; D'Onofrio, Mara; Giangaspero, Felice; Nicoletti, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8388-8397</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Moving from the evidence that activation of type 4 metabotropic glutamate (mGlu4) receptors inhibits proliferation and promotes differentiation of cerebellar granule cell neuroprogenitors, we examd. the expression and function of mGlu4 receptors in medulloblastoma cells.  MGlu4 receptors were expressed in 46 of 60 human medulloblastoma samples.  Expression varied in relation to the histotype (nodular desmoplastic>classic>>large-cell anaplastic) and was inversely related to tumor severity, spreading, and recurrence.  MGlu4 receptors were also found in D283med, D341med, and DAOY medulloblastoma cell lines, where receptor activation with the selective enhancer PHCCC inhibited adenylyl cyclase and the phosphatidylinositol-3-kinase pathway without affecting the mitogen-activated protein kinase, Sonic Hedgehog, and Wnt pathways.  Interestingly, mGlu4 receptor activation reduced DNA synthesis and cell proliferation in all three cell lines.  This effect was abrogated by the phosphatidylinositol-3-kinase inhibitor LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one].  In in vivo expts., repeated s.c. injections of N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) reduced the growth of D283med and DAOY cell xenografts in nude mice.  More remarkably, s.c. or intracranial injections of PHCCC during the first week of life prevented the development of medulloblastomas in mice lacking one Patched-1 allele and x-irradiated 1 d after birth.  These data suggest that mGlu4 receptor enhancers are promising drugs for the treatment of medulloblastomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwH_YpxJPttrVg90H21EOLACvtfcHk0lhXaak8TkPCcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xos1Kju70%253D&md5=98d72e960bdce899cabe1df422a2bb0e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2285-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2285-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DIacovelli%26aufirst%3DL.%26aulast%3DArcella%26aufirst%3DA.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DPazzaglia%26aufirst%3DS.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3DSpinsanti%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DDe%2BSmaele%26aufirst%3DE.%26aulast%3DSaran%26aufirst%3DA.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Onofrio%26aufirst%3DM.%26aulast%3DGiangaspero%26aufirst%3DF.%26aulast%3DNicoletti%26aufirst%3DF.%26atitle%3DPharmacological%2520activation%2520of%2520mGlu4%2520metabotropic%2520glutamate%2520receptors%2520inhibits%2520the%2520growth%2520of%2520medulloblastomas%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D8388%26epage%3D8397%26doi%3D10.1523%2FJNEUROSCI.2285-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Goudet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschalier, A.</span><span> </span><span class="NLM_article-title">Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.pain.2007.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.pain.2007.08.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2008&pages=112-124&author=C.+Goudetauthor=E.+Chapuyauthor=A.+Allouiauthor=F.+Acherauthor=J.+P.+Pinauthor=A.+Eschalier&title=Group+III+metabotropic+glutamate+receptors+inhibit+hyperalgesia+in+animal+models+of+inflammation+and+neuropathic+pain&doi=10.1016%2Fj.pain.2007.08.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2007.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2007.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DChapuy%26aufirst%3DE.%26aulast%3DAlloui%26aufirst%3DA.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DEschalier%26aufirst%3DA.%26atitle%3DGroup%2520III%2520metabotropic%2520glutamate%2520receptors%2520inhibit%2520hyperalgesia%2520in%2520animal%2520models%2520of%2520inflammation%2520and%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2008%26volume%3D137%26spage%3D112%26epage%3D124%26doi%3D10.1016%2Fj.pain.2007.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zussy, C.; Gomez-Santacana, X.; Rovira, X.; De Bundel, D.; Ferrazzo, S.; Bosch, D.; Asede, D.; Malhaire, F.; Acher, F.; Giraldo, J.; Valjent, E.; Ehrlich, I.; Ferraguti, F.; Pin, J. P.; Llebaria, A.; Goudet, C.</span><span> </span><span class="NLM_article-title">Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4</span>.  <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span>DOI <span class="refDoi"> DOI: 10.1038/mp.2016.223</span> , <a href="https://www.ncbi.nlm.nih.gov/pubmed/27994221" class="extLink">https://www.ncbi.nlm.nih.gov/pubmed/27994221</a> (accessed December 20, 2016).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fmp.2016.223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+Zussy&author=X.+Gomez-Santacana&author=X.+Rovira&author=D.+De+Bundel&author=S.+Ferrazzo&author=D.+Bosch&author=D.+Asede&author=F.+Malhaire&author=F.+Acher&author=J.+Giraldo&author=E.+Valjent&author=I.+Ehrlich&author=F.+Ferraguti&author=J.+P.+Pin&author=A.+Llebaria&author=C.+Goudet&title=Dynamic+modulation+of+inflammatory+pain-related+affective+and+sensory+symptoms+by+optical+control+of+amygdala+metabotropic+glutamate+receptor+4&doi=10.1038%2Fmp.2016.223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fmp.2016.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2016.223%26sid%3Dliteratum%253Aachs%26aulast%3DZussy%26aufirst%3DC.%26atitle%3DDynamic%2520modulation%2520of%2520inflammatory%2520pain-related%2520affective%2520and%2520sensory%2520symptoms%2520by%2520optical%2520control%2520of%2520amygdala%2520metabotropic%2520glutamate%2520receptor%25204%26jtitle%3DMol.%2520Psychiatry%26date%3D2016%26doi%3D10.1038%2Fmp.2016.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fallarino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notartomaso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busceti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicciato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioretti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohmann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, R.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">902</span><span class="refDoi"> DOI: 10.1038/nm.2183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1038%2Fnm.2183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=20657581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1artr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=897-902&author=F.+Fallarinoauthor=C.+Volpiauthor=F.+Fazioauthor=S.+Notartomasoauthor=C.+Vaccaauthor=C.+Buscetiauthor=S.+Bicciatoauthor=G.+Battagliaauthor=V.+Brunoauthor=P.+Puccettiauthor=M.+C.+Fiorettiauthor=F.+Nicolettiauthor=U.+Grohmannauthor=R.+Di+Marco&title=Metabotropic+glutamate+receptor-4+modulates+adaptive+immunity+and+restrains+neuroinflammation&doi=10.1038%2Fnm.2183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation</span></div><div class="casAuthors">Fallarino, Francesca; Volpi, Claudia; Fazio, Francesco; Notartomaso, Serena; Vacca, Carmine; Busceti, Carla; Bicciato, Silvio; Battaglia, Giuseppe; Bruno, Valeria; Puccetti, Paolo; Fioretti, Maria C.; Nicoletti, Ferdinando; Grohmann, Ursula; Di Marco, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">897-902</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High amts. of glutamate are found in the brains of people with multiple sclerosis, an inflammatory disease marked by progressive demyelination.  Glutamate might affect neuroinflammation via effects on immune cells.  Knockout mice lacking metabotropic glutamate receptor-4 (mGluR4) were markedly vulnerable to exptl. autoimmune encephalomyelitis (EAE, a mouse model of multiple sclerosis) and developed responses dominated by interleukin-17-producing T helper (TH17) cells.  In dendritic cells (DCs) from those mice, defective mGluR4 signaling-which would normally decrease intracellular cAMP formation-biased TH cell commitment to the TH17 phenotype.  In wild-type mice, mGluR4 was constitutively expressed in all peripheral DCs, and this expression increased after cell activation.  Treatment of wild-type mice with a selective mGluR4 enhancer increased EAE resistance via regulatory T (Treg) cells.  The high amts. of glutamate in neuroinflammation might reflect a counterregulatory mechanism that is protective in nature and might be harnessed therapeutically for restricting immunopathol. in multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_TVkLsW3vDbVg90H21EOLACvtfcHk0lhqZAd-1w3Ywg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1artr4%253D&md5=56b1aeff47dd2351eb63654c19a76dda</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.2183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2183%26sid%3Dliteratum%253Aachs%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFazio%26aufirst%3DF.%26aulast%3DNotartomaso%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBusceti%26aufirst%3DC.%26aulast%3DBicciato%26aufirst%3DS.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DDi%2BMarco%26aufirst%3DR.%26atitle%3DMetabotropic%2520glutamate%2520receptor-4%2520modulates%2520adaptive%2520immunity%2520and%2520restrains%2520neuroinflammation%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D897%26epage%3D902%26doi%3D10.1038%2Fnm.2183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebois, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchalski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5626</span><span class="NLM_x">–</span> <span class="NLM_lpage">5630</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.bmcl.2008.08.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5626-5630&author=C.+M.+Niswenderauthor=E.+P.+Leboisauthor=Q.+Luoauthor=K.+Kimauthor=H.+Muchalskiauthor=H.+Yinauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+subtype+4+%28mGluR4%29%3A+Part+I.+Discovery+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+as+novel+mGluR4+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2008.08.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.087%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLebois%26aufirst%3DE.%2BP.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DMuchalski%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25204%2520%2528mGluR4%2529%253A%2520Part%2520I.%2520Discovery%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520novel%2520mGluR4%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5626%26epage%3D5630%26doi%3D10.1016%2Fj.bmcl.2008.08.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlo, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Paulis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Days, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalywajko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1358</span><span class="refDoi"> DOI: 10.1124/mol.108.049551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1124%2Fmol.108.049551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=18664603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCntrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1345-1358&author=C.+M.+Niswenderauthor=K.+A.+Johnsonauthor=C.+D.+Weaverauthor=C.+K.+Jonesauthor=Z.+Xiangauthor=Q.+Luoauthor=A.+L.+Rodriguezauthor=J.+E.+Marloauthor=T.+de+Paulisauthor=A.+D.+Thompsonauthor=E.+L.+Daysauthor=T.+Nalywajkoauthor=C.+A.+Austinauthor=M.+B.+Williamsauthor=J.+E.+Ayalaauthor=R.+Williamsauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Discovery%2C+characterization%2C+and+antiparkinsonian+effect+of+novel+positive+allosteric+modulators+of+metabotropic+glutamate+receptor+4&doi=10.1124%2Fmol.108.049551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4</span></div><div class="casAuthors">Niswender, Colleen M.; Johnson, Kari A.; Weaver, C. David; Jones, Carrie K.; Xiang, Zixiu; Luo, Qingwei; Rodriguez, Alice L.; Marlo, Joy E.; de Paulis, Tomas; Thompson, Analisa D.; Days, Emily L.; Nalywajko, Tasha; Austin, Cheryl A.; Williams, Michael Baxter; Ayala, Jennifer E.; Williams, Richard; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1345-1358</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is caused by the death of dopamine neurons in the basal ganglia and results in motor symptoms such as tremor and bradykinesia.  Activation of metabotropic glutamate receptor 4 (mGluR4) has been shown to modulate neurotransmission in the basal ganglia and results in antiparkinsonian effects in rodent PD models.  N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) is a pos. allosteric modulator (PAM) of mGluR4 that has been used to further validate the role of mGluR4 in PD, but the compd. suffers from a lack of selectivity, relatively low potency, and poor soly.  Via high-throughput screening, we discovered more than 400 novel PAMs of mGluR4.  Compds. derived from a novel chem. scaffold were characterized in vitro at both rat and human mGluR4 using two distinct assays of mGluR4 function.  The lead compd. was approx. 8-fold more potent than PHCCC, enhanced the potency of glutamate at mGluR4 by 8-fold, and did not show any significant potentiator or antagonist activity at other mGluR subtypes.  Resoln. of the regioisomers of the lead revealed that the cis regioisomer, (±)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041), contained the majority of the mGluR4 PAM activity and also exhibited partial agonist activity at mGluR4 at a site that was distinct from the glutamate binding site, suggesting that this compd. is a mixed allosteric agonist/PAM of mGluR4.  VU0155041 was sol. in an aq. vehicle, and intracerebroventricular administration of 31 to 316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats.  These exciting results provide continued support for mGluR4 as a therapeutic target in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfO7Oi9u7buLVg90H21EOLACvtfcHk0lgv2soL-GZ0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCntrfE&md5=c6316915f428898340313b7003f2e605</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049551%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DMarlo%26aufirst%3DJ.%2BE.%26aulast%3Dde%2BPaulis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DNalywajko%26aufirst%3DT.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%2BB.%26aulast%3DAyala%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%252C%2520characterization%252C%2520and%2520antiparkinsonian%2520effect%2520of%2520novel%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptor%25204%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1345%26epage%3D1358%26doi%3D10.1124%2Fmol.108.049551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">962</span><span class="NLM_x">–</span> <span class="NLM_lpage">966</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.bmcl.2008.11.104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=962-966&author=R.+Williamsauthor=C.+M.+Niswenderauthor=Q.+Luoauthor=U.+Leauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+subtype+4+%28mGluR4%29.+Part+II%3A+Challenges+in+hit-to-lead&doi=10.1016%2Fj.bmcl.2008.11.104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.104%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DLe%26aufirst%3DU.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25204%2520%2528mGluR4%2529.%2520Part%2520II%253A%2520Challenges%2520in%2520hit-to-lead%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D962%26epage%3D966%26doi%3D10.1016%2Fj.bmcl.2008.11.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGluR4</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1021/cn9000318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn9000318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=411-419&author=R.+Williamsauthor=Y.+Zhouauthor=C.+M.+Niswenderauthor=Q.+Luoauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=C.+R.+Hopkins&title=Re-exploration+of+the+PHCCC+scaffold%3A+discovery+of+improved+positive+allosteric+modulators+of+mGluR4&doi=10.1021%2Fcn9000318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4</span></div><div class="casAuthors">Williams, Richard; Zhou, Ya; Niswender, Colleen M.; Luo, Qingwei; Conn, P. Jeffrey; Lindsley, Craig W.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes a detailed structure-activity relation (SAR) anal. of the metabotropic glutamate receptor 4 (mGluR4) pos. allosteric modulator, (-)-N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC).  The authors have now developed compds. with improved potency and efficacy; in addn., compds. are presented that show selectivity for mGluR4 vs. the other mGluR subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2WcP_RojsbVg90H21EOLACvtfcHk0lgv2soL-GZ0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVOgu70%253D&md5=e2d43eefe332164e71002af710ba1fd8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fcn9000318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn9000318%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DRe-exploration%2520of%2520the%2520PHCCC%2520scaffold%253A%2520discovery%2520of%2520improved%2520positive%2520allosteric%2520modulators%2520of%2520mGluR4%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D411%26epage%3D419%26doi%3D10.1021%2Fcn9000318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Schann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span> </span><span class="NLM_article-title">Novel screening paradigms for the identification of allosteric modulators and/or biased ligands for challenging G-protein-coupled receptors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/B978-0-12-800167-7.00018-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FB978-0-12-800167-7.00018-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=285-300&author=S.+Schannauthor=P.+Neuvilleauthor=M.+Bouvier&title=Novel+screening+paradigms+for+the+identification+of+allosteric+modulators+and%2For+biased+ligands+for+challenging+G-protein-coupled+receptors&doi=10.1016%2FB978-0-12-800167-7.00018-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800167-7.00018-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800167-7.00018-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchann%26aufirst%3DS.%26aulast%3DNeuville%26aufirst%3DP.%26aulast%3DBouvier%26aufirst%3DM.%26atitle%3DNovel%2520screening%2520paradigms%2520for%2520the%2520identification%2520of%2520allosteric%2520modulators%2520and%252For%2520biased%2520ligands%2520for%2520challenging%2520G-protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2014%26volume%3D49%26spage%3D285%26epage%3D300%26doi%3D10.1016%2FB978-0-12-800167-7.00018-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwakabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigemoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, S.</span><span> </span><span class="NLM_article-title">Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">11868</span><span class="NLM_x">–</span> <span class="NLM_lpage">11873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=11868-11873&author=Y.+Nakajimaauthor=H.+Iwakabeauthor=C.+Akazawaauthor=H.+Nawaauthor=R.+Shigemotoauthor=N.+Mizunoauthor=S.+Nakanishi&title=Molecular+characterization+of+a+novel+retinal+metabotropic+glutamate+receptor+mGluR6+with+a+high+agonist+selectivity+for+L-2-amino-4-phosphonobutyrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DIwakabe%26aufirst%3DH.%26aulast%3DAkazawa%26aufirst%3DC.%26aulast%3DNawa%26aufirst%3DH.%26aulast%3DShigemoto%26aufirst%3DR.%26aulast%3DMizuno%26aufirst%3DN.%26aulast%3DNakanishi%26aufirst%3DS.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520novel%2520retinal%2520metabotropic%2520glutamate%2520receptor%2520mGluR6%2520with%2520a%2520high%2520agonist%2520selectivity%2520for%2520L-2-amino-4-phosphonobutyrate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D11868%26epage%3D11873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Duty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">–</span> <span class="NLM_lpage">1391</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01426.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%E2%80%99s+disease%3A+a+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease&doi=10.1111%2Fj.1476-5381.2011.01426.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lhxkBs97SC_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391%26doi%3D10.1111%2Fj.1476-5381.2011.01426.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Blandini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armentero, M. T.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">1156</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08491.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1111%2Fj.1742-4658.2012.08491.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2012&pages=1156-1166&author=F.+Blandiniauthor=M.+T.+Armentero&title=Animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1742-4658.2012.08491.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08491.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08491.x%26sid%3Dliteratum%253Aachs%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFEBS%2520J.%26date%3D2012%26volume%3D279%26spage%3D1156%26epage%3D1166%26doi%3D10.1111%2Fj.1742-4658.2012.08491.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Deumens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1006/exnr.2002.7891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1006%2Fexnr.2002.7891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=12061862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2002&pages=303-317&author=R.+Deumensauthor=A.+Bloklandauthor=J.+Prickaerts&title=Modeling+Parkinson%E2%80%99s+disease+in+rats%3A+an+evaluation+of+6-OHDA+lesions+of+the+nigrostriatal+pathway&doi=10.1006%2Fexnr.2002.7891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway</span></div><div class="casAuthors">Deumens, Ronald; Blokland, Arjan; Prickaerts, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-317</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Human idiopathic Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by degeneration of the dopaminergic neurons of the nigrostriatal pathway.  Different 6-OHDA rat models of PD were developed in which this toxin was injected into different parts of the nigrostriatal pathway: (a) the medial forebrain bundle which leads to extensive dopamine (DA) depletion; (b) the substantia nigra pars compacta, which leads to more specific and moderate DA depletions; and (c) subregions of the caudate-putamen complex (CPu), which also leads to specific DA depletions.  In this article we review the dopaminergic depletion and behavioral consequences of 6-OHDA lesions in the rat.  It was examd. whether the relation between DA depletion and behavioral deficits mimic idiopathic PD.  In addn., it was evaluated which model most closely approximates the human situation, esp. in relation to the stage of this progressive disease.  It was concluded that with respect to the site of the lesion, rats with partial lesions of the ventrolateral CPu are the most appropriate models to study early and late stages of PD.  The choice of the behavioral parameters dets. the use of unilateral or bilateral lesions, although it is obvious that the bilateral model mimics the human situation more closely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraF6nvJly4p7Vg90H21EOLACvtfcHk0lhxkBs97SC_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVequr0%253D&md5=4489ac8336d1bedbe02f52fe3a1ac2bb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2002.7891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2002.7891%26sid%3Dliteratum%253Aachs%26aulast%3DDeumens%26aufirst%3DR.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DModeling%2520Parkinson%25E2%2580%2599s%2520disease%2520in%2520rats%253A%2520an%2520evaluation%2520of%25206-OHDA%2520lesions%2520of%2520the%2520nigrostriatal%2520pathway%26jtitle%3DExp.%2520Neurol.%26date%3D2002%26volume%3D175%26spage%3D303%26epage%3D317%26doi%3D10.1006%2Fexnr.2002.7891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carta, A. R.</span><span> </span><span class="NLM_article-title">The 6-hydroxydopamine model of Parkinson’s disease</span> <span class="citation_source-journal">Neurotoxic. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1007/BF03033565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1007%2FBF03033565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=17449457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFymu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=151-167&author=N.+Simolaauthor=M.+Morelliauthor=A.+R.+Carta&title=The+6-hydroxydopamine+model+of+Parkinson%E2%80%99s+disease&doi=10.1007%2FBF03033565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The 6-hydroxydopamine model of Parkinson's disease</span></div><div class="casAuthors">Simola, Nicola; Morelli, Micaela; Carta, Anna R.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3,4</span>),
    <span class="NLM_cas:pages">151-167</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">F. P. Graham Publishing Co.</span>)
        </div><div class="casAbstract">A review.  The neurotoxin 6-hydroxydopamine (6-OHDA) continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease in the rat.  The classical method of intracerebral infusion of 6-OHDA, involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochem. dysfunctions in Parkinson's disease.  Subsequently, more subtle models of partial dopaminergic degeneration have been developed with the aim of revealing finer motor deficits.  The present review will examine the main features of 6-OHDA models, namely the mechanisms of neurotoxin-induced neurodegeneration as well as several behavioral deficits and motor dysfunctions, including the priming model, modeled by this means.  An overview of the most recent morphol. and biochem. findings obtained with the 6-OHDA model will also be provided, particular attention being focused on the newly investigated intracellular mechanisms at the striatal level (e.g., A2A and NMDA receptors, PKA, CaMKII, ERK kinases, as well as immediate early genes, GAD67 and peptides).  Thanks to studies performed in the 6-OHDA model, all these mechanisms have now been hypothesised to represent the site of pathol. dysfunction at cellular level in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkyWlIkKbjbVg90H21EOLACvtfcHk0lgQpYMRZCLRQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFymu7c%253D&md5=61ddf5d5b32a7d12630a9416e5b9f401</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2FBF03033565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033565%26sid%3Dliteratum%253Aachs%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DA.%2BR.%26atitle%3DThe%25206-hydroxydopamine%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2007%26volume%3D11%26spage%3D151%26epage%3D167%26doi%3D10.1007%2FBF03033565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Jenkins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poutiainen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kil, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruppu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aytan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedeoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brownell, A. L.</span><span> </span><span class="NLM_article-title">Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2015.11.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=462-473&author=B.+Jenkinsauthor=A.+Zhuauthor=P.+Poutiainenauthor=J.+K.+Choiauthor=K.+E.+Kilauthor=Z.+Zhangauthor=D.+Kuruppuauthor=N.+Aytanauthor=A.+Dedeogluauthor=A.+L.+Brownell&title=Functional+modulation+of+G-protein+coupled+receptors+during+Parkinson+disease-like+neurodegeneration&doi=10.1016%2Fj.neuropharm.2015.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DPoutiainen%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DJ.%2BK.%26aulast%3DKil%26aufirst%3DK.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DKuruppu%26aufirst%3DD.%26aulast%3DAytan%26aufirst%3DN.%26aulast%3DDedeoglu%26aufirst%3DA.%26aulast%3DBrownell%26aufirst%3DA.%2BL.%26atitle%3DFunctional%2520modulation%2520of%2520G-protein%2520coupled%2520receptors%2520during%2520Parkinson%2520disease-like%2520neurodegeneration%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D108%26spage%3D462%26epage%3D473%26doi%3D10.1016%2Fj.neuropharm.2015.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desbois, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blache, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span> </span><span class="NLM_article-title">Synthesis of carbamoylpyridine and imidazo[1,5-a]pyridin-1,3-diones via ortho-acetalhydantoin intermediates</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2003.10.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.tetlet.2003.10.200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=553-556&author=J.+M.+Chezalauthor=E.+Moreauauthor=N.+Desboisauthor=Y.+Blacheauthor=O.+Chavignonauthor=J.+C.+Teulade&title=Synthesis+of+carbamoylpyridine+and+imidazo%5B1%2C5-a%5Dpyridin-1%2C3-diones+via+ortho-acetalhydantoin+intermediates&doi=10.1016%2Fj.tetlet.2003.10.200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2003.10.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2003.10.200%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DDesbois%26aufirst%3DN.%26aulast%3DBlache%26aufirst%3DY.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520of%2520carbamoylpyridine%2520and%2520imidazo%255B1%252C5-a%255Dpyridin-1%252C3-diones%2520via%2520ortho-acetalhydantoin%2520intermediates%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D553%26epage%3D556%26doi%3D10.1016%2Fj.tetlet.2003.10.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberknecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, J.</span><span> </span><span class="NLM_article-title">Amino acids and peptides. XLIII: Dehydroamino acids. XVIII: Synthesis of dehydroamino acids and amino acids from <i>N</i>-acyl-2-(dialkyloxyphosphinyl)-glycin esters: II</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">1984</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1055/s-1984-30730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1055%2Fs-1984-30730" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1984&publication_year=1984&pages=53-60&author=U.+Schmidtauthor=A.+Lieberknechtauthor=J.+Wild&title=Amino+acids+and+peptides.+XLIII%3A+Dehydroamino+acids.+XVIII%3A+Synthesis+of+dehydroamino+acids+and+amino+acids+from+N-acyl-2-%28dialkyloxyphosphinyl%29-glycin+esters%3A+II&doi=10.1055%2Fs-1984-30730"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1055%2Fs-1984-30730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1984-30730%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DLieberknecht%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DJ.%26atitle%3DAmino%2520acids%2520and%2520peptides.%2520XLIII%253A%2520Dehydroamino%2520acids.%2520XVIII%253A%2520Synthesis%2520of%2520dehydroamino%2520acids%2520and%2520amino%2520acids%2520from%2520N-acyl-2-%2528dialkyloxyphosphinyl%2529-glycin%2520esters%253A%2520II%26jtitle%3DSynthesis%26date%3D1984%26volume%3D1984%26spage%3D53%26epage%3D60%26doi%3D10.1055%2Fs-1984-30730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Minguez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaquero, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez-Builla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castano, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J. L.</span><span> </span><span class="NLM_article-title">Pyrrolodiazines. 5. Synthesis, structure, and chemistry of pyrrolo[1,2-<i>c</i>]pyrimidine. Dipolar cycloaddition of pyrrolo[1,2-<i>c</i>]pyrimidinium ylides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7788</span><span class="NLM_x">–</span> <span class="NLM_lpage">7801</span><span class="refDoi"> DOI: 10.1021/jo9907080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9907080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=7788-7801&author=J.+M.+Minguezauthor=J.+J.+Vaqueroauthor=J.+Alvarez-Buillaauthor=O.+Castanoauthor=J.+L.+Andr%C3%A9s&title=Pyrrolodiazines.+5.+Synthesis%2C+structure%2C+and+chemistry+of+pyrrolo%5B1%2C2-c%5Dpyrimidine.+Dipolar+cycloaddition+of+pyrrolo%5B1%2C2-c%5Dpyrimidinium+ylides&doi=10.1021%2Fjo9907080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo9907080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9907080%26sid%3Dliteratum%253Aachs%26aulast%3DMinguez%26aufirst%3DJ.%2BM.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DAlvarez-Builla%26aufirst%3DJ.%26aulast%3DCastano%26aufirst%3DO.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.%2BL.%26atitle%3DPyrrolodiazines.%25205.%2520Synthesis%252C%2520structure%252C%2520and%2520chemistry%2520of%2520pyrrolo%255B1%252C2-c%255Dpyrimidine.%2520Dipolar%2520cycloaddition%2520of%2520pyrrolo%255B1%252C2-c%255Dpyrimidinium%2520ylides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D7788%26epage%3D7801%26doi%3D10.1021%2Fjo9907080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Wishka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groppi, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanchar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornburgh, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Burgos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raub, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arneric, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B. N.</span><span> </span><span class="NLM_article-title">Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4425</span><span class="NLM_x">–</span> <span class="NLM_lpage">4436</span><span class="refDoi"> DOI: 10.1021/jm0602413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0602413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4425-4436&author=D.+G.+Wishkaauthor=D.+P.+Walkerauthor=K.+M.+Yatesauthor=S.+C.+Reitzauthor=S.+Jiaauthor=J.+K.+Myersauthor=K.+L.+Olsonauthor=E.+J.+Jacobsenauthor=M.+L.+Wolfeauthor=V.+E.+Groppiauthor=A.+J.+Hancharauthor=B.+A.+Thornburghauthor=L.+A.+Cortes-Burgosauthor=E.+H.+Wongauthor=B.+A.+Statonauthor=T.+J.+Raubauthor=N.+R.+Higdonauthor=T.+M.+Wallauthor=R.+S.+Hurstauthor=R.+R.+Waltersauthor=W.+E.+Hoffmannauthor=M.+Hajosauthor=S.+Franklinauthor=G.+Careyauthor=L.+H.+Goldauthor=K.+K.+Cookauthor=S.+B.+Sandsauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=A.+S.+Kalgutkarauthor=S.+P.+Arnericauthor=B.+N.+Rogers&title=Discovery+of+N-%5B%283R%29-1-azabicyclo%5B2.2.2%5Doct-3-yl%5Dfuro%5B2%2C3-c%5Dpyridine-5-carboxamide%2C+an+agonist+of+the+alpha7+nicotinic+acetylcholine+receptor%2C+for+the+potential+treatment+of+cognitive+deficits+in+schizophrenia%3A+synthesis+and+structure%2D%2Dactivity+relationship&doi=10.1021%2Fjm0602413"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm0602413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0602413%26sid%3Dliteratum%253Aachs%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DReitz%26aufirst%3DS.%2BC.%26aulast%3DJia%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%2BK.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DWolfe%26aufirst%3DM.%2BL.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DHanchar%26aufirst%3DA.%2BJ.%26aulast%3DThornburgh%26aufirst%3DB.%2BA.%26aulast%3DCortes-Burgos%26aufirst%3DL.%2BA.%26aulast%3DWong%26aufirst%3DE.%2BH.%26aulast%3DStaton%26aufirst%3DB.%2BA.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DHigdon%26aufirst%3DN.%2BR.%26aulast%3DWall%26aufirst%3DT.%2BM.%26aulast%3DHurst%26aufirst%3DR.%2BS.%26aulast%3DWalters%26aufirst%3DR.%2BR.%26aulast%3DHoffmann%26aufirst%3DW.%2BE.%26aulast%3DHajos%26aufirst%3DM.%26aulast%3DFranklin%26aufirst%3DS.%26aulast%3DCarey%26aufirst%3DG.%26aulast%3DGold%26aufirst%3DL.%2BH.%26aulast%3DCook%26aufirst%3DK.%2BK.%26aulast%3DSands%26aufirst%3DS.%2BB.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DArneric%26aufirst%3DS.%2BP.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26atitle%3DDiscovery%2520of%2520N-%255B%25283R%2529-1-azabicyclo%255B2.2.2%255Doct-3-yl%255Dfuro%255B2%252C3-c%255Dpyridine-5-carboxamide%252C%2520an%2520agonist%2520of%2520the%2520alpha7%2520nicotinic%2520acetylcholine%2520receptor%252C%2520for%2520the%2520potential%2520treatment%2520of%2520cognitive%2520deficits%2520in%2520schizophrenia%253A%2520synthesis%2520and%2520structure--activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4425%26epage%3D4436%26doi%3D10.1021%2Fjm0602413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Adams, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittingham, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, C. L.</span><span> </span><span class="NLM_article-title">Diastereoselective synthesis of cyclopropane amino acids using diazo compounds generated in situ</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9433</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span><span class="refDoi"> DOI: 10.1021/jo035060c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo035060c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVClsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=9433-9440&author=L.+A.+Adamsauthor=V.+K.+Aggarwalauthor=R.+V.+Bonnertauthor=B.+Bresselauthor=R.+J.+Coxauthor=J.+Shepherdauthor=J.+de+Vicenteauthor=M.+Walterauthor=W.+G.+Whittinghamauthor=C.+L.+Winn&title=Diastereoselective+synthesis+of+cyclopropane+amino+acids+using+diazo+compounds+generated+in+situ&doi=10.1021%2Fjo035060c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective Synthesis of Cyclopropane Amino Acids Using Diazo Compounds Generated in Situ</span></div><div class="casAuthors">Adams, Luke A.; Aggarwal, Varinder K.; Bonnert, Roger V.; Bressel, Bettina; Cox, Russell J.; Shepherd, Jon; De Vicente, Javier; Walter, Magnus; Whittingham, William G.; Winn, Caroline L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9433-9440</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A simple and high-yielding method for the prepn. of cyclopropane amino acids is described.  The novel method involves the one-pot cyclopropanation of readily available dehydroamino acids using aryl and unsatd. diazo compds. generated in situ from the corresponding tosylhydrazone salts.  It was found that thermal 1,3-dipolar cycloaddn. followed by nitrogen extrusion gave the cyclopropane amino acid derivs. with good trans selectivity, while reactions in the presence of catalyst meso-tetraphenylporphyrin iron chloride gave predominantly the corresponding cis isomers.  The synthetic utility of this process was demonstrated in the synthesis of (cis)-2,3-methanophenylalanine, (trans)-2,3-methano-m-tyrosine, and (±)-coronamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-ZBlJ1Q99LVg90H21EOLACvtfcHk0ljSaCOWoaOClw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVClsrw%253D&md5=3a84664f044b47afe42ec966efb8f75e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjo035060c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo035060c%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DL.%2BA.%26aulast%3DAggarwal%26aufirst%3DV.%2BK.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBressel%26aufirst%3DB.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3Dde%2BVicente%26aufirst%3DJ.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DWhittingham%26aufirst%3DW.%2BG.%26aulast%3DWinn%26aufirst%3DC.%2BL.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520cyclopropane%2520amino%2520acids%2520using%2520diazo%2520compounds%2520generated%2520in%2520situ%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D9433%26epage%3D9440%26doi%3D10.1021%2Fjo035060c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Plewe, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dress, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehler, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahavendran, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanis, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7211</span><span class="NLM_x">–</span> <span class="NLM_lpage">7219</span><span class="refDoi"> DOI: 10.1021/jm900862n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900862n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7211-7219&author=M.+B.+Pleweauthor=S.+L.+Butlerauthor=K.+R.+Dressauthor=Q.+Huauthor=T.+W.+Johnsonauthor=J.+E.+Kuehlerauthor=A.+Kukiauthor=H.+Lamauthor=W.+Liuauthor=D.+Nowlinauthor=Q.+Pengauthor=S.+V.+Rahavendranauthor=S.+P.+Tanisauthor=K.+T.+Tranauthor=H.+Wangauthor=A.+Yangauthor=J.+Zhang&title=Azaindole+hydroxamic+acids+are+potent+HIV-1+integrase+inhibitors&doi=10.1021%2Fjm900862n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm900862n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900862n%26sid%3Dliteratum%253Aachs%26aulast%3DPlewe%26aufirst%3DM.%2BB.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKuehler%26aufirst%3DJ.%2BE.%26aulast%3DKuki%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DNowlin%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DRahavendran%26aufirst%3DS.%2BV.%26aulast%3DTanis%26aufirst%3DS.%2BP.%26aulast%3DTran%26aufirst%3DK.%2BT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DAzaindole%2520hydroxamic%2520acids%2520are%2520potent%2520HIV-1%2520integrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7211%26epage%3D7219%26doi%3D10.1021%2Fjm900862n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delmas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueiffier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blache, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lartigue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span> </span><span class="NLM_article-title">Heterocyclization of functionalized vinylic derivatives of imidazo</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6576</span><span class="NLM_x">–</span> <span class="NLM_lpage">6584</span><span class="refDoi"> DOI: 10.1021/jo015582x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo015582x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=6576-6584&author=J.+M.+Chezalauthor=E.+Moreauauthor=G.+Delmasauthor=A.+Gueiffierauthor=Y.+Blacheauthor=G.+Grassyauthor=C.+Lartigueauthor=O.+Chavignonauthor=J.+C.+Teulade&title=Heterocyclization+of+functionalized+vinylic+derivatives+of+imidazo&doi=10.1021%2Fjo015582x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo015582x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo015582x%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DDelmas%26aufirst%3DG.%26aulast%3DGueiffier%26aufirst%3DA.%26aulast%3DBlache%26aufirst%3DY.%26aulast%3DGrassy%26aufirst%3DG.%26aulast%3DLartigue%26aufirst%3DC.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26atitle%3DHeterocyclization%2520of%2520functionalized%2520vinylic%2520derivatives%2520of%2520imidazo%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D6576%26epage%3D6584%26doi%3D10.1021%2Fjo015582x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Gao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikai, N.</span><span> </span><span class="NLM_article-title">Cobalt-catalyzed ortho alkylation of aromatic imines with primary and secondary alkyl halides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">9279</span><span class="NLM_x">–</span> <span class="NLM_lpage">9282</span><span class="refDoi"> DOI: 10.1021/ja403759x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja403759x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVehu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=9279-9282&author=K.+Gaoauthor=N.+Yoshikai&title=Cobalt-catalyzed+ortho+alkylation+of+aromatic+imines+with+primary+and+secondary+alkyl+halides&doi=10.1021%2Fja403759x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cobalt-Catalyzed Ortho Alkylation of Aromatic Imines with Primary and Secondary Alkyl Halides</span></div><div class="casAuthors">Gao, Ke; Yoshikai, Naohiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">9279-9282</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here cobalt-N-heterocyclic carbene catalytic systems for the ortho alkylation of arom. imines with alkyl chlorides and bromides, which allows the introduction of a variety of primary and secondary alkyl groups at room temp. [e.g., PhC(:N-PMP)Me + n-C8H17Cl in presence of CoBr2, preligand 1,3-diisopropylbenzimidazolium bromide, and tBuCH2MgBr → o-octylacetophenone].  The stereochem. outcomes of the reaction of secondary alkyl halides suggest that the present reaction involves single-electron transfer from a cobalt species to the alkyl halide to generate the corresponding alkyl radical.  A cycloalkylated product obtained by this method can be transformed into unique spirocycles through manipulation of the directing and cycloalkyl groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8dQ8iwElS8LVg90H21EOLACvtfcHk0ljvCCyr0UHjPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVehu78%253D&md5=208c65ba47a73504224ee53485533ec9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja403759x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja403759x%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DK.%26aulast%3DYoshikai%26aufirst%3DN.%26atitle%3DCobalt-catalyzed%2520ortho%2520alkylation%2520of%2520aromatic%2520imines%2520with%2520primary%2520and%2520secondary%2520alkyl%2520halides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D9279%26epage%3D9282%26doi%3D10.1021%2Fja403759x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Bovonsombat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leykajarakul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pla-on, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanthapura, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doowa, N.</span><span> </span><span class="NLM_article-title">Regioselective iodination of phenol and analogues using <i>N</i>-iodosuccinimide and <i>p</i>-toluenesulfonic acid</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2664</span><span class="NLM_x">–</span> <span class="NLM_lpage">2667</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2009.03.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.tetlet.2009.03.128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=2664-2667&author=P.+Bovonsombatauthor=J.+Leykajarakulauthor=C.+Khanauthor=K.+Pla-onauthor=M.+M.+Krauseauthor=P.+Khanthapuraauthor=R.+Aliauthor=N.+Doowa&title=Regioselective+iodination+of+phenol+and+analogues+using+N-iodosuccinimide+and+p-toluenesulfonic+acid&doi=10.1016%2Fj.tetlet.2009.03.128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.03.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.03.128%26sid%3Dliteratum%253Aachs%26aulast%3DBovonsombat%26aufirst%3DP.%26aulast%3DLeykajarakul%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DC.%26aulast%3DPla-on%26aufirst%3DK.%26aulast%3DKrause%26aufirst%3DM.%2BM.%26aulast%3DKhanthapura%26aufirst%3DP.%26aulast%3DAli%26aufirst%3DR.%26aulast%3DDoowa%26aufirst%3DN.%26atitle%3DRegioselective%2520iodination%2520of%2520phenol%2520and%2520analogues%2520using%2520N-iodosuccinimide%2520and%2520p-toluenesulfonic%2520acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D2664%26epage%3D2667%26doi%3D10.1016%2Fj.tetlet.2009.03.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Colle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1016/S0028-3908(98)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2FS0028-3908%2898%2900091-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=1043-1051&author=I.+Brabetauthor=M.+L.+Parmentierauthor=C.+De+Colleauthor=J.+Bockaertauthor=F.+Acherauthor=J.+P.+Pin&title=Comparative+effect+of+L-CCG-I%2C+DCG-IV+and+gamma-carboxy-L-glutamate+on+all+cloned+metabotropic+glutamate+receptor+subtypes&doi=10.1016%2FS0028-3908%2898%2900091-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2898%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252898%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DParmentier%26aufirst%3DM.%2BL.%26aulast%3DDe%2BColle%26aufirst%3DC.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DComparative%2520effect%2520of%2520L-CCG-I%252C%2520DCG-IV%2520and%2520gamma-carboxy-L-glutamate%2520on%2520all%2520cloned%2520metabotropic%2520glutamate%2520receptor%2520subtypes%26jtitle%3DNeuropharmacology%26date%3D1998%26volume%3D37%26spage%3D1043%26epage%3D1051%26doi%3D10.1016%2FS0028-3908%2898%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Frauli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vol, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Among the twenty classical L-amino acids, only glutamate directly activates metabotropic glutamate receptors</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2005.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1016%2Fj.neuropharm.2005.09.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=245-253&author=M.+Frauliauthor=P.+Neuvilleauthor=C.+Volauthor=J.+P.+Pinauthor=L.+Prezeau&title=Among+the+twenty+classical+L-amino+acids%2C+only+glutamate+directly+activates+metabotropic+glutamate+receptors&doi=10.1016%2Fj.neuropharm.2005.09.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2005.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2005.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DFrauli%26aufirst%3DM.%26aulast%3DNeuville%26aufirst%3DP.%26aulast%3DVol%26aufirst%3DC.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DAmong%2520the%2520twenty%2520classical%2520L-amino%2520acids%252C%2520only%2520glutamate%2520directly%2520activates%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2006%26volume%3D50%26spage%3D245%26epage%3D253%26doi%3D10.1016%2Fj.neuropharm.2005.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Gomeza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restituito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=923-930&author=J.+Gomezaauthor=S.+Maryauthor=I.+Brabetauthor=M.+L.+Parmentierauthor=S.+Restituitoauthor=J.+Bockaertauthor=J.+P.+Pin&title=Coupling+of+metabotropic+glutamate+receptors+2+and+4+to+G+alpha+15%2C+G+alpha+16%2C+and+chimeric+G+alpha+q%2Fi+proteins%3A+characterization+of+new+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DMary%26aufirst%3DS.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DParmentier%26aufirst%3DM.%2BL.%26aulast%3DRestituito%26aufirst%3DS.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DCoupling%2520of%2520metabotropic%2520glutamate%2520receptors%25202%2520and%25204%2520to%2520G%2520alpha%252015%252C%2520G%2520alpha%252016%252C%2520and%2520chimeric%2520G%2520alpha%2520q%252Fi%2520proteins%253A%2520characterization%2520of%2520new%2520antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D923%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Tora, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovira, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dione, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Koninck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudet, C.</span><span> </span><span class="NLM_article-title">Allosteric modulation of metabotropic glutamate receptors by chloride ions</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4174</span><span class="NLM_x">–</span> <span class="NLM_lpage">4188</span><span class="refDoi"> DOI: 10.1096/fj.14-269746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;key=10.1096%2Ffj.14-269746" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=4174-4188&author=A.+S.+Toraauthor=X.+Roviraauthor=I.+Dioneauthor=H.+O.+Bertrandauthor=I.+Brabetauthor=Y.+De+Koninckauthor=N.+Doyonauthor=J.+P.+Pinauthor=F.+Acherauthor=C.+Goudet&title=Allosteric+modulation+of+metabotropic+glutamate+receptors+by+chloride+ions&doi=10.1096%2Ffj.14-269746"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-269746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-269746%26sid%3Dliteratum%253Aachs%26aulast%3DTora%26aufirst%3DA.%2BS.%26aulast%3DRovira%26aufirst%3DX.%26aulast%3DDione%26aufirst%3DI.%26aulast%3DBertrand%26aufirst%3DH.%2BO.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DDe%2BKoninck%26aufirst%3DY.%26aulast%3DDoyon%26aufirst%3DN.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DAcher%26aufirst%3DF.%26aulast%3DGoudet%26aufirst%3DC.%26atitle%3DAllosteric%2520modulation%2520of%2520metabotropic%2520glutamate%2520receptors%2520by%2520chloride%2520ions%26jtitle%3DFASEB%2520J.%26date%3D2015%26volume%3D29%26spage%3D4174%26epage%3D4188%26doi%3D10.1096%2Ffj.14-269746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00991">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38602"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00991">10.1021/acs.jmedchem.7b00991</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General methods for the synthesis of all compounds, and methods for the in vitro and in vivo DMPK protocols and supplemental figures (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and the associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_001.pdf">jm7b00991_si_001.pdf (658.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00991/suppl_file/jm7b00991_si_002.xlsx">jm7b00991_si_002.xlsx (42.12 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00991&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-20%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00991%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00991" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c74f3f29dd3d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
